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Abstract 
The University of Manchester 
Gavin Batman, February 2011 
Degree of Doctor of Philosophy in the Faculty of Medical and Human Sciences 
 
The Mode of Action of the HIV protease inhibitor against HPV 
 
Human papillomavirus (HPV) related cervical cancer is still the most common 
gynaecological malignancy in developing countries and, as yet, there is no 
alternative to surgery for the treatment of HPV-associated pre-malignant lesions. 
HPV ‘hijack’s’ the host-cell ubiquitin-proteasome system to degrade the p53 and 
Rb tumour suppressor proteins which in turn, leads to the development of cancer. 
Previous studies have shown that the HIV protease inhibitor lopinavir selectively 
inhibits the chymotryptic-like activity of the 26S proteasome which stabilises p53 
and induces the apoptosis of HPV positive cervical carcinoma cells. Based on this 
it was hypothesised that lopinavir treatment of HPV positive cervical carcinoma 
cells would produce changes in the levels of a wide range of cellular proteins that 
are dis-regulated by HPV-related activation of the proteasome. In order to address 
this, antibody microarray screening was carried out on lopinavir treated and control 
untreated HPV positive SiHa cervical carcinoma cells. This showed lopinavir 
induced alterations in 51 proteins including the cellular antiviral defence protein 
RNase L. Lopinavir induced both a dose and time dependent increase in RNase L 
which was subsequently confirmed by western blotting. Transient siRNA silencing 
of RNase L expression reduced the lopinavir-dependent toxicity in SiHa cells, 
suggesting an important role for this protein in the toxicity of lopinavir in HPV 
infected cells. SiHa cells were much more sensitive to lopinavir than CaSKi 
cervical carcinoma cells which had much higher levels of the E6 protein and did 
not up regulate RNase L. Furthermore, lopinavir treated HPV16 E6/E7 
immortalised keratinocytes were also shown to up regulate RNase L protein 
expression and these cells were much more sensitive to lopinavir induced 
apoptosis than mortal control keratinocytes. In addition, transient expression of 
RNase L in RNase L-deficient C33A cells and the same cells stably transfected 
with HPV16 E6 (C33AE6) demonstrated that E6 protected these cells from RNase 
L-induced cell death. Surprisingly, analysis of RNase L protein levels in these cells 
demonstrated that E6 did not induce the degradation of the RNase L protein. 
Instead it was found that E6 stabilised the interaction between RNase L and its 
endogenous inhibitor protein, ABCE1, and that lopinavir de-stabilised this 
interaction. Given that C33A tumour cells, E6/E7 immortalised keratinocytes and 
hTert immortalised keratinocytes are all sensitive to lopinavir, this implies that this 
compound does not specifically target HPV immortalised cells but rather targets 
immortalised cells in general, regardless of how this was achieved. The optimum 
concentration of lopinavir for all these effects was 25 µM, which is 15-fold higher 
than is observed in cervico-vaginal secretions following oral dosing with the drug 
Kaletra. In conclusion these results have confirmed the potential of lopinavir to 
treat HPV related pre-cancerous cervical lesions and provided at least part of the 
mode-of-action. Indeed they strongly support the use of lopinavir as a low-cost, 
self-applied topical alternative to surgery for this disease which will be of particular 
benefit in low-resource countries. Finally, the ability of lopinavir to induce 
apoptosis of non-HPV related immortalised cells merits further investigation since 
this indicates this drug may be useful for the treatment of other non HPV related 
pre-malignant conditions.     
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1. Cervical Cancer and the Human Papillomavirus  
 
Globally, it is estimated that there were 529,409 new cases of cervical cancer in 2008, leading 
to 274,883 deaths [1] making cervical cancer the 2nd most common malignancy affecting women 
worldwide [2].  
While the infectious nature of the common wart was identified as early as 1907 [3], the 
transmissible agent was not identified as human papillomavirus (HPV) until 1949 [4]. The 
significance of these findings were not truly appreciated until the work of Harald Zur Hausen 
proposed a link between persistent HPV and the development of squamous cell carcinoma of the 
cervix [5]. Research has now shown that infection with specific types of HPV (e.g. 16 or 18 – see 
section 1.1.1) is associated with over 99% of cervical carcinoma cases, unequivocally implicating 
HPV as a causative agent in the development of cervical cancer [6].  
 
1.1. High-risk HPV and Cervical Carcinogenesis 
 
1.1.1. Transmission of HPV and Associated Risk Factors 
 
HPV is a sexually transmitted infection and as such, the transmission route of ano-genital 
HPV infection is primarily as a result of mucosa-to-mucosa contact through penetrative sex [7] and 
concurrent infections with multiple HPV types is not uncommon [8, 9]. Accordingly, the risk factors 
associated with HPV infection relate to an individuals’ sexual practices namely; an early age of first 
sexual contact, a high number of sexual partners and exposure to high-risk contacts including 
prostitutes and promiscuous sexual partners [10]. 
 
 
1.1.2. Environmental Cofactors for Carcinogenic Progression 
 
Whilst HPV DNA has been detected in up to 99% of cervical carcinomas [6], it is also 
known that during the ages of greatest sexual activity, the prevalence of HPV DNA in sub-clinical 
infections (i.e. presence of viral DNA with normal cytology) can be as high as 40% in the female 
population [10]. In sexually active women up to the age of 30, the annual rate of infection with HPV 
is estimated to be 10-15% [10]. However, it is estimated that for every 1,000,000 women infected 
with HPV only ~100,000 women will develop pre-cancerous changes in cervical tissues [11]. 
Assuming no therapeutic intervention, of these 100,000 women, approximately 8,000 (8%) will go 
on to develop carcinoma in situ [11], which is <1% of those women originally infected with the virus. 
This observation suggests that infection with HPV is necessary yet it is insufficient to cause cervical 
cancer in isolation. This has led to the identification of alternative additional co-factors that are now 
known to play a role in tumorigenesis such as immunosuppression, smoking and use of oral 
contraceptives. HIV positive individuals or patients under induced immunosuppression (e.g. renal 
transplant patients) demonstrate increased levels of both HPV infection and cervical cancer 
 [17] 
 
(reviewed in [12] and [13-18]. The metabolic by-products of cigarette smoke have been detected in 
cervico-vaginal fluids, and this is thought to increase the risk of cervical cancer through a number 
of mechanisms - directly through mutagenic effects on cervical cells, and also by mediating a 
reduction in antigen presenting Langerhans cells which impairs local immunity [12]. Whilst the risks 
associated with the use of oral contraceptive are low, there is evidence to suggest that 16α-
hydroxyestrone, a metabolite of oestrogen, is associated with DNA damage that may lead to 
mutations acting synergistically with HPV to bring about carcinogenesis [11]. 
 
 
1.1.3. Human Papillomavirus Classification and Genomic Variation 
 
The papillomaviruses belong to a distinct taxonomic grouping, the  Papillomaviridae [19]. 
Examples of papillomaviruses have been found in a wide range of mammalian and avian hosts, 
and they are extremely species specific [20]. Regardless of host species, the papillomaviruses 
have strikingly similar structures; they are small, non enveloped viruses with an icosahedral capsid 
of approximately 55 nm diameter which contains a dsDNA genome 8kb in size [21]. HPVs 
demonstrate specific tropisms for squamous epithelial cells where they induce a state of 
hyperproliferation at HPV type-specific anatomical sites [22].  
There are over 100 known papillomaviruses which are split into numerous genera (Figure 
1.1, from [19]) and further grouped by sequence similarity. Changes in HPV DNA sequences occur, 
as in many viruses, through point mutations, deletions and insertions. Unlike RNA viruses, the HPV 
genome is much more stable due to the proofreading capabilities of DNA polymerases [23]. 
However, selective pressures can allow chance mutations to become established in a population 
and in conjunction with the process of genetic drift, allow variants, types and subtypes to evolve 
[23]. 
The classification of HPV types depends on the L1 open reading frame (ORF) of the HPV 
genome (L1 is discussed in Section 1.2.1.2). The L1 ORF which codes for the major capsid protein 
is highly conserved between HPV types, and as such, nucleotide sequence analysis of L1 is a 
suitable marker by which new HPV types are defined. A new HPV type is defined as having DNA 
sequence for the L1 ORF that differs by >10% when compared to its closest match. A subtype is 
defined by an L1 ORF difference of between 2% and 10%, and an HPV variant is defined by an L1 
ORF difference of less than 1%, when compared to its closest match [19]. 
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Figure 1.1 - Phylogenetic Classifications of Papillomaviruses. 
 
Figure 1.1 - Phylogenetic classifications of known human papillomaviruses (HPVs). HPVs are split 
into 5 evolutionary genus groups, alpha, beta, gamma, mu and nu and further grouped into 
separate species within each genus. The alpha and beta subgroups encompass 90% of the known 
HPV types that are implicated in cervical infection, including the high-risk types HPV16 and HPV18. 
Figure from [19]. 
 
 
The known HPVs can be broadly split into two groups based on their specific tropisms [10]:  
 
• Cutaneotropic types (e.g. HPV 1, 2, 3, 8, 41, 48, 60, 63 and 65) frequently 
isolated from plantar warts, in cutaneous lesions of patients with verruciform 
epidermodysplasia and common skin warts.  
• Mucosotropic types (e.g. 6, 11, 16, 18, 26, 30, 31, 32, 33, 34, 35, 39, 42, 44, 45, 
51, 52, 53, 54, 55, 56, 58, 59, 64, 66, 67, 68, 69, 70, 73) are associated with both 
benign and malignant infections of the anogenital tract of both sexes .  
 
HPV types can be further sub-classified as being either high-risk (HR) or low-risk (LR) 
based on their propensity to induce malignant transformation in infected cells. The HPV α-genus 
contains many mucosotropic HPV types of clinical importance including several low-risk types 
associated with benign common skin warts (e.g. HPV-2) [23]. However, of more clinical 
importance, the α-genus also contains 15 HPV types associated with cervical neoplasms termed 
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high-risk types (e.g. types 16 and 18). There are also three potential high-risk types and 12 low-risk 
HPV types which are rarely associated with malignant progression [24]. Along with cervical 
neoplasia, the high-risk types are also associated with vulval, vaginal, penile, anal and 
oropharyngeal neoplasias [24]. 
 Phylogenetic analysis of the known HPV variants demonstrates that these tend to cluster 
within specific geographical regions and within specific ethnic groups (reviewed in [23]). Due to its 
association with malignant progression, intratypic sequence heterogeneity within the high-risk HPV 
type 16 has been most extensively studied [23]. To date, 5 distinct Phylogenetic branches of HPV-
16 have been identified; European (E), which contains the prototype HPV-16 type, Asian (As), 
Asian American (AA), and two African variants (Af-1/Af-2). The most studied variants are the Asian-
American (AA), the L83V and the European variant (E). The AA variant is predominantly found in 
North and South America and studies have shown that HPV type 16 (AA) is detected in almost a 
quarter of cervical cancers diagnosed in Mexico. When compared to HPV type 16 infection with a 
European (E) variant, epidemiological evidence suggests that the AA variant possesses an 
increased oncogenic capability. Secondary to this, when compared to the E variant, infection with 
the AA variant is associated with an increased risk of progression to cervical cancer, and is found 
in younger women, who present with a more aggressive carcinoma [25, 26].  
The L83V variant falls within the larger European variant group and a nucleotide 
substitution at position 350 (350G) produces a leucine to valine amino acid change. The presence 
of HPV type 16 is associated with viral genome integration and disease progression and it has also 
been demonstrated that further to this, when compared to the prototype HPV type 16, infection with 
the L83V variant increases the risk of viral persistence and disease progression [27]. 
 
1.1.4. Site of Infection 
 
The cervical canal is lined with two cell types: squamous cells and columnar cells. 
Squamous cell carcinomas (SCC) develop at sites of active squamous metaplasia, which occur at 
the boundary between these two cell types [28]. This is labelled the cervical transformation zone 
(Figure 1.2) and is a region of active squamous metaplasia wherein the squamous cells of the 
ectocervix gradually envelop and replace the columnar cells of the endocervix. This makes the 
region particularly susceptible to HPV-related malignancy. 
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Figure 1.2 – The cervical transformation zone 
 
Figure 1.2 – The cellular boundary between the columnar cells of the endocervix and the 
squamous cells of the ectocervix form the cervical transformation zone. The transformation zone is 
the location from which cervical cancer is thought to develop. 
 
 
 
 
1.1.5. HPV and malignant progression 
 
HPV infection leads to a deregulation of the normal cell cycle control, leading to 
uncontrolled cellular proliferation. The process from initial HPV infection through to cervical 
carcinoma follows a clearly defined path consisting of 4 distinct stages; HPV infection, viral 
persistence, progression of a clone of persistently infected cells towards precancerous lesions, and 
invasion leading to malignancy [28]. Cervical squamous cell carcinomas originate from non-
invasive, premalignant precursor lesions termed Cervical Intraepithelial Neoplasia (CIN) [29]. There 
are varying degrees of CIN, labelled I, II and III, which correlate with the degree of atypia observed 
– CIN I refers to mild dysplasia, CIN II to moderate dysplasia whilst CIN III refers to severe 
dysplasia leading to carcinoma in situ. The progressive development of CIN and the development 
of cervical cancer along with the associated cellular atypia are depicted in Figure 1.3. This shows 
the cytology, assessed by Papanicolaou (Pap) staining (top row), and also lesions as viewed by 
colposcopy (bottom row). 
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Figure 1.3 – PAP staining and colposcopy imaging of cervical cancer progression 
 
 
 
Figure 1.3 - The progressive development of cervical cancer and the associated cellular atypia is 
depicted, shown both in terms of cytology by PAP staining (top row) and also colposcopy (bottom 
row). Diagram adapted from [28]. 
 
 
 
 
 
1.2. Cervical HPV infection and the molecular basis of carcinogenesis  
 
1.2.1. HPV Genome 
 
The HPV genome is split into eight open reading frames (ORF) that are transcribed as one 
polycistronic message from a single strand of the dsDNA genome (as reviewed in [20, 30]). Figure 
1.4, (adapted from [31]) is a schematic representation of the circular dsDNA genome of HPV 16, 
which is representative of the known HPVs. The genome can be split into three sections; the early 
region (E), which is approximately 4kb in size and codes for the non structural E1-E7 proteins, the 
late region (L) which is approximately 3kb and codes for the viral capsid proteins L1 and L2, the 
major and minor capsid proteins respectively, and finally the non-coding long control region (LCR). 
The latter is approximately 1kb, and contains cis elements that govern viral replication and gene 
expression. 
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Figure 1.4 – Schematic diagram of HPV type-16 genome 
 
   
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 - Schematic diagram of HPV type-16 genome. The genome of HPV type 16 is 
approximately 8kb in size, and codes for 8 genes (LCR, long coding region). The expression of the 
viral early proteins (E6 & E7) is directed by the p97 promoter, whilst expression of the remaining 
early proteins and late structural proteins is directed by the p670 promoter (diagram adapted from 
[31]). 
 
 
 
 
1.2.1.1. HPV Early Proteins 
 
The E6 and E7 proteins are the first viral proteins, and their transcription is driven by the 
early p97 promoter. The specific roles of E6 and E7 in carcinogenesis are discussed in greater 
detail in subsequent sections (1.2.2.3 and 1.2.2.4 respectively).  
The E2 protein is a DNA binding protein which interacts with ACCN6GGT motifs within the 
viral LCR and its expression is controlled by the p670 promoter [32]. E2 is 360 amino acids and 
contains three functional domains, a C-terminal DNA binding domain, an N-terminal transcription 
activation/DNA replication domain, and a central domain which forms a flexible hinge [33]. Upon 
binding, E2 forms a complex with the E1 protein which possesses ATP-dependent helicase 
capabilities promoting the unwinding of the viral DNA [34, 35]. The E2 protein is also responsible 
for viral genome segregation during cell division, carrying this out by tethering the viral genome to 
mitotic chromosomes by interaction with the bromodomain protein, Brd4 [36] [37]. One final role is 
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that of a repressor activity on the viral early promoter, which limits expression of the E6 & E7 early 
proteins [21, 30, 38] a key factor in the carcinogenic process. 
The E4 ORF is translated from spliced transcripts with the first five amino acids of the E1 
protein to generate an E1^E4 fusion protein [39]. The viral E1^E4 protein is the most highly 
expressed of all HPV proteins [29]. It is expressed in the later stages of replication in the upper 
layers of the differentiating epithelia, however little is known about its function. In vitro over 
expression studies have demonstrated that the E4 fusion protein interacts with the cellular 
cytokeratin network to facilitate its collapse, which suggests that the E4 protein plays a role in viral 
egress [29].   
The E5 protein of HPV is a small hydrophobic protein made up of 83 amino acids [29]. It is 
found primarily in the golgi apparatus, the endoplasmic reticulum and also in the plasma membrane 
[29]. E5 is the primary transforming protein of bovine papillomavirus (BPV) however, the E5 protein 
of HPV possesses only weak transforming abilities on its own. Indeed, the E5 ORF is often deleted 
in cervical carcinomas, suggesting that it is not essential for viral maintenance and malignant 
progression in HPV infection [40]. 
Since the E6 and E7 proteins are the key transforming proteins of high-risk HPV types their 
structure and function are summarised in greater detail in sections 1.2.2.3 and 1.2.2.4 respectively. 
 
 
1.2.1.2. The HPV Late Proteins and Viral Entry 
 
Expression of the structural late viral proteins, L1 and L2, is driven by the late viral 
promoter, p670. The HPV capsid is composed of 360 copies of L1 and 12 copies of the L2 protein, 
arranged into an icosahedral lattice composed of 72 pentamers of L1 protein with L2 proteins 
located at the vertices [41]. Whilst L1 forms the major structural protein, L2 is located internally, 
and is a multifunctional protein, with roles in genome encapsidation, L1 interaction and capsid 
stabilisation, endosomal escape of virions and nuclear transport of the HPV genome [42]. 
In order for HPV virions to infect proliferating basal cells there must first be a break or 
microtrauma in the epithelia. Viral attachment is achieved through heparin sulphate proteoglycans 
(HSPG) and requires the L1 major capsid protein [42-48]. Binding with HSPG induces a 
conformational change in both L1 and L2 proteins resulting in the exposure of the L2 amino 
terminus and internalisation of the HPV genome [47]. 
 
1.2.2. The High-risk HPV E6 and E7 Proteins and the Ubiquitin-proteasome System 
 
Within cells, proteins undergo a constant cycle of synthesis and degradation. There are two 
systems by which cells bring about this constant turnover of proteins; the lysosomal system and the 
ubiquitin-proteasome system. 
The ubiquitin-proteasome system is responsible for the rapid degradation of damaged, 
abnormal or incorrectly folded proteins. The system is also responsible for the tightly regulated 
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control of a wide range of proteins, including those involved with transcription (reviewed in [49]), 
cell cycle progression [50, 51], IkB which regulates NFkB mediated transcription [52], antigen 
presentation [53, 54], cell surface receptors and apoptosis [54]. 
However, the ubiquitin-proteasome system also plays a role in diseases such as cystic fibrosis 
[55] and tumour development, as highlighted by the virally induced degradation of p53 through 
interaction with the E6 protein of HPV [56, 57]. 
 
1.2.2.1. Ubiquitination 
 
Aharon Ciechanover and Avram Hershko are credited with the discovery of a heat-stable 
polypeptide that was shown to play an essential role in the recently discovered non-lysosomal 
pathway of protein degradation [58]. That polypeptide was later termed ubiquitin - a 76 amino acid 
protein, and its covalent attachment to a particular target protein is one of many essential steps that 
must occur prior to proteasomal degradation [59]. Prior to entering the proteasome, proteins 
become targeted for degradation by covalent attachment of multiple ubiquitin units, in what is 
known as the ubiquitination cascade. Initially, the E1 enzyme activates ubiquitin, creating a high-
energy intermediate [60-62]. Following this step, the activated ubiquitin is transferred to an E2 
ubiquitin conjugating enzyme [63]. The ubiquitin is then transferred to the target protein, which is 
conjugated to an E3 ubiquitin-ligase enzyme [54, 62, 64]. This process is repeated, with each 
ubiquitin polypeptide acting as the substrate for the attachment of further ubiquitin polypeptides. 
Attachment of four or more ubiquitin molecules is required before the proteasomal degradation can 
occur [65, 66]. Ubiquitinated products are recognised by the 19S regulatory subunits of the 
proteasome, at which point they are de-ubiquitinated and unfolded before being transferred to the 
20S catalytic core of the proteasome, where they are degraded in an ATP-dependent manner [54]. 
 
1.2.2.2. The Proteasome complex 
 
Research into degradation of abnormal proteins led to the discovery of an ATP-dependent, 
non-lysosomal proteolytic system in Escherichia Coli [67], a system which was also later identified 
in rabbit reticulocytes [68]. Hough et al later identified the main catalytic complex within this system 
[69], which was later termed the proteasome [70]. 
The proteasome (extensively reviewed in [71]) is a 2.5 MDa complex composed of several 
interacting units: the tubular 20S active core unit, which is flanked by two 19S regulatory subunits 
[72], which are capable of recognising poly-ubiquitinated proteins. Upon complete ubiquitination, 
protein substrates are translocated into the core of the proteasome through a gated channel 
consisting of seven α-units. In its native state, this gated channel is too narrow to allow passage of 
folded proteins [73]. Upon binding with 19S regulatory subunits, there is a conformational change in 
the 20S core, which widens the entry channel, and together, they are referred to as the 26S 
proteasome [70]. The 20S core subunit, contains two inner rings consisting of seven β units that 
have a range of activities – β1 expresses caspase-like activity, β2 expresses tryptic-like activity and 
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β5 expresses chymotrypsin-like activities [74], splitting peptide bonds after acidic, basic and 
hydrophobic amino acid residues respectively [73]. Following degradation within the core of the 
proteasome, peptides of 2-25 amino acid residues in length are released [75]. 
 
1.2.2.3. The HPV E6 Protein 
 
The E6 protein is the first gene expressed by HPV and along with E7, is a key protein 
responsible for the increased malignant transformation following infection with high-risk HPV types. 
The E6 protein is 150 amino acids in size and contains two Cys-x-x-Cys motifs arranged into two 
zinc binding domains [76] and its expression is driven by the P97 early promoter [30].  
 The association of E6 protein with malignancy was initially investigated by two independent 
research groups. These authors speculated that the link between high-risk HPV types and cervical 
cancer was associated with an innate ability to modulate or alter the activity of cellular pathways or 
proteins that govern the cell cycle [57]. They concluded that it was directly related to the 
association of the HPV E6 protein with cellular p53 that played a role in modulating cellular control 
[56, 57]. 
 The ‘guardian of the genome’, p53, is a site specific DNA binding protein that is expressed 
following DNA damage or aberrant initiation of the cell cycle (as defined in [30]). It can induce the 
expression of negative regulators of the cell cycle such as the cyclin-dependent kinase inhibitor 
p21CIP and trigger the apoptosis of damaged cells [77, 78]. Normal p53 turnover, however, is also 
regulated by the ubiquitin-proteasome pathway (see section 1.2.2.1), and this process is regulated 
by the MDM2 protein, which functions as a physiological ubiquitin-ligase (E3) enzyme [79].  
 The transforming capabilities of high-risk HPV types are linked with the ability of E6 to 
completely abrogate the regulatory functions of p53. This is achieved through binding of the E6 
protein with an E6 accessory protein (E6-AP) [80] which is a member of the ‘homology to E6 C 
terminus’ (HECT) family of E3 ubiquitin ligases [81]. This forms a complex with p53 that produces 
the poly-ubiquitination of lysine residues on p53 [82], inappropriately targeting p53 for rapid 
degradation by the cellular proteasome [82, 83]. 
 Studies have shown that the E6 protein of high-risk HPV type 16 is able to bind E6-AP 
more efficiently than low-risk HPV types which produces greater effects on p53 than low-risk types. 
As a consequence, HPV 16 E6 is able to bring about the degradation of p53 much more rapidly 
than other HPV types [84]. In the absence of p53-mediated cell cycle control, the cell is free to 
undergo successive rounds of unhindered replication. During this unchecked proliferation, the viral 
oncogenes promote genetic instability, which promotes errors in replication fidelity that may 
eventually lead to malignant transformation [21].  The E6 protein is crucial for this process since it 
abolishes, misdirects and degrades the cellular proteins in order to redress the vast stoichiometric 
imbalance between viral and cellular proteins. It is noticeable that E6 from low-risk types can still 
bind p53 but with a much weaker bond, and as such, fails to target p53 for improper degradation 
[85]. 
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1.2.2.4. The HPV E7 Protein 
 
The E7 protein, driven by the viral early promoter, is 98 amino acids in size and is divided into 
three conserved domains termed CR1, CR2 and CR3, all showing homology to the adenovirus E1A 
protein [77]. The CR1 domain contains the amino terminus; the CR2 domain contains an L-X-C-X-
E region that allows for binding of the retinoblastoma tumour suppressor protein (Rb) and CR3 
consists of two zinc finger motifs, similar to that of E6 [29]. The actions of the E7 protein, in some 
respects, are the primary mechanisms involved in the immortalisation process. E7 is able to 
interact with cellular members of the retinoblastoma (Rb) tumour repressor proteins, and like E6, 
facilitates the progression of otherwise quiescent cells into the S phase of cell cycle [86]. The 
retinoblastoma protein (Rb) is a nuclear phosphoprotein [87, 88] and was the first tumour 
suppressor protein to be identified [89]. Its physiological role is to control elements of the cell cycle 
[90], more specifically, the transition of the cell between the G1 and S phase of the cell cycle, and 
achieves this through the repression of transcription of genes required to overcome the G1/S 
checkpoint [91]. Within the uninfected cell, Rb exists in an unphosphorylated form in the G1 phase. 
In its hypophosphorylated state, Rb is able to bind to members of the E2F transcription factor 
family of proteins [92], repressing transcription of genes directed by E2F factors. Phosphorylation 
of Rb inactivates it, and removes its ability to bind E2F which allows transcription to proceed. This 
sequential phosphorylation is carried out by cyclins and cyclin-dependent kinases, namely cyclin-D 
and Cdk-4 and Cdk-6 [93] and also cyclin-E and Cdk-2 [94, 95]. At the peak of phosphorylation, Rb 
releases E2F, which is then free to promote the transcription of factors essential for S phase 
transition. 
E7 is also able to completely compromise the activity of Rb by incorrectly targeting it for 
proteasomal-mediated degradation [96]. It has been shown that E7 facilitates ubiquitination of Rb 
via inappropriate activation of an E3 ubiquitin ligase, and as a consequence, inappropriately targets 
it for degradation by the cellular 26S proteasome [96]. The co-operative actions of E6 and E7 are 
shown in Figure 1.5. Working in unison, the E7 is able to bring about the degradation of the Rb 
protein, thus eliminating normal cell cycle control. In conjunction with this action, HPVs are also 
equipped to circumvent the cellular fail safe mechanism provided by p53. In eliminating p53, HPV 
can ensure complete unhindered genome replication.  
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Figure 1.5 - (previous page) – Synergistic actions of E6 & E7 
 
In the uninfected cell, the Rb-E2F interaction governs cell cycle progression from the G1 through to 
the S phase. In its hypophosphorylated state, Rb binds E2F, preventing E2F from initiating 
transcription of genes necessary for cell cycle progression. Phosphorylation of Rb occurs through 
the actions of Cyclin D and Cyclin E in conjunction with cyclin-dependent kinases 4, 6 and 2 
respectively. At the peak of phosphorylation as the cell approaches the G1/ S boundary, Rb 
releases E2F which is then free to initiate transcription of the necessary cell cycle proteins. In the 
presence of DNA damage or aberrant cellular proliferation, p53 is activated and inhibits cell cycle 
progression and also initiates apoptosis. The synergistic actions of E6 and E7 overcome this tight 
regulation of cell cycle progression. (A) The E7 protein is thought of as the primary transforming 
protein of HPV. It binds to Rb in its hypophosphorylated state, thus releasing E2F to initiate 
transcription of proteins necessary for cell cycle progression. (B) In the presence of the atypical 
cellular proliferation caused by E7/Rb binding, p53 would normally regain cellular control, or initiate 
the apoptotic cascade. The HPV E6 protein is able to overcome this cellular failsafe mechanism by 
inappropriately targeting p53 for proteasomal-mediated degradation. The ubiquitin-proteasome 
system is tightly regulated and involves addition of multiple targeting molecules named ubiquitin to 
the target protein; in the cascade, ubiquitin is transferred from an E1 ubiquitin activating enzyme to 
an E2 ubiquitin conjugating molecule, before being transferred to the target protein by means of an 
E3 ubiquitin-ligase molecule. In the case of E6 mediated degradation, E6AP binds directly to p53 
and functions as the E3 ubiquitin-ligase. This leads to poly-ubiquitination of p53 which targets it for 
proteasomal mediated degradation.  
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1.2.2.5. Alternative Binding Partners for E6 and E7 
 
The inhibition of the normal functions of p53 and Rb through virally encoded oncoproteins is a 
key step in the life cycle of many small DNA tumour viruses including HPV, HBV and Simian Virus 
40 (SV40) [97]. Whilst overcoming G1/S checkpoint restriction through inhibition of p53 and Rb are 
key events in HPV pathogenesis, it is also apparent that in order to fully subvert normal cell 
function the association of E6 and E7 with several other cellular proteins plays an important role. 
As mentioned, the HPV genome is a fraction of the size of the human target cell and given this vast 
stoichiometric imbalance, it is clear that viral proteins must be extremely pleiotropic in nature. 
These p53/Rb-independent interactions can take the form of both inappropriate protein activation, 
and also a loss of protein function as a consequence of misdirected protein degradation at the 
proteasome [98]. The known E6 and E7 interacting proteins, and the consequence of the 
interaction, are detailed in Table 1.1. 
Previous work from this laboratory has indicated that the PDZ domain Tax interacting protein 1 
(Tip-1), a target of the HTLV-1 Tax protein and RhoA activator, also interacts with the HPV type 16 
E6 protein [99]. The data suggested that E6 may increase cell motility by augmenting GTP RhoA 
mediated activation of RhoA-kinases (ROCK) and that this is dependent on the expression of Tip-1 
protein [99]. Furthermore, recent data, also from this laboratory suggests that HPV type 16 E6, Tip-
1 and guanine nucleotide exchange factor 16 (ARHGEF16) may co-operate to activate the Rho 
protein Cdc42 [100]. This is significant as guanidine exchange factor-catalysed activation of Cdc42 
is known to play a crucial role in cellular transformation, malignant progression and invasion and 
suggests a functional link between E6 and Cdc42 activation [100]. 
 
 
 
 
 
 Table 1.1 – E6 & E7 binding partners 
 
E6 Binding 
Partner Cellular Function of the binding partner Possible consequence of interaction for the cell/degradation (+/-) 
p53 Tumour suppressor protein: Regulation of cell response to mitogenic 
events Loss of cell cycle control: antiapoptotic effect (+) 
E6AP Regulation of signal transduction in proliferation Deregulation of signal transduction in proliferating cells (+) 
E6BP 
(ERC55) 
Member of calcium-binding proteins; involved in signalling pathways 
of cell growth and differentiation 
Inhibition of terminal differentiation of epithelial cells. P53-independent 
inhibition of apoptosis (+) 
Paxillin Focal adhesion protein: has a role in cell adhesion and regulation of the actin cytoskeleton Change of the cellular morphology and disruption of the actin cytoskeleton (+) 
hDLG 
Human homologue of the Drosophila Dlg tumour suppression 
protein; plays an important role in epithelial cell growth and in 
formation and maintenance of tight junctions 
Change of cell growth, adhesion and polarity; invasiveness of the transformed 
cell (+) 
MCM7 Minichromosome maintenance protein 7; a component of replication licensing factors 
Induction of chromosomal abnormalities; overriding the early G1-phase arrest 
point (+) 
IRF-3 Transactivator of Interferons; induction of IFN-β mRNA Disruption of the antiviral response (-) 
myc Transcription factor Induction of hTert expression and modulation of cell proliferation and differentiation (+) 
bak A member of Bcl-2 family; proapoptotic protein Antiapoptotic effects (+) 
E6TP1 GTPase activating protein; negative regulator of Rab Inhibition of Rab-mediated mitogenic signalling; E6-induced oncogenesis (+) 
CBP/p300 p53 co-activator; regulation of signalling modulating events Down-regulation of p53-dependent transcription (-) 
hScrib 
Human homologue of the Drosophila Scribble tumour suppressor 
protein; controls formation of cell junctions and inhibition of epithelial 
cell growth 
Loss of epithelial cell adhesion and polarity (+) 
PKN Protein kinase Affects Rho-mediated signalling (+) 
MUPP1 Multi-PDZ scaffold protein; regulation of signal transduction Disruption of the assembly of signalling complexes at the epithelia cell 
membrane (+) 
MAGI-1/2/3 Tight junction proteins; regulation of PTEN tumour suppressor p53-independent inhibition of apoptosis (+) 
Gps2 G-protein pathway suppressor protein; enhanced p300 activity Suppression of Gsp2 (+) 
XRCC1 DNA repair protein Interference with DNA repair efficiency (-) 
Tip-1 PDZ domain Tax interacting protein 1; RhoA Kinase Activator 
E6 may increase cell motility by augmenting GTP RhoA mediated activation 
of ROCKs and that this is dependent on the expression of the Tip-1 protein 
(+) 
 E7 Binding 
Partner Cellular Function of the binding partner 
Possible consequence of interaction for the cell/degradation (+/-
) 
pRb Regulation of cell cycle control via complex formation of E2F transcription factors 
Phosphorylation of pRb and subsequent release from E2F, ubiquitination 
and subsequent degradation 
pRb-pocket 
proteins Regulation of cell cycle control 
Loss of cell cycle control and activation of specific genes for cell cycle 
progression 
Cyclin A,E Kinase activity Enhancement of HPV replication by directly altering cyclin-dependent kinase-2 activity 
p21(cip) Cyclin-dependent kinase inhibitor Growth stimulation via loss of cell cycle control 
p27(kip1) Cyclin-dependent kinase inhibitor Growth stimulation via loss of cell cycle control 
α-glucosidase Glycolytic control enzyme Key role in the genesis of cervical carcinoma 
M2 pyruvate 
kinase Modulation of the activity of glycolytic enzyme 2 Promotion of cell transformation and proliferation 
AP-1 Transcription factor Transactivation abrogation of IRF-1 transcriptional activity 
p48 IFN regulatory protein; key messenger protein Inhibition of IFN signalling pathways via nuclear translocation of p48 of IFN-
α signalling 
IRF-1 Regulates expression of IFN-β E7-mediated immune evading mechanism by interfering with IFN signaling  
Mpp2 Forkhead transcription factor Abrogation of IRF-1 transcriptional activation 
TBP TATA-box binding protein; initiator of transcription  Interference with the activation of p53-responsive promoters 
TAF110 Initiator of transcription Modulation of transcription 
Mi2 Histon deacetylase Abrogation of IRF-1 transcriptional activation 
S4 subunit S4 subunit of the 26S proteasome pRb degradation via targeting to the proteasome 
hTid-1 Human homologue of the Drosophila tumour suppressor protein Tid56 Activation of E2F-responsive promoters 
IGFBP-1 Insulin-like growth factor-binding protein Antiapoptotic effect 
Histon H1 
kinase Kinase Activity Interference with G2/M transition of cell cycle 
 
(Table from [99, 101]
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1.2.3. HPV Viral life cycle 
 
Reviewed in Hebner and Laimins (2006), HPV are highly epitheliotrophic and the life cycle 
of HPV is entirely dependent on actively differentiating cells that are found only in stratified 
epithelium. Normal non-infected epithelial cells grow in distinct layers, where the basal layer stem 
cells are the only layer capable of active division [29]. Following division, one of the daughter cells 
then begins to migrate through the stratified layers. At this stage, the cell exits the cell cycle and 
begins the process of terminal differentiation. During this process, the cells begin to produce high 
molecular weight keratins, which accumulate in the cell. As the cell is no longer undergoing normal 
cell cycle, the nuclear membrane begins to deteriorate, and cells in the upper most layers exist as 
keratin filled membranes, which are no longer viable cells. At this point shedding of dead cells 
occurs with the journey from basal membrane to shedding taking approximately 10-14 days to 
occur [102] (Figure 1.6). 
 
 
 
 
Figure 1.6 - Normal development and stratification of the epithelium 
 
 
  
 
 
Figure 1.6 – Development and stratification of cells in the uninfected epithelium. Cells in the basal 
level undergo active division, before undergoing terminal differentiation, cornification and 
desquamation (adapted from [103]). 
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 In a HPV infected epithelium, the scenario is quite different. Following infection and 
internalisation, the viral genome is established as an episome and the early viral promoter, p97, is 
activated which results in low level viral replication, maintaining the viral genome at 50-100 copies 
per cell [30]. As the cells of the epithelium divide, the viral genome also undergoes replication and 
division between daughter cells and it is at this point that the paths of uninfected and infected cells 
start to differ [29]. A differentiating daughter cell containing the replicating HPV episome begins to 
rise through the epithelial layers; however, it does not exit the cell cycle as occurs in non-infected 
cells. As the reproduction of the viral episome is totally dependent on the replicative machinery of 
the infected cell, HPV has developed a means by which it can overcome the terminal differentiation 
of the host cell. The synergistic actions of the HPV E6 and E7 proteins (Figure 1.5) force the 
infected cell back into the S-phase of the cell cycle, thus allowing continued viral replication [104]. 
As infected cells pass into the stratum spinosum (see Figure 1.6), the late promoter is activated, 
leading to expression of the late proteins and a massive up regulation in viral replication [29]. As 
the still actively dividing cells reach the highest layer the DNA is packaged into a complete virion 
and release of infectious virus is aided by the disintegration of the upper most cell layer [41]. 
 
 
1.2.4. HPV, the immune response and interferon. 
  
The mammalian host immune response is composed of two interlinked pathways; the innate 
and adaptive immune response pathways. The innate immune response provides a fast-acting, 
generalised, non-pathogen specific response and is associated with a local inflammatory response. 
Prolonged activation of the innate immune response will eventually culminate in activation of T-
helper lymphocytes which regulate the cell mediated immunity of the adaptive immune response. 
Recruitment of both phagocytic and antigen presenting cells leads to activation of the adaptive 
immune pathway which provides a longer lasting antibody-dependent and pathogen-specific 
response [105]. As discussed previously, the life cycle of HPV is exclusively linked to the terminally 
differentiated stratified cells of the epithelial basement membrane cells. In addition, HPVs are non-
lytic viruses as their life cycle is exclusively restricted to the stratified epithelium composed of cells 
that are fated to undergo programmed cell death. As a consequence, these cells are therefore free 
from immune surveillance and as a consequence, HPV infection fails to induce any sort of local 
inflammatory response, and therefore fails to trigger the adaptive immune response accordingly. 
Furthermore, HPV does not induce viraemia [106]. 
Interferons (IFN) [107] (Discussed in greater detail in Section 5.1.1) are a group of 
multifunctional secreted proteins involved with antiviral defence, cell growth regulation and immune 
activation and can be split into two broad categories, type I and Type II; the type I IFNs, IFN-α and 
IFN-β, are produced as a direct consequence of viral infection and mediate the host antiviral 
response. In addition to the well known effects on p53 and Rb, E6 and E7 also possess abilities 
that allow them to subvert the interferon response. High risk HPV E7 has been shown to inhibit 
IFN-α signalling through binding with P48/IRF-9 which subsequently prevents nuclear translocation 
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and activation of the nuclear Interferon specific response element (ISRF) [106]. In addition E7 has 
also been shown to associate with interferon response factor-1 (IRF-1), thus inhibiting IFN-β 
dependent transcription. Furthermore, E6 has been shown to bind with TYK2, preventing its 
binding with the interferon response receptor, thus inhibiting the JAK-STAT signalling cascade 
associated with the IFN pathways [106]. 
However, despite this apparent ability of HPV to successfully evade the host immune 
response, approximately 90% of HPV infections are eventually cleared within two years of the initial 
infection [108]. A cell-mediated immune response is eventually directed against the HPV early E2 
and E6 proteins, characterised by the infiltration of specific helper and cytotoxic T-lymphocytes, 
macrophages and pro-inflammatory cytokines [105]. Subsequently, low levels of serum neutralizing 
antibodies directed against the HPV L1 major capsid protein are produced, with low levels of IgG 
and IgA antibodies found in cervical mucosa [105]. Subsequently, HPV infections may undergo full 
clearance, or in a subset of infections, viral persistence (See section 1.3, below). 
  
1.3. Viral persistence and Viral integration 
 
1.3.1. Viral Persistence 
 
HPV infection is a necessary but insufficient stage in the development of cervical cancer. 
As stated, less that 1% of those women infected with HPV will go on to develop malignant changes 
[11] highlighting the complex nature of the virus-host relationship. For example, HPV is known to 
evade the host immune system, its replication does not induce cytolysis, necrosis or viraemia and 
viral proteins are released in high numbers in terminally differentiated cells which are pre-
programmed to undergo apoptosis and are therefore free from immune surveillance [24]. HPV has 
also been demonstrated to elicit a weak immune response as a consequence of inhibition of 
interferon synthesis [24]. Regardless, the majority of HPV infections (~90%) are successfully 
cleared or suppressed within 2 years of infection. Those infections that fail to resolve naturally 
within 2 years are considered persistent infections [28]. The definition of viral persistence is poorly 
defined yet many studies define it as having two or more HPV-positive colposcopy clinic visits with 
a medium interval between HPV tests of 6 months (range 2-72) [28]. Whilst both environmental and 
host factors may contribute to viral persistence, the greatest predictor of the likelihood of 
persistence remains HPV type and variant. High-risk HPV types (e.g. 16 & 18) are known to persist 
longer than low-risk types, and more specifically, non-European (Section 1.1.3) HPV 16/18 types 
have been shown to persistent longer than European types [24]. With increased length of viral 
persistence the probability of viral clearance reduces and accordingly, the risk of malignant 
progression increases [28]. 
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1.3.2. Persistence and Viral Genome Integration 
 
The integration of the HPV genome into the host genome is frequently associated with 
invasive squamous cell carcinoma [28, 109], the frequency of which increases with increasing 
severity of carcinoma [110].  
 
 
Figure 1.7 – HPV genome integration 
 
 
 
 
Figure 1.7 - HPV genome integration. In the majority of cervical cancers, the HPV genome is no 
longer reproduced episomally, and has instead become integrated into the host cell at a common 
fragile site. Typically, disruption of the viral genome occurs, and integrants have an interrupted E2 
ORF, with subsequent loss of E2 mediated transcriptional repression of the E6 and E7 proteins. 
 
 
 
The HPV E2 protein regulates HPV gene transcription, with arguably its most important 
role being transcriptional repression of E6 and E7 mRNA. The HPV genome most commonly 
integrates into host DNA at the E2 ORF, whereby this is disrupted. Thus, HPV integrants retain 
both E6 and E7 genes however since the E2 ORF is disrupted the E2-mediated transcriptional 
repression of E6 and E7 proteins is lost [111]. This loss of transcriptional repression leads to an 
uncontrolled up regulation of these proteins, with inevitable consequences for cell immortalisation 
and proliferation [21, 109, 112]. In conjunction with this, E2 has also been shown to regulate 
human telomerase (hTert) expression in cell culture models and again, loss of transcriptional 
control would result in up-regulation of hTert and an enhancement of cellular immortalisation [113]. 
In addition, HPV genome integration has been shown to occur at common fragile sites in 
host cell chromosomes [114]. Furthermore, integration has a number of consequences. When 
compared to episomal viral transcripts, E6 and E7 mRNAs from integrated virus display increased 
stability and half-life, which in turn induces increased genomic instability in the host thereby 
enhancing the possibility of malignant progression [115] when compared to episomal transcripts 
and an increase HPV protein expression and integration status as it relates to CIN progression is 
shown below in Figure 1.8 (Figure adapted from [110]). 
 
 
 
Host cell L1 LCR E6     Host cell E2 E7 
 Figure 1.8 HPV protein expression and progression to squamous cell carcinoma 
Integrated genome Episomal genome 
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Figure 1.8 (previous page) – Viral genome integration and progression to cervical carcinoma 
Infection of the actively dividing basal cell membrane occurs through micro-abrasions in the 
cervical epithelium. Following infection, the viral genome is maintained as an episome (purple 
nuclei) and infection manifests itself as a non-cancerous CIN-type lesion. The expression of both 
early and late viral proteins is carefully regulated by the early and late viral promoters culminating 
in the release of infectious viral particles. Left untreated, the progression from CIN-1 type lesion 
through to invasive SCC is associated with viral genome integration (red nuclei). Upon integration, 
E2 is known to become interrupted resulting in loss of transcriptional repression and over 
expression of the oncogenic E6 and E7 proteins resulting in the progression to invasive squamous 
cell carcinoma of the cervix (Diagram from [110]). 
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1.4. The Burden of HPV infection and Therapeutic Intervention Strategies for HPV-
related malignancy 
 
When comparing developed and developing countries, the age-standardised incidence rates 
(per 100,000 women) for cervical cancer vary dramatically (Figure 1.9); of the estimated 529,409 
new cases of cervical cancer in 2008, >80% were shown to occur in developing countries, with 
Africa, in particular, suffering a disproportionately high incident rate [10].  
 
 
 
 
Figure 1.9 – World Age Standardised Incident Rates for Cervical Cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9 – World age standardised incident rates for cervical cancer. Approximately 80% of the 
estimated 529,409 new cervical cancer cases (2008) occurred in developing nations (ASR, Age 
standardised incident rate per 100,000 women. Figure from [1]) 
 
 
It is estimated that in Europe, with a population of 321.8 million women at risk of HPV 
infection, approximately 6.6% of women within the general population are estimated to harbour 
HPV infections. This results in approximately 59,931 new cases of cervical cancer annually and 
29,812 deaths, making cervical cancer the 7th most frequent cancer of women in Europe. In 
contrast to this, approximately 24.9% of African women in the general population are estimated to 
harbour HPV infections. With a population of 267.9 million women at risk of cervical cancer, there 
are an estimated 78,897 new cases and 61,671 deaths each year making cervical cancer the most 
frequent cancer of women in Africa [10]. 
This disparity in cervical cancer incident rates between developed and developing nations 
is partly related to the heavy burden of HIV infection, particularly in Africa, and the lack of effective 
cervical screening programmes. 
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1.4.1. HPV and HIV in Developing countries 
 
By the end of 2008, there were an estimated 33.4 million people living with Human 
Immunodeficiency Virus (HIV). Of these infections, 22.4 million were living in sub-Saharan Africa 
(Figure 1.10,), representing ~67% of all HIV infections worldwide, 68% of all new HIV infections 
worldwide and 91% of all new HIV infections among children. These infections accounted for 72% 
of all World AIDS-related deaths in 2008 [1]. 
 
 
Figure 1.10 – Global Prevalence of HIV infection 
 
 
Figure 1.10 – Global prevalence of HIV infection, 2008 (Figure from [1]). 
 
 
Interestingly, HIV infection amongst women and girls in sub-Saharan Africa is still 
disproportionately high, with female HIV infections accounting for 60% of the total cases in the 
region (UNAIDS/ WHO AIDS Epidemic Update, 2009; (Full Report available online 
ttp://www.unaids.org/en/dataanalysis/epidemiology/2009aidsepidemicupdate/).  
As a consequence of HIV-induced immunosuppression, opportunistic infections such as 
Human Herpesvirus 8 (HHV8) are now common. This in turn leads to the development of Kaposi’s 
Sarcoma (KS) which is now a defining marker of HIV infection [116]. Squamous cell carcinoma was 
classified as an AIDS-defining illness in 1993 based on evidence of an increased prevalence of 
cervical cancer in HIV-positive women [117]. Women with HIV demonstrate an overall higher 
prevalence of HPV infection when compared to HIV negative women [118]. Furthermore, they 
demonstrate infections with both a broader range of HPV types and also an increased prevalence 
of co-infection with multiple HPV types when compared to the general population [118, 119]. 
Interestingly, HPV-16 was less commonly associated high grade CIN lesions when compared to 
women in the general population [118, 120], a finding which will undoubtedly limit the effectiveness 
of either of the currently available vaccines, should they be introduced into the region (See Section 
1.6). 
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 As stated previously, persistent infection with a high-risk HPV type is associated with an 
increased risk of disease progression [28]. It has been demonstrated that HIV positive women have 
a higher risk of persistent infection than HIV negative women, regardless of the high-risk HPV type, 
and hence, have an increased risk of early CIN-type lesions progressing to cervical cancer [118, 
121]. Indeed, women with HIV infection have been shown to have a five-fold increased risk of 
developing cervical cancer when compared to HIV negative women in the general population [122].  
  
 
1.4.1.1. Effects of Highly Active Antiretroviral Therapy (HAART) on HIV and HPV 
 
The ‘Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and 
Adolescents report 2011’ has been used for information regarding HAART (available online from 
http://www.aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf). In the absence of an effective 
cure and/or vaccine targeting HIV infection, the specific aims for Highly Active Antiretroviral 
Therapy (HAART) are to (i) reduce HIV-associated morbidity and prolong the duration/ quality of 
survival, (ii) restore and preserve immunological function, (iii) maximally and durably suppress 
plasma HIV viral load and (iv) to prevent HIV transmission. Currently there are 20 approved 
antiretroviral drugs for HIV management, from 6 mechanistic classes: 
 
• Nucleoside/Nucleotide Reverse Transcriptase inhibitors (NRTIs) 
• Non-Nucleoside Reverse Transcriptase inhibitors (NNRTIs) 
• Protease Inhibitors (PIs) 
• Fusion Inhibitors (FIs) 
• CCR5 Antagonists 
• Integrase strand transfer inhibitors (INSTIs) 
 
HAART takes the form of combined therapy, utilising drugs from a range of these 
mechanistic classes with the aim of achieving long lasting suppression of viral load which leads to 
restoration of host immunity. However, the exact components of the HAART regime can vary 
dramatically depending on factors such as previous HAART treatments used which may generate 
drug resistance, pregnancy status, drug-drug interactions with other treatments, HAART-
associated adverse effects, patient adherence and convenience. 
 
Lopinavir is a highly potent and specific peptidomimetic inhibitor of the HIV-1 protease, 
which is an homodimeric aspartic protease involved in the post-translational processing of the HIV 
gag-pol polyprotein [123]. This is an essential step in the maturation process of infectious HIV 
particles and HIV PIs prevent the cleavage of gag and gag-pol  polyproteins, arresting maturation 
thereby blocking the infectivity of nascent virions [123]. Therefore, the main antiviral mechanism of 
HIV PIs is to prevent further infection of susceptible cells. Indeed, these compounds possess no 
antiviral effects against cells in which HIV proviral DNA has integrated into the host genome [123].  
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Derived from the PI drug ritonavir, lopinavir (Figure 1.11) overcomes the problems of HIV 
drug-resistance commonly associated with ritonavir-based therapy [124] although there are 
limitations to its use; Lopinavir demonstrates poor bioavailability and undergoes extensive and 
rapid oxidative hepatic metabolism regulated by the Cytochrome P450 3A4 isozyme [125]. This 
results in a short elimination half life, effectively prohibiting the use of lopinavir as a single agent in 
HAART regimes [123].  
 
 
 
Figure 1.11 – Chemical structure of lopinavir and ritonavir 
 
 
 
Figure 1.11 - Chemical structures of lopinavir, C37H48N4O5 (left) and ritonavir, C37H48N6O5S2, (right) 
which are the main components of Kaletra, mixed in a 4:1 ratio. (Images taken from 
http://pubchem.ncbi.nlm.nih.gov). 
 
 
 
 
To circumvent this problem, lopinavir is now routinely co-administered with a sub-
therapeutic dose of ritonavir, a potent inhibitor of the Cytochrome P450 3A4 isozyme, which inhibits 
the metabolism of lopinavir resulting in an enhancement of its pharmacokinetic properties [126, 
127]. This formulation, marketed as Kaletra®, is prepared in a ratio of 4:1 (lopinavir:ritonavir), and 
is available in tablet and soft gel capsule forms (reviewed in [128]), but also as an oral solution 
containing 42.4% alcohol (v/v) (Kaletra® data sheet available from 
http://www.rxabbott.com/pdf/kaletratabpi.pdf). 
Whilst initially designed as an HIV-specific antiretroviral, previous work has demonstrated 
an off-target ability of lopinavir to inhibit the 26S proteasome [129, 130]. More importantly it was 
demonstrated that selective inhibition of the 26S proteasome in HPV positive cervical carcinoma 
cells lead to a stabilisation of the p53 protein [131]. 
 [42] 
 
Following the introduction of HAART the incidence of HIV-related KS fell dramatically in 
high-resource countries [132]. It was anticipated that the restoration of the host immune system 
would also result in improved clearance of HPV infection leading to a reduction in persistent 
infections which would ultimately result in a reduction in HPV-related cervical cancer [132]. 
Disappointingly, whilst subsequent studies went on to demonstrate potential regression of HPV-
related CIN lesions in HIV positive women receiving HAART [133-135]  it was also demonstrated 
that there were no improvements in cervical carcinoma incidence levels over the same time period 
[136-139].  
Prior to the introduction of HAART, the lack of cervical screening programmes for HIV 
positive women in developing countries had little impact on life expectancy due to the competing 
mortality associated with other causes [140]. However, the restoration of the host immune system 
following the introduction of HAART, has lead to a significant reduction in the morbidity and 
mortality associated with HIV infection [141]. As a consequence, the average life-expectancy of 
HIV positive individuals has also increased  hence increasing the opportunity for persistent HPV 
infections to progress to carcinoma over time [142]. Therefore, prevention of carcinoma in HIV 
positive women receiving HAART through cytology screening is essential [140]. 
  
 
1.4.2. National Health Service Cervical Screening Program (NHSCSP) and lack of 
screening in developing countries 
 
Globally, the malignant burden attributable to HPV infection is estimated to be 3.7% of all 
cancers [143] representing a significant proportion of cancers that are, in theory, entirely 
preventable. The mean age for diagnosis of cervical cancer is 52 years of age, however CIN-I type 
lesions are generally observed in younger women [144, 145] indicating that the progression from 
CIN to malignancy may take several years. Clearly, this provides a window of opportunity to 
intervene in the development of HPV-related malignancies. 
The purpose of the National Health Service Cervical Screening Program (NHSCSP) is to 
reduce cervical cancer incidence and mortality. The Cervical screening program does not aim to 
detect cervical cancer, instead it aims to reduce the burden of HPV-related malignancy through 
early detection and eradication of premalignant CIN-type precursor lesions [146]. An automated 
and systematic cervical screening program was introduced in England in 1988 (reviewed in [146]) 
wherein all women between the ages of 25-64 are now invited for gynaecological examination - 
every 3 years between the ages of 25-49 and every 5 years between the ages of 50-64. Exfoliated 
cell are collected around the neck of the cervix, the cervical transformation zone, and analysed by 
cytologists for signs of cellular atypia (Figure 1.3). Introduced in 2006, exfoliative Liquid Based 
Cytology (LBC) has now largely replaced the traditional Papanicolaou (‘pap smear’) method of cell 
collection. The main improvement being a major reduction in inadequate sample collection, along 
with an increased rate of sample throughput and an increased rate of detection of histologically 
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high grade CIN lesions (The Cervical Screening Programme 2009-10 report, 
http://www.cancerscreening.nhs.uk/cervical/statistics.html) [146, 147].  
The NSHCSP has proven itself to be highly effective - since its inception, there has been 
an increase in screening coverage from 40% to over 80% of women in the target age group (25-
64), which has seen a 50% reduction in invasive cervical cancer incidence and mortality in the 
United Kingdom [146, 148]. 
 Whilst clearly effective in developed countries there are however considerable barriers to 
setting up efficient cytology-based screening programs in developing countries [149]. Sub-Saharan 
Africa, in particular, suffers from widespread poverty: only 41% of the total population has access 
to safe drinking water, and only 26% have access to sanitation [149]. This widespread poverty is 
reflected in the poor availability of facilities for screening or treatment; for example, as of 2006, 
Malawi, with a cervical cancer incident rate of 47/10,000 women, had one pathologist, one 
colposcope and no trained cytologists, a situation representative of many sub-Saharan countries 
[149]. Where they exist, primary health care facilities, where screening would take place, are often 
under-resourced, under-staffed and over-burdened and unable to offer effective screening [149].  
 
 
1.5.  Current Surgical Strategies for the management of HPV-related malignancy 
 
Regardless of geographical location, socio-economic status or screening procedure, the 
treatment approach following detection of pre-cancerous cervical lesions remains the same – 
excisional or ablative removal of pre-cancerous cells from the cervical transformation zone [150]. 
While locally destructive/ ablative techniques such as radical diathermy and laser vaporisation are 
effective, excisional removal of the entire cervical transformation zone is preferred [150]. As 
approximately 60-70% of histologically abnormal cases will revert to normal over time surgical 
treatment of CIN-1 type lesions is generally not advocated. Clinical guidelines recommend an 
observational follow-up approach based on repeat screening visits [150]. For more advanced CIN 
lesions, there are a number of techniques for the complete removal of the cervical transformation 
zone [150]: 
• Large Loop Excision of Transformation Zone (LLETZ) 
• Cold Knife Conisation 
• Laser excision 
• Needle Excision of Transformation Zone (NETZ) 
 
While surgery remains the treatment of choice for mid/high grade cervical lesions, the surgical 
techniques employed are evolving and the preservation of obstetric function is now paramount 
[151, 152].  
Women treated for high grade cervical lesions require extensive post-surgical cervical cytology 
screening, which usually takes place at 6, 12 and 24 months followed by annual cytological 
screening for a further 5 years [150]. However surgical intervention for HIV-positive women is 
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known to be less effective and, despite follow up screening, CIN recurrence rates in these women 
are much higher than in HIV-negative women [153]. Alongside this it has also been demonstrated 
that surgical intervention for CIN in HIV-positive women can result in an extensive (10,000-fold) 
increase in HIV titre in vaginal secretions, clearly increasing the risk of HIV transmission [154, 155]. 
Interestingly, it has recently been demonstrated that HPV infection actually increases the risk of 
HIV infection [156]. 
 
 
 
1.6. HPV Vaccination – Developed versus Developing countries 
 
It is known that approximately 70% of cervical cancers are attributed to infection with HPV 
types 16 & 18 [10], therefore prophylactic vaccination against these specific high-risk HPV types 
has the potential to significantly reduce HPV-related cervical malignancy.  
There has been extensive research into HPV-specific vaccines based on an early observation 
that the antibody response to papillomavirus infection is in the form of a serum neutralising 
antibody against the major capsid protein, L1 [157, 158]. The viral life cycle is entirely dependent 
on differentiating epithelia, and as a result, HPV cannot be grown in bulk in cell culture, precluding 
the use of inactive/ attenuated virus vaccines [148]. As a result, HPV vaccines are subunit 
vaccines, composed of L1 protein self-assembled into a virus-like particle (VLP) [148] - essentially 
an empty capsid that is geometrically and antigenically identical to native virions [158]. The VLPs 
generate serum neutralising antibodies, yet contain no DNA and are therefore non-infectious [148]. 
To date, two HPV vaccines have been developed: Gardasil™, developed by Merck Vaccines 
(Merck and Co Inc, Whitehouse Station, NJ,USA) is a quadrivalant vaccine targeting HPV types 16, 
18, 6 & 11, whilst Cervarix™ developed by GlaxoSmithKline Biologicals (Rixensart, Belgium) is a 
bivalent vaccine targeting HPV types 16 & 18. Both vaccines are almost 100% effective in the 
prevention of incident and persistent HPV infection (against HPV types covered by the vaccine in 
use) [159-162], however Cervarix™ was eventually licensed for use as a prophylactic vaccination 
in the European Union in 2007  (www.ema.europa.eu/humandocs/Humans/EPAR/cervarix/cervarix.htm). 
 In the U.K, a nationwide school-based vaccination scheme was introduced in 2008. Aiming 
to vaccinate girls prior to sexual debut, girls aged 12-13 years old were initially invited for 
vaccination with a follow up program for girls up to 18 years of age [163]. By maintaining 80% 
coverage, it is predicted that in time there will be a 63% reduction in invasive cancer, a 51% 
reduction in CIN-3 type lesions, and a 27% reduction in cytological abnormalities in women before 
the age of 30 [163]. However, while effective, vaccination programmes would need to achieve 
cervical cancer prevention rates of 85-90% before the pre-existing cervical screening procedures 
could be discontinued [148] and are therefore not considered a replacement. 
 Whilst initial results regarding vaccination in developed countries are encouraging, the 
economic barriers that prevent an effective cervical screening program will again limit the success 
of any vaccination scheme in developing countries. The current Cervarix™-based vaccination 
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regime follows a three-dose schedule, with doses at 0, 1 and 6 months, at a current cost of 
$120/dose [164]. Regardless of the lack of infrastructure required to implement a vaccination 
scheme, the cost of vaccine alone is clearly prohibitively expensive for developing countries. It is 
estimated that for developing countries, where extreme poverty is common, that the ‘per dose’ cost 
would need to be as low as $1 to $2 to make vaccination a financially viable option [165]. 
Economic restrictions aside, it is currently unknown whether L1-based vaccines will be 
efficacious in immunocompromised/HIV positive women. With limited access to antiretrovirals there 
are concerns over safety, immunogenicity and the ability of the vaccine to induce an effective and 
meaningful immune memory in these individuals [158].  
It is thought that for every five year delay in implementing a vaccination program in 
developing countries there will be an additional 1,500,000 – 2,000,000 deaths as a result of HPV-
related malignancy [165]. For the foreseeable future, HPV vaccination in low-resource nations will 
not be a financially viable option. In light of this, and in combination with the reduced efficacy of 
surgical intervention in HIV-positive women, who form a large proportion of the HPV/CIN affected 
women in developing countries, it is clear that research into alternative therapies for HPV infection 
is important. 
 
 
1.7. Future Therapeutic Strategies 
 
1.7.1. Emerging Strategies for Cervical Cancer Management 
 
Despite significant improvements in the understanding of the molecular biology of HPV and 
its role in cervical malignancy, the mortality rates, particularly in low-resource countries remains 
high. Whilst HPV vaccination is expected to play a key role in reducing the burden of HPV-related 
malignancy, the true impact will not be observed for many years [166]. Thus, it is thought that the 
greatest chances to reduce the HPV burden will centre on primary prevention through improved 
screening techniques and the restriction of the spread of HPV [166]. The recent/ on-going 
investigations are detailed in Table 1.2 and extensively reviewed in [166]. 
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Table 1.2 Current research patents relating to HPV therapy 
Patent Number Invention Mechanism of Action
US20080171051 c-FLIP inhibitor Enhances cytotoxicity of Chemotherapy 
US20080113340 Biomarkers Target therapy
US20080187513 Angeloyl substituted ingenanes
Induce primary necrosis; activate the immune 
system
US20080286781 Biomarkers Target therapy
US20080213220 Viral vectors Target cancer cells
WO2008104804 Biomarkers Target therapy
US20080260729 VEGF-B antagonist Target therapy
US20070269407 Interleukin-19 Activate the immune system
US20070166328 Alphavirus vectors Activate the immune system
US20060029613 Metabolically active yeast cells Retard tumor growth; prolong survival
US20060039919 Fusion protein Activate the immune system
US20046825226 Adamantly derivates Induce apoptosis of cancer cells
US20030161811  IL-20 Activate the immune system
 
(Table adapted from [166]). 
 
 
1.7.2. Repositioning of Existing Drugs for Novel Uses – The Antitumour effects of 
Antiretroviral therapy 
 
The development of a new drug can be an extremely lengthy and costly procedure. For 
example, the time from initial research through to launch and post-marketing safety surveillance, 
can be as long as 15 years and cost ≥ $900 million. As a consequence, the repositioning of an 
existing drug for novel purposes is an attractive alternative. Indeed, Sir James W. Black, 
pharmacologist and 1988 Nobel Laureate in medicine, once said “The most fruitful basis for the 
discovery of a new drug is to start with an old drug”. There are clear advantages to the 
repositioning of an existing drug, namely an implicit understanding of its proposed mode of action, 
an understanding of its pharmacokinetic, metabolic and toxicity profile along with an understanding 
of drug-drug interactions [167]. Perhaps the most relevant example of the repositioning of an 
existing drug for a novel use is that of zidovudine (azidothymidine). Originally designed as an anti-
cancer agent, its use as a monotherapy in a clinical setting was limited due to poor anti-cancer 
activity and unacceptable toxicity levels [167]. Designed in 1964, the ability of zidovudine to limit 
HIV growth in vitro, through inhibition of the viral reverse transcriptase, was not discovered until 
1984. In 1987 zidovudine went on to become the first pharmacological agent to be approved for the 
treatment of HIV infection [167] and is a good example of the potential successes of drug 
repositioning.  
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Drugs used in the treatment of HIV target many pathways of the HIV viral life cycle; NRTIs/ 
NNRTIs target the viral reverse transcriptase, PIs target the viral protease, whilst newer agents 
(reviewed in [168]) prevent the binding, fusion and integration of HIV within the host cell. Whilst 
both NRTI and NNRTI compounds have demonstrated limited anti-cancer activities extensive 
research has involved protease inhibitors and their potential for use as anti-cancer therapeutics 
(reviewed in [167, 169]). 
 
1.7.2.1. Protease Inhibitors as anti-cancer agents –Kaposi’s Sarcoma (KS) 
 
The regression of KS and an increase in KS-free survival has been observed in patients 
receiving HAART [170, 171]. Whilst initially attributed to the restoration of the host immune system, 
the regression of KS was, however, shown to precede both a drop in HIV titre and the restoration of 
the host immune response [167]. Furthermore, when comparing PI-based HAART regimes to 
NRTI/NNRTI-based regimes, it was noted that whilst both were associated with disease regression, 
complete disease remission was more commonly associated with PI-based regimes. Furthermore, 
relapses in KS-related disease were observed in patients switched from PI-based to NRTI/NNRTI-
based regimes indicating that the anti-cancer properties were directly related to a previously 
unknown, non-immune based mechanism(s) of HAART-PIs [167, 169].   
KS is an angio-proliferative disease characterised by angiogenesis, endothelial spindle cell 
growth (KS cells), inflammatory-cell infiltration and edema [172]. Angiogenesis is a complex 
sequential process, requiring degradation of the basement membrane by the matrix 
metalloproteinase (MMP) MMP2 (MMPs reviewed in [173]). This leads to endothelial cell migration 
and proliferation towards the site of invasion [172]. Latent MMP2 is highly expressed in both KS-
cells and endothelial cells and proteolytic activation of MMP2 is initiated by membrane type-1 MMP 
(MT1-MMP). MT1-MMP cleaves latent MMP to produce pre-MMP2 which then undergoes 
autoproteolytic cleavage mediated by αvβ3-integrin to produce functional MMP2. At physiological 
concentrations, saquinavir and ritonavir inhibit the activation of MMP2 through inhibition of MT1-
MMP and/or αvβ3-integrin [169]. Furthermore, KS lesions demonstrate increased levels of 
inflammatory cytokines such as TNF-α, IL-6, and IL-8, and also the cell adhesion molecules 
VCAM1, ICAM1 and Selectin E, which are all essential in lesion development [169, 172]. Protease 
inhibitors have been shown to inhibit the activation of monocytes, lymphocytes and endothelial 
cells, thereby limiting inflammatory cytokine production [174]. Inflammatory cytokines are further 
associated with the production of pro-angiogenic factors, including Basic Fibroblast Growth Factor 
(bFGF) and Vascular Endothelial Growth Factor (VEGF) [172]. Saquinavir and ritonavir have been 
shown to inhibit the formation of angiogenic lesions following the inoculation of pro-angiogenic 
factors in nude mice [172], as well as bFGF and VEGF-induced angiogenesis in the chicken 
chorioallantoic membrane (CAM) assay [172]. Whilst in vitro test systems demonstrated that PI 
treatment did not inhibit bFGF-induced cell proliferation, it was however, shown to completely block 
the angiogenic invasion by both bFGF-induced endothelial and KS-cell types. This was shown to 
occur at PI concentrations similar to those found in the plasma samples of patients receiving 
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HAART (0.1-1.0µM) [172]. Thus, the off-target anti-angiogenic effects associated with PI treatment 
are thought to be mediated by a combination of inhibition of VEGF and bFGF function [172], 
inhibition of MMP2 activation, and a reduction in inflammatory cytokine synthesis [169, 172, 174]. 
In addition to these anti-inflammatory, anti-angiogenic actions, perhaps more importantly, 
protease inhibitors can modulate and indeed block the function of the cellular proteasome [175]. 
HIV-1 maturation relies on proteasomally-mediated processing of the gag polyprotein, and it is now 
thought that part of the antiviral actions of HAART-PIs in HIV patients relies on inhibition of the 26S 
proteasome [176]. However, the inhibitory actions on the proteasome require drug concentrations 
above those present in sera of treated patients (5-100µM) [175]. At these elevated concentrations 
ritonavir led to a selective inhibition of intracellular protein degradation and a fully reversible arrest 
of the cell cycle in the G1/S phase [177]. It was demonstrated that these effects were a 
consequence of selective binding between ritonavir and the MB-1(X) and LMP7 subunits of the 20S 
active core of the proteasome, known to regulate chymotryptic-like activity [177]. Interestingly, 
whilst virtually eliminating the chymotryptic-like activity, ritonavir was actually shown to induce a 
modest increase in the tryptic-like activity of the proteasome [177] demonstrating the importance of 
the chymotryptic-like activity of the proteasome in regulating the G1/S transition. 
The proteasome controls several important pathways through the rapid degradation of 
damaged, abnormal or incorrectly folded proteins. The system is responsible for the tightly 
regulated control of a wide range of proteins, including those involved with transcription (reviewed 
in [49]), cell cycle progression [50, 51], IkB which regulates NFkB mediated transcription [52], 
antigen presentation [53, 54], cell surface receptors  and apoptosis [54]. Thus, the PI-mediated 
inhibition of these activities can inhibit tumour cell survival, tumour cell proliferation in association 
with limiting tumour-associated inflammation and endothelial cell activation [169]. Significantly, PI 
treatment can also sensitise tumour cells to ionising radiation and promote apoptosis [98, 178, 
179].  
 
1.7.2.2. The proteasome as a drug target 
 
The proteasome is clearly a potential target for cancer therapy. For example, in non- virally 
induced cancer, NFkB plays a key role in cancer development. NFkB is responsible for the 
transcription of several genes involved with growth, apoptosis and cell adhesion. Its activity is 
regulated by an endogenous inhibitor, IkB, which is a substrate for the cellular proteasome and 
studies have shown that NFkB promotes oncogenesis and is over expressed in malignant cells 
[130]. Inhibition of the degradation of IkB by the 26S proteasome would therefore allow for the 
binding and repression of the transcriptional activities of NFkB  with subsequent restrictions on 
abnormal cellular proliferation [130]. In virally induced cancers, such as those linked with HPV, it is 
predicted that inhibition of the proteasome could lead to an accumulation of cell cycle regulatory 
proteins, such as p53 [98] and Rb that would, otherwise be misdirected for inappropriate 
proteasomal-mediated degradation by the action of viral proteins. Following the identification of the 
tubular, multi unit structure of the 26S proteasome, selective and specific proteasome inhibitors 
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were able to be synthesised. The tripeptide aldehyde MG-132 (Carbobenzoxy-L-leucyl-L-leucyl-L-
leucinal) is able to reversibly inhibit the actions of β2 and β5 through the formation of aducts with 
the active sites on the β subunits [74]. However, due to their poor specificity, and association with 
widespread toxicity, they have limited use in vivo [180]. Following from this research, more 
selective and potent proteasome inhibitors were synthesised, best characterised by the boronic 
acid dipeptide Bortezomib, which brings about proteasome inhibition through a stable but reversible 
intermediary compound that binds to amino-threonine residues of the catalytic core region [74]. 
When compared to the relatively non-specific inhibitor MG-132, Bortezomib displays 1000 fold 
greater potency, with selectivity for the chymotrypsin-like activity of the core [74].  
Bortezomib (Velcade ® - data sheet available from 
http://www.velcade.com/Files/PDFs/VELCADE_PRESCRIBING_INFORMATION.pdf) has since 
been licensed as the first therapeutic inhibitor of the proteasome, and is now in use for the 
treatment of chronic myelagenous leukaemia, relapsed mantle cell lymphoma and a subset of B-
acute lymphoblastic leukaemias [181, 182]. 
  
 
 
 
1.7.3. Proof of Concept 
 
The development of Bortezomib has provided a ‘proof of concept’ regarding the use of 
proteasome inhibition as a means of targeted cancer therapy. However Bortezomib-induced p53 
activation has been shown to be reduced in E6-expressing LNCaP-Pro5 cells, potentially limiting 
the use of Bortezomib in targeting HPV-immortalised cells [183].  
Despite being originally developed for the specific inhibition of the HIV-1 viral protease, 
HAART-PIs have since demonstrated anti-proliferative, anti-angiogenic and anti-inflammatory 
properties, whilst promoting apoptosis and radiosensitisation mediated through inhibition of the 26S 
proteasome and MMP2. Clearly, this suggests that their use may be of benefit in non HIV-
associated tumours. Accordingly it was proposed that HAART-PIs, either as a monotherapy or in 
combination with other cytotoxic agents would be of use against tumours known to  be sensitive to 
anti-angiogenic therapy, including colon and renal cancer, and also multiple myeloma, or to prevent 
the invasion of pre-malignant diseases such as in situ carcinomas of the cervix and oral cavity 
[169].  
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1.8. Project Rationale and Aims 
 
In light of these observations it is clear that a non-surgical, preferably self-applied, 
treatment for HPV related cervical dysplasia would be extremely useful particularly in low-resource 
countries where high levels of HIV infection exacerbate the situation. 
Previous work from this laboratory investigated the ability of HIV protease inhibitors to 
combat HPV infection and demonstrated that the antiretroviral drug lopinavir could stabilise the p53 
protein and induce apoptosis of HPV positive cervical carcinoma cells in-vitro albeit at higher doses 
than those achieved by oral administration [98]. These data indicated that lopinavir could potentially 
be used as an anti HPV therapeutic. Prior to a clinical trial to test this new indication work was 
carried out in order to further characterise how lopinavir works against HPV. In this regard we have 
used Fourier Transformation Infra Red spectroscopy to analyse the metabolic changes occurring in 
lopinavir treated cervical carcinoma cells [184] and direct Raman spectroscopic imaging to identify 
the site of action of the drug in cells [185]. Evidence is provided here to further support these initial 
observations and present data on the specific molecular mechanisms by which lopinavir works 
against HPV with two specific aims:  
 
 To identify cellular proteins, in addition to p53, degraded by HPV that are stabilised in the 
presence of lopinavir 
 
 To identify potential new effectors of lopinavir that account for its anti-HPV activity and to 
fully characterise the potential mechanism(s) 
 
 
 
1.9. Conferences and Presentations 
 
This work has been presented as a poster at the 2008 National Cancer Research Institute 
conference, Birmingham, and also as a poster at the 2009 International Papillomavirus conference 
in Malmö, Sweden. 
 
This work has also been presented as an oral presentation at the 2008 Central Manchester and 
Manchester children’s university hospitals Research and Innovation meeting, and also as an oral 
presentation at the 2009 Gynaecological Visiting Society meeting, Manchester. 
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2. Chapter 2 - Does Lopinavir Inhibit the Proteasome in HPV positive cells? 
 
2.1.  Introduction 
 
Mincheva et al (1987) used in-situ hybridisation analysis of metaphase chromosomes to 
demonstrate that SiHa cervical cancer cells contain 1-2 integrated copies of HPV 16 DNA. Their 
work showed that the HPV genome persists in an integrated state, in the host chromosome 13, at 
region q21-q31 [186] making the SiHa cell particularly useful for lab based investigations into HPV.  
In order to further assess proteasomal inhibition, SiHa cells stably expressing a commercially 
available proteasome sensor vector, pZsProSensor-1 (Appendix 1, Clontech) were generated. The 
pZsProSensor-1 plasmid is a eukaryotic expression vector which expresses a naturally occurring 
green fluorescence protein (GFP) from the button polyp coral (zoanthus sp.) as a fusion complex 
coupled to a mouse ornithine decarboxylase (MODC) degradation domain  at its C-terminus region. 
Ornithine decarboxylase is a key enzyme in the synthesis of polyamines involved in cell 
proliferation  and has an extremely high turnover rate [187]. The MODC domain contains several 
PEST sequences, defined as a region rich in proline (P), glutamic acid (E), serine (S) and threonine 
(T) which are involved with the rapid degradation and turnover of many regulatory proteins [188, 
189]. MODC is degraded by the proteasome, although in contrast to other proteins, the process is 
not linked to polyubiquitination of the target protein; instead, MODC degradation is mediated by a 
polyamine induced enzyme inhibitor, antizyme, that destabilises the complex and leads to its 
degradation at the proteasome [190]. In cells containing a fully functioning proteasome, the 
GFP/MODC fusion protein is rapidly targeted for proteasomal degradation. In contrast, following 
proteasomal inhibition, the GFP accumulates within the cell to levels that can be detected by 
fluorescent microscopy or flow cytometry (Figure 2.1). 
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Figure 2.1 – Function of the pZsProSensor-1 vector in SiHa cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 – SiHa cells were engineered to stably express the pZsProSensor-1 proteasome sensor 
vector. The eukaryotic vector expresses the coral reef green fluorescent protein (GFP) coupled to a 
mouse ornithine decarboxylase degradation domain (MODC). The MODC domain targets the GFP 
for rapid proteasomal degradation. In the control DMSO treated cells (upper panel), the GFP is 
rapidly degraded at the proteasome. In contrast, the addition of lopinavir leads to inhibition of 
proteasomal function, therefore leading to an accumulation of GFP, detectable by fluorescent 
microscopy with a FITC filter. 
 
 
 
2.2.  Aims  
 
2.2.1. Transiently transfect C33A parent and C33AE6 cells with the pZsProSensor-1 
proteasome sensor vector in order to confirm its function and to allow optimisation 
of GFP detection techniques. Proteasome inhibition by lopinavir and MG-132 will 
be assessed by flow cytometric  measurement of GFP levels 
 
2.2.2. Generate stable pZsProSensor-1 transfected SiHa cells in order to assess the 
ability of lopinavir to inhibit the proteasome in an HPV positive cell line. Analysis of 
proteasome inhibition will be assessed by flow cytometry and fluorescence 
microscopy to determine GFP level 
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2.3.  Methods 
 
Details of all solutions used throughout this thesis are detailed in Appendix 2. All reagents, 
unless otherwise stated were purchased from Sigma-Aldrich (Dorset, UK) or Invitrogen (Paisley, 
UK). All PCR primers were purchased from Eurofins Genetic Services Ltd. (Ebersberg, Germany).  
 
2.3.1. General Cell Culture  
 
All cell culture was carried out using a class II biological safety cabinet (Envair, Lancashire, 
UK) and unless otherwise stated, all cells were cultured using RPMI-1640 growth medium 
(Invitrogen, Paisley, UK) supplemented with 10% foetal bovine serum (Sigma-Aldrich, Dorset, UK) 
and 2 mM L-Glutamine (Sigma-Aldrich, Dorset, UK) at 37°C in a humidified atmosphere containing 
5% CO2 (incubator from Forma Scientific, Loughborough, UK). Stocks of C33A parent, C33AE6 
[191], C33A Vector [191], SiHa cells were provided by Dr Lynne Hampson and the ATCC. C33A 
and C33AE6 have been extensively used as a model test system through which to study the 
effects of E6 in the context of HPV infection. SiHa cells were also included as previous work, on 
which this current thesis is based, investigated the effects of lopinavir in HPV positive SiHa cells, 
as they contain a fully integrated HPV genome. SiHa cells are therefore more representative of the 
intended target cell. 
 
2.3.2. Thawing Cells 
 
Cells were removed from liquid nitrogen and rapidly thawed in a 37°C water bath. A 
disposable Pasteur pipette was used to transfer cells to a culture flask containing complete RPMI-
1640 growth medium and these returned to the incubator. Twenty-four hours later the RPMI-1640 
growth medium was aspirated and replaced with fresh complete medium and cells maintained at 
37°C/ 5% CO 2. 
 
2.3.3. Sub Culture of Cells 
 
Cells were routinely passaged on reaching 80% confluency. The growth medium was 
aspirated, and cells were washed with PBS. Following this, pre-warmed trypsin/ EDTA (0.25%) 
(Invitrogen, Paisley, UK) (230 µl for T-25 culture flasks or 800µl for T-75 culture flasks) was added, 
and the flasks returned to the 37°C incubator for 3  – 4 minutes or until all cells had rounded up and 
detached. The trypsin was neutralised by addition of 10 ml complete medium before being 
transferred to a 50 ml falcon tube, and cells counted using a haemocytometer. Cells were reseeded 
at 5 x 105 cells per T-25 in a total volume of 10 ml medium, and 1 x 106 cells per T-75 in a total 
volume of 20 ml medium.  
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2.3.4. Freezing Cells 
 
At 80% confluency, cells were harvested and counted as detailed in section 2.3.3. These 
were then pelleted by centrifugation at 528 x g for 5 min using a Sigma Aldrich 1-14 bench top 
microfuge (Sigma Aldrich, Dorset, UK). Following centrifugation, the growth medium was aspirated 
and the cell pellet was thoroughly resuspended in freezing medium (10% DMSO in FBS) at a 
concentration of 1 x 106/ml in labelled cryovials (Nunc, Roskilde, Denmark). Cryovials were 
transferred to an isopropanol gradient freezing pot (Nalgene, Roskilde, Denmark), and placed at -
80°C overnight before being transferred to liquid n itrogen for long term storage. 
 
2.3.5. Drug Preparations 
 
Lopinavir was provided as a kind gift by Abbott Laboratories (Park Road, Abbott Park, IL 
60064-6187, USA). A 20 mM working stock solution of lopinavir was prepared in DMSO (Sigma-
Aldrich, Dorset, UK). MG-132 (Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal) was purchased from 
(Calbiochem, Nottingham, UK) and a 10 mM working stock solution was prepared in DMSO. 
 
 
2.3.6. Preparation of Competent XL-1 Blue E.coli 
 
An LB agar plate was streaked with 10 µl of the XL-1 Blue strain of Escherichia coli 
(Stratagene, CA, USA) before being incubated overnight at 37°C. A single colony was picked and 
used to inoculate a 5 ml volume of Luria-Bertani (LB) medium without antibiotics, and left overnight 
at 37°C with gentle shaking. The 5 ml starter cultu re was then added to 250 ml LB containing 20 
mM MgSO4 and grown at 37°C to an optical density of between  OD600 0.4 - 0.6. At this point, the 
culture was put on ice for 10 min, with all solutions, pipette tips, eppendorf tubes and falcons also 
placed on ice. The culture was split into 5 x 50 ml falcon tubes and the cells were pelleted by 
centrifugation at 1646 x g for 5 min at 4°C. The su pernatant was discarded and the cells in each 
falcon were resuspended in 2 ml of TFB-1 buffer using a Pasteur pipette. Once resuspended, the 
resulting solutions were pooled into a single 50 ml falcon, and placed on ice for 30 min. This was 
then made up to a volume of 50 ml with TFB-1. All falcon tubes were left on ice for 10 min before 
centrifugation for 5 min at 1646 x g at 4°C. The su pernatant was discarded and the cells were 
gently resuspended in 5 ml TFB-2 buffer and left on ice for 30 mins. Subsequently, 50 µl of this was 
aliquoted into chilled eppendorf tubes and immediately frozen at -80°C. Control transformations 
with 100 ng of a control plasmid were carried out to confirm competency. 
 
2.3.7. Transformation of XL-1 Blue E. coli  cells 
 
Competent cells were thawed on ice and incubated with 50-100 ng of plasmid DNA on ice for 
30mins. The cells were heat shocked at 42°C for 45 sec and then returned to ice for 2 min. 
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Following this, 1 ml of pre warmed LB media was then added and the mixture incubated at 37°C for 
30 minutes with shaking (150 rpm). During this incubation, LB agar plates were prepared, with a 
negative control plate containing 100 µg/ml of carbenicillin antibiotic. Following the incubation 
period, 100 µl of the transformation mix was then plated onto one LB agar plate containing 100 
µg/ml of carbenicillin antibiotic. The remaining mix was then pelleted, and the supernatant 
aspirated and the cells resuspended in 100 µl fresh LB media which was then plated onto a 
separate LB agar plate containing 100 µg/ml of carbenicillin. Positive control plates contained 
plasmid but no antibiotic and negative control plates contained antibiotic but no plasmid. All plates 
were incubated at 37°C overnight. 
 
 
2.3.8.  Maxi Prep of pZsProSensor-1 Vector plasmid 
 
The large scale plasmid purification protocol of Sambrook et al., (1989) was used for 
plasmid purification [192]. A single colony from the plates grown in section 2.3.6 was picked and 
used to inoculate 5 ml of carbenicillin-containing LB media (100 µg/ml). This was then incubated at 
37°C for 6 hr with shaking at 150 rpm and then made  up to a total volume of 250 ml with fresh LB 
media containing carbenicillin (100 µg/ml), and incubated at 37°C overnight with shaking at 150 
rpm before being split equally between 50 ml falcon tubes and centrifuged at 1646 x g for 15 min at 
4°C. Subsequently, the supernatant was discarded an d 9 ml of solution-1 used to resuspend and 
pool all cell pellets. A small amount of lysozyme was added to the falcon, and the tube gently 
shaken and incubated for 10 mins at room temperature. Following this, 20 ml of solution-2 was 
added, and the tube gently shaken until the contents became a clear viscous and homogenous 
solution after which, 15 ml of solution-3 was added to the falcon, and the tube gently inverted for 
several minutes before placing on ice for 10 min. The mixture was then pelleted by centrifugation at 
1646 x g for 15 min at 4°C and the supernatant filt ered through several layers of gauze into a fresh 
falcon tube and 0.6 x volume isopropanol added and incubated on ice for 10 min. The falcon was 
centrifuged at 1646 x g for 15 min at room temperature and the supernatant aspirated carefully. 
The pellet and walls of the falcon were rinsed in 70% ethanol, which was discarded and the pellet 
allowed to air dry. The pellet was subsequently dissolved in 3 ml of 1 x tris-
Ethylenediamenetetraacetic acid (TE) buffer (pH 8) and 3 ml of ice cold lithium chloride added and 
the tube mixed by inversion. This was then centrifuged at 2150 x g for 10 min at 4°C, and the 
supernatant decanted into a fresh falcon tube. An equal volume of isopropanol was added and 
centrifuged at 2150 x g for 10 mins at room temperature. The isopropanol was aspirated and the 
pellet washed in 70% ethanol and allowed to air dry at room temperature. The pellet was dissolved 
in 500 µl 1 x TE buffer containing 1 µl RNAase (10 µg/ml) and transferred to an eppendorf and 
stored at room temperature for 30 min. Following this, 500 µl of polyethylene glycol (PEG)/NaCl 
was added, mixed well by inversion, and the eppendorf centrifuged at 10,625 x g for 5 mins. The 
supernatant was aspirated, and the pellet of plasmid DNA dissolved in 400 µl 1 x TE and an equal 
volume of phenol-chloroform and mixed well. The tube was centrifuged at 10,625 x g for 3 min, and 
 [56] 
 
the aqueous phase aspirated into a fresh eppendorf. To this eppendorf, 1/10th x volume of sodium 
acetate was added and mixed well and 2 x total volume of 100% ethanol added, and the tube 
stored at -20°C for 5 min. Following this, the tube  was centrifuged at 7,378 x g for 10 min after 
which, the supernatant was aspirated and 200 µl of 70% ethanol (at 4°C) added. Following a brief 
vortex, the tube was centrifuged at 10,625 x g for 2 min, after which, the supernatant was removed 
and the tube allowed to air dry at room temperature. Finally, the pellet was dissolved in 500µl 1xTE 
and stored at -20°C. 
The plasmid yield was determined by measuring the optical density (OD) at a wavelength 
of 260nm using a UV1101 photometer (WPA, Cambridge, UK) since an optical density of 1.0 
equates to 50 µg dsDNA/ml at this wavelength. 
 
 
 
2.3.9. Transient transfection with Lipofectamine-2000  
 
C33A vector cells and C33AE6 cells were grown as described (section 2.2.1) to 80% 
confluency whereupon cells were transfected using the lipofectamine-2000 method (Invitrogen, 
Paisley UK) according to the manufacturer’s instructions. Initially, a lacZ reporter plasmid, pcDNA 
3.1 V5/his was used to check transfection efficiency. In brief, for one T-25 a 7.5 µl aliquot of 
lipofectamine-2000 was mixed with 116.7 µl OptiMem (reduced serum medium, Invitrogen, Paisley 
UK), and in a separate vial, 2.5 µg pcDNA 3.1 V5/his LacZ was mixed with 116.7 µl OptiMem and 
both vials were incubated for 5 min at room temperature. The contents of both tubes were 
combined, incubated at room temperature for a further 20 min and added drop wise to the cell 
culture flasks, containing fresh medium. This was then incubated over night at 37oC/5%CO2. 
 
2.3.10. ß-Galactosidase staining 
 
Twenty-four hours post-transfection, the medium was aspirated, the cells were washed 
once in PBS and fixed with 1 ml 2% paraformaldehyde for 10 min at room temperature. ß-
Galactosidase staining solution was prepared (for 1ml of stain: 10 µl 200 mM magnesium chloride, 
10µl 400 mM potassium ferricyanide, 10 µl 400 mM potassium ferrocyanide, 50 µl 20 mg/ml X-Gal 
in 920 µl PBS. Cells were gently washed twice in PBS and 2 ml/T25 of staining solution was added 
and these incubated at 37°C for 0.5-2 h until colou r began to develop. Once staining was complete 
the staining solution was aspirated and the reaction quenched using PBS. 
 
2.3.11. Calculating transfection efficiency 
 
To calculate transfection efficiency, one hundred cells were counted in a vertical line, within 
5 random fields of view, using a Nikon Eclipse TS100 microscope. The number of blue transfected 
cells was expressed as a percentage of the total number of cells counted. 
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2.3.12. Analysis of transient transfected pZsProsensor-1  vector activity by flow 
cytometry 
 
Transient transfection of 80% confluent C33A vector and C33AE6 cells with 
pZsProSensor-1 was carried out as detailed in section 2.3.8 with Lipofectamine-2000 only treated 
cells used as a negative control. Twenty-four hours post-transfection the medium was aspirated 
and replaced with  fresh medium supplemented with 10 µM MG-132 (Calbiochem, Nottingham, UK) 
or an equal volume of DMSO (Sigma Aldrich, Dorset, UK). All flasks were incubated at 37°C/5% 
CO2 for 4 hrs, after which cells were trypsinised and counted as detailed in section 2.3.3. 1 x 106 
cells were aliquoted, pelleted by centrifugation at 528 x g for 5 min in a Beckman-GP bench top 
centrifuge (Beckman Coulter UK Ltd, High Wycombe, UK) and fixed by incubation with 2% 
paraformaldehyde (PFA) in PBS for 10 min at room temperature. Following this the cells were 
washed with PBS as above and finally resuspended in fresh PBS prior to analysis by flow 
cytometry using a Dako Cyan flow cytometry machine (Beckman Coulter UK Ltd, High Wycombe, 
UK) according to the manufacturers’ instructions for the detection of GFP. 
 
 
2.3.13. pZsProSensor-1 Vector digestion 
 
The pZsProsensor-1 vector was linearised by digestion with Apa-L1 prior to its use for 
stable transfection since this cuts within the pUC origin of the vector which is not essential for its 
function in eukaryotic cells (for the supplied vector map see Appendix 1). Ten microlitres of 
digestion buffer was added to 20 µg vector, along with 1 µl 3% BSA and 2 µl of Apa-L1 which was 
made up to 99 µl total volume using sterile distilled water. The resulting mix was then placed in a 
water bath at 37°C for 75 min, after which a furthe r 1 µl Apa-L1 added and the digestion again 
incubated for 75 min at 37°C. Agarose gel electroph oresis was carried out to confirm a successful 
digestion. 
 
 
2.3.14. Agarose Gel Electrophoresis 
 
Agarose gel electrophoresis was carried out using a thermo Minicell Primo EC320 system 
according to manufacturers’ instructions. Agarose gels were prepared in 1 x tris-acetate-EDTA (1 x 
TAE) buffer with 2 µl ethidium bromide added per 40 ml agarose gel solution. Sample loading 
buffer was added to the samples prior to loading into the wells. Appropriate 100 bp and 1 kb DNA 
ladders (New England Biolabs, Hertfordshire, UK) were separated alongside the samples which 
were separated by electrophoresis at 80 V for 30 mins. DNA bands were visualised using a UVP 
GDS 7500 Gel documentation system (Ultra violet Products Ltd., Cambridge, UK) 
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2.3.15. Post-digestion processing of plasmid 
 
An equal volume of a 50:50 solution of phenol chloroform was added to the digested 
plasmid and the eppendorf was spun at 14,462 x g for 2 min. The upper phase of the solution was 
then removed carefully to a fresh eppendorf and 1/10th of the volume recovered of 3M sodium 
acetate (pH 5.2) was added. The eppendorf was mixed by inversion. Twice the total eppendorf 
volume of ethanol was then added, and the contents mixed and stored overnight at -20°C after 
which the eppendorf was spun for 10 min at full speed. Two hundred microlitres of 80% ethanol 
was then added, and incubated for 5 min. The eppendorf was again spun at full speed for 5 min, 
before aspirating the ethanol. Washing with ethanol was repeated once more. Following the final 
spin, the ethanol was aspirated, and the eppendorf inverted and allowed to air dry. Finally, the 
pellet was dissolved in 1 x TE buffer providing a stock solution at 1 µg/µl, which was and stored at  
-20°C until future use. 
 
 
2.3.16. G-418 Kill Curve 
 
Prior to using G-418-sulphate / Genetecin® (Invitrogen Paisley UK) for selection of 
resistant cells it was necessary to identify a suitable concentration of this antibiotic that results in 
total cell death in 7-10 days. Untransfected SiHa cells were seeded at 1 x 106 cells in 5 x T-25 cell 
culture flasks in complete RPMI-1640 growth medium. Twenty-four hours later, the growth medium 
was aspirated and replaced with growth medium supplemented with G-418 at a range of 
concentrations from 200 to 1000 µg/ml. Cells were maintained at 37oC/5%CO2 and daily visual 
inspections carried out to assess cell growth and death over a period of 10 days. Following this, 
cells were washed, resuspended in medium minus G418 and returned to the incubator for a further 
period to monitor for signs of rebound growth of surviving cells. A G-418 concentration that resulted 
in 100% cell death in approximately 7-10 days was chosen for selection of stable transfectants. 
 
 
2.3.17. Stable transfection and single cell colony selection 
 
Stable transfection was carried out on SiHa parent cells as detailed in section 2.3.8, using 
the pZsProSensor-1 vector linearised in section 2.3.13. Twenty-four hours post-transfection the 
transfected cells were washed, trypsinised, resuspended in 10 ml medium, as detailed in section 
2.3.3, and counted. In order to facilitate single colony isolation, transfected cells were seeded in 9 
cm dishes at range of concentrations from 0.25 -10 x 105 in a total volume of 15 ml fresh medium. 
These were incubated overnight then the growth medium was replaced with 15 ml fresh medium 
supplemented with 500 µg/ml G-418 solution. The cells were monitored over a period of several 
weeks with a G-418 selection medium change every 2-3 days. Over dense plates were discarded 
as single colonies could not be discriminated. 
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Once single celled colonies had expanded to contain approximately 20-30 cells, they were 
transferred to a 96-well plate. In order to do this, the growth medium was aspirated and the cells 
were washed in PBS. For colony picking, sterile loops were prepared by cutting the lower rim of a 
yellow tip and autoclaving. The lower rim of a sterile hoop was coated in sterile Vaseline and gently 
placed over the colony, a process which was repeated for each colony to be picked. Subsequently, 
30 µl of trypsin was added into the sterile hoop and the dish incubated at 37°C for 2 min, or until 
complete cell rounding had occurred. Once cells had fully detached they were resuspended in 50 
µl RPMI-1640, transferred to a 96-well plate, and made up to a total volume of 200 µl. This was 
repeated for each colony to be picked, with each colony transferred to a separate well of the 96-
well plate. Twenty-four hours later, the growth medium was aspirated from the 96-well plate and 
replaced with 200 µl medium supplemented with G-418. Cells were expanded before being 
trypsinised and transferred from 96-well plate to 24-well plates and eventually to 6-well plates with 
changes of selection medium every 2-3 days. 
Cells were eventually transferred to T-25 culture flasks and grown to 80% confluency 
whereupon stocks of cells were frozen as detailed in section 2.3.4. In total, 4 colonies were 
successfully picked and expanded to T-25 culture flasks. These colonies were labelled A4, A5, A7 
and C5. 
 
 
2.3.18. Assessment of lopinavir and proteasome inhibition of stable transfected 
pZsProsensor-1 cells 
 
2.3.18.1. Fluorescent Microscopy 
 
Stable pZsProsensor-1 transfected SiHa cells (SiHa-PSV) were seeded in duplicate wells 
of an 8-well slide flask (BD Biosciences, Bedford, UK) at a concentration of 2 x 104 cells/well in a 
total volume of 500 µl of growth medium and maintained overnight at 37oC/5%CO2. Following this 
the medium was replaced with 500 µl G418 selection medium and the cells allowed to attain 80% 
confluency. The medium was then replaced with fresh medium supplemented with either 10 µM 
MG-132 (Merck (Calbiochem), Nottingham, UK) or 25 µM lopinavir and incubated at 37oC/5%CO2 
for 4 and 6 hours respectively. Duplicate wells were treated with an equivalent volume of DMSO as 
a control. Cells were washed in PBS, treated with 2% paraformaldehyde (PFA) for 10 min, re-
washed with PBS and stained with 40 µl 0.5 µg/ml Hoechst  3345 (Sigma-Aldrich, Dorset, UK) for 
10mins at room temperature. The cells were rinsed with PBS, the cover slip mounted and the GFP 
fluorescence visualised using an FITC filter on an Olympus Heinrich widefield microscope 
(Olympus, Essex, UK) using the Metavue software package. 
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2.3.18.2. Reverse Transcriptase Polymerase Chain reaction 
 
All RT-PCR work was carried out using an Applied Biosystems - GeneAmp PCR System 
2700 (Applied Biosystems, California, USA). Stable pZsProSensor-1transfected SiHa cells were 
thawed as detailed in section 2.3.2 and grown to a confluency of 80%, at which point they were 
harvested and counted as detailed in section 2.3.3, and 1 x 105 cells transferred to sterile 
eppendorf and spun at 528 x g for 5 min. Following this, the supernatant was aspirated and PBS 
used to wash the cells. Cells were pelleted with one final centrifugation at 528 x g, and the PBS 
aspirated, allowing the pellet to air dry 
A master mix of resuspension buffer (Invitrogen, Paisley, UK) and lysis enhancer solution 
(Invitrogen, Paisley, UK) was prepared at a ratio of 1:9 and 50 µl was used to thoroughly 
resuspend the cell pellet. This was then transferred to a PCR tube which was heated to 75°C for 20 
min, followed by 5 min at 85°C. A DNAse treatment m aster mix was also prepared containing 7 µl 1 
x DNAse (Ambion, Warrington, UK) combined with 2 µl 10 x DNAse buffer (Ambion, Warrington, 
UK). Subsequently, 9 µl of the DNAse treatment master mix was combined with 11 µl of the RNA 
sample and this incubated at 37°C for 90 min follow ed by 5 min at 75°C. The remaining RNA 
sample was stored at -80°C for future use. Reverse transcription (RT) master mix (A) was prepared 
which contained 6 µl dNTP mix (Roche, West Sussex, UK) and 9 µl random decamer mix. A 5 µl 
volume of this was added to the DNAse-treated RNA sample which was heated to 70°C for 3 min 
and then placed on ice for 3 mins. Prior to the RT step, 5 µl of this sample was removed and mixed 
with 5 µl sdH2O to act as an RT negative control. For the RT step, master mix (B) was prepared 
which contained 7 µl 5 x RT buffer, 7 µl sdH20, 0.5 µl of RTase and 0.5 µl RTase inhibitor and 15 µl 
of this was then added to the sample tube. The RT step was carried out by heating to 42°C for 60 
min followed by 10 min at 70°C. The final cDNA samp le volume of 35 µl was then stored at -20°C 
for future use. All RT reagents were purchased from Bioline, London, UK.  
The PCR step was carried out using a master mix containing 10µl Biomix red (Bioline, 
London, UK), and 0.5 µl of pZsProSensor-1 specific forward and reverse primer (from 20pmol stock 
solutions), detailed in (Appendix 3), and 1 µl cDNA sample in a total reaction volume of 20µl. 
Thermal cycle parameters are detailed in Appendix 3. Agarose gel electrophoresis was used to 
visualise PCR products, as described in section 2.3.14.  
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2.4. Results 
 
2.4.1. Transient transfection of C33A vector and C33AE6 cells with pZsProSensor-1 
vector 
 
The results of the ß-Galactosidase staining (section 2.3.10) of pcDNA 3.1V5/His LacZ 
transfected C33A vector and E6 cells is shown in Figure 2.2. It demonstrates equivalent levels of 
transfection between cell types (Representative Figures are shown). Figure 2.3 shows the results 
from the flow cytometry analysis of pZsProSensor-1 transfected C33A vector and E6 cells following 
MG-132 treatment. Each data set was repeated in triplicate. Mean values, standard deviations and 
p values were calculated in Microsoft Excel, and a p value below 0.05 was considered significant. 
 
Figure 2.2 - Transient transfection of C33A vector and C33AE6 cells with 
pZsProSensor-1 vector – B-Galactosidase staining 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 - In order to confirm transfection efficiency C33A vector and C33AE6 cells were 
transiently transfected using a lacZ expressing plasmid (pcDNA 3.1 V5/his LacZ). Twenty-four 
hours following transfection, cells were fixed and stained for ß-Galactosidase activity. ß-
Galactosidase staining was similar in vector and E6 cells. Representative images from several 
fields of view. 
 
 
 
 
Mean values for each cell type are shown below in Figure 2.3. Untransfected cells, as 
expected, produced only minimal background interference. Both C33A vector and C33AE6 
pZsProSensor-1 transfected cells demonstrated an increase in GFP signal, however as these cells 
contain an active proteasome, the newly synthesised GFP was rapidly targeted for proteasomally 
mediated degradation. In contrast, the levels of GFP in pZsProSensor-1 transfected C33A vector 
and C33AE6 cells were significantly elevated following MG-132 treatment, when compared to 
corresponding pZsProSensor-1 transfected untreated cells (p<0.01 for both C33A vector and 
C33AE6 cells). 
 
 
C33A E6 C33A Vect
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Figure 2.3 Flow cytometry analysis of pZsProSensor-1 transiently transfected C33A vector 
and E6 cells 
 
 
 
 
 
Figure 2.3 - C33A vector and C33AE6 cells were transiently transfected with pZsProSensor-1. 
Duplicate samples of C33A vector and E6 cells were treated with MG-132 for 4hrs at 10µM after 
which, cells were harvested and counted. 1 x 106 cells were fixed and processed for flow cytometry 
analysis. Green fluorescence protein levels were measured and expressed as a percentage for 
each cell type, both with and without MG-132 treatment. Values shown are mean values from a 
triplicate data set from a single experiment. Standard deviations were calculated in Microsoft Excel 
2003. 
  
 
 
Interestingly, the data also demonstrated that following MG-132 treatment of pZsProSensor-1 
transfected C33A E6 cells resulted in a significantly higher GFP expression (p<0.05) than the 
corresponding C33A vector cells. 
 
 
 
2.4.2. Production of a pZsProSensor-1 stable transfected cell line 
 
2.4.2.1. Stable Transfection 
 
SiHa cells were stably transfected pZsProSensor-1 vector after this was linearised by 
digestion with Apa-L1 which cuts within the pUC origin of the vector. Successful digestion of the 
vector was confirmed by agarose gel electrophoresis, on a 1% agarose gel (section 2.3.14) as 
shown in Figure 2.4. 
pZsProsensor-1 pZsProsensor-1 
+ MG-132 
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Figure 2.4 Confirmation of Restriction Digest of pZsProSensor-1 vector using Apa-L1 
restriction enzyme 
 
 
 
 
 
 
Figure 2.4 – Successful digestion of pZsProSensor-1 was confirmed by agarose gel 
electrophoresis. Undigested vector was included for control purposes. The digested plasmid 
presented a band of the expected size, approximately 4.8kb. 
  
 
 
 
Following linearisation and stable transfection, 4 colonies (termed A4, A5, and A7 and C5) were 
successfully picked and expanded from 9 cm dishes, to T-25 culture flasks. Aliquots of each 
expanded stable cell colony were frozen for long term storage in liquid nitrogen (section 2.3.4). 
 
 
2.4.2.2. Confirmation of pZsProSensor-1 expression by fluorescent 
microscopy 
 
The results following fluorescent microscopy assessment of GFP levels are shown below 
in Figure 2.5. Of the 4 cell lines tested, both ‘C5’ and ‘A4’ cells produced detectable levels of GFP 
following proteasomal inhibition with 10 µM MG-132 treatment, indicating a functional proteasome 
sensor vector. Surprisingly, GFP was not detected in any of the remaining cell lines. 
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Figure 2.5 – Fluorescent microscopy on pZsProSensor-1 stable transfected SiHa cells 
following proteasomal inhibition with MG-132 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 –stable transfected cells were cultured to 80% confluency then treated with MG-132 at a 
final concentration of 10µM for 4hrs, before being fixed and counterstained with Hoechst 3345 
nuclear counter stain. GFP was visualised using a FITC filter on an Olympus Heinrich widefield 
microscope at the Michael Smith Building, University of Manchester. Images acquired using the 
Metavue software package. A GFP signal was observed in pZsProSensor-1 transfected SiHa 
treated with MG132 whereas the same cells without MG132 showed no signal. 
 
 
 
 
 
 
 
2.4.2.3. Confirmation of pZsProSensor-1 expression by RT-PCR 
 
 
Having used fluorescent microscopy to confirm the pZsProSensor-1 was functioning 
correctly in stable transfected SiHa cells reverse transcriptase polymerase chain reaction (RT-
PCR) analysis of stable pZsProSensor-1 transfected SiHa cells was carried out to confirm the 
integration and stable expression within the cell line (as described in section 2.3.18.2). RT-PCR 
data are shown below in Figure 2.6. 
 
 
 
 
 
 
 
 
 
 
C5 pZsProSensor-1 Transfected cell 
No Proteasome inhibition 
C5 pZsProSensor-1 Transfected cell 
10 µM/ 4hr incubation with MG-132 
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Figure 2.6 –RT-PCR analysis of pZsProSensor-1 stable transfected SiHa cells 
 
 
 
 
 
 
 
 
 
Figure 2.6 - Stable transfected cells were cultured. At 80% confluency cells were harvested and 
counted and cell pellets of 1 x 105 cells used to generate cDNA for each cell line. PCR products 
visualised with agarose gel electrophoresis and ethidium bromide staining. (A) PCR was carried 
out using pZsProSensor-1 specific primers (A4,A5,A7,C5, stable transfected cell colonies;  N, PCR 
negative control) (B) PCR was also carried out using ß-actin specific primers to confirm equal 
loading. RT negative control samples (-) were also included to rule out genomic contamination of 
cDNA samples. 
 
 
 RT-PCR confirmed the presence of pZsProSensor-1 vector within the cell lines. PCR using 
ß-Actin specific primers demonstrated the four cDNA samples were well balanced and free from 
genomic contamination (Figure 2.6(B)). PCR carried out using the pZsProSensor-1 primers 
demonstrated the presence of pZsProSenso-1 sequences within the cell line although the signal 
strength varied significantly between samples (Figure 2.6(A)). Colonies ‘A4’ and ‘A7’ produced 
markedly stronger signals than both the ‘C5’ and ‘A5’ colonies, however the C5 colony was the only 
cell line to produce easily detectable levels of GFP. 
 
 
 
 
2.4.3. pZsProSensor-1 activity, following lopinavir treatment, assessed by 
fluorescent microscopy 
 
Previous data demonstrated that the ‘C5’ colony stable transfected cell line produced high 
levels of detectable GFP following proteasome inhibition mediated by MG-132 treatment (Figure 
2.5). RT-PCR also demonstrated the presence of pZsProSenor-1 within this cell line (Figure 2.6). 
 The ability of lopinavir to inhibit the proteasome in these stably transfected HPV positive 
cell line was assessed using ‘C5’ cells. Figure 2.7 demonstrates that lopinavir leads to a substantial 
pZsProSensor-1 
A 
ß-Actin 
A4  -  A5   -    A7  -    C5    -   B 
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increase in visible GFP in pZsProSensor-1 stable transfected cell lines, when compared to both 
DMSO treated stable transfected control and MG-132 treated cells. 
 
 
 
Figure 2.7 - Fluorescent microscopy analyses of stable transfected pZsProSensor-1 
SiHa cells following lopinavir treatment 
 
 
 
 
 
Figure 2.7 – Fluorescent microscopy analysis of stable transfected SiHa cells expressing the 
proteasome sensor vector pZsProSensor-1. Cells were cultured in slide flasks to a confluency of 
80%, at which point one well was treated for 6hrs with lopinavir at a final concentration of 25µM. 
The control cells were treated with an equal volume of DMSO. Cells were fixed and stained with a 
nuclear counterstain. GFP was visualised using a FITC filter on an Olympus Heinrich widefield 
microscope. Lopinavir treated cells demonstrated extremely high levels of GFP when compared to 
untreated transfected control cells. 
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2.5.  Chapter Summary and Discussion  
 
MG-132 is a potent (Ki = 4 nM) reversible, and cell-permeable proteasome inhibitor. However, 
although potent, MG-132 lacks specificity and it is known that wide spread non-specific proteasome 
inhibition is toxic in both in vitro [98] and in vitro settings [193] clearly limiting the potential clinical 
use of MG-132 outside laboratory test systems. In contrast, previous work has demonstrated the 
ability of lopinavir to selectively inhibit the human cellular proteasome [129, 130]. More importantly, 
previous work carried out in this laboratory has demonstrated that lopinavir treatment of SiHa cells 
specifically inhibited the chymotrypsin-like activity of the proteasome, producing a 7% reduction in 
activity [98]. This could potentially eliminate the toxicity associated with non-specific proteasomal 
inhibitors.  
The pZsProSensor-1 proteasome sensor vector was used to further assess the ability of 
lopinavir to inhibit the proteasome in several cell lines, namely HPV negative C33A and HPV 
positive SiHa cell lines. Transient transfection of C33A vector and C33AE6 cells with the 
pZsProSensor-1 using the lipofectamine-2000 method was carried out in order to confirm the 
vector was functioning correctly. Flow cytometry analysis of transiently transfected C33A Vector 
and E6 cells demonstrated a significant increase in detectable GFP levels in both C33A vector 
(p<0.01) and C33AE6 (p<0.01) following MG-132 treatment (Figure 2.3). Surprisingly, the data also 
demonstrated that HPV E6 expressing cells produced a significant increase in detectable GFP 
following MG-132 treatment when compared to pZsProSensor-1 transfected vector cells. As 
preliminary experiments with the pZsProSensor-1 vector, this data confirmed the vector was 
functioning as expected within the cell line. 
Stable transfection using linearised vector was carried out in order to generate SiHa cells 
stably expressing the pZsProSensor-1 vector. Following RT-PCR analysis to confirm 
pZsProSensor-1 expression within cells, fluorescent microscopy on stable transfected cells 
following treatment both with MG-132 (Figure 2.5) and lopinavir (Figure 2.7) demonstrated marked 
accumulation of GFP within the cells. However, whilst fluorescence microscopy clearly 
demonstrated detectable GFP within both MG-132 and lopinavir treated cells, RT-PCR data 
generated interesting results, as can be seen in Figure 2.6. The C5 clone of pZsProSensor-1 
vector cells demonstrated a low RT-PCR signal, in contrast to both the A4 and A7 clones which 
both demonstrated high expression of pZsProSensor-1 vector, yet undetectable levels of GFP. This 
may relate to random integration-generated errors within in the pZsProSensor-1 vector or 
difficulties associated with mRNA transcript processing. Fluorescence-coding transcripts are being 
synthesised by the C5 colony cells, as evidently without these, we would not detect any GFP 
through microscopy. It may simply be that the low expression level seen for C5 colony cells in 
Figure 2.6 represents basal transcript levels. Highly efficient ribosomal processing of GFP mRNA 
transcripts would result in their limited detection. In contrast random integration events may have 
resulted in an altered mRNA transcript sequence from the remaining stable cell lines. An inability of 
a transcript to be successfully processed in the ribosome would ultimately result in failure to 
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synthesise GFP protein, as was observed with the current findings. In addition, this may also result 
in an accumulation of transcripts, as was seen in Figure 2.6.  
The consequences of targeted proteasome inhibition on the cellular protein expression profile 
of lopinavir treated HPV positive cells will be assessed in subsequent chapters. 
 
 
 
2.6.  Further work 
 
The data presented in this chapter has demonstrated that the proteasome in SiHa cells, C33A 
vector and C33AE6 is inhibited following incubation with lopinavir/MG-132 at a fixed concentration, 
as has previously been demonstrated [129-131]. This does not, however, demonstrate the dose or 
time dependent nature of the inhibition process; is the lopinavir induced inhibition of the 
proteasome a simple on/off switch? Does the proteasome function gradually degrade with an 
increasing concentration of lopinavir, or following an extended increase in incubation time? Time 
and dose dependent assays of proteasome function could be carried out, with the proteasome 
function assessed by means of flow cytometry initially. Facilities permitting, live fluorescent imaging 
of cells could also be carried out using cells treated with both an escalating lopinavir dose and also 
an increasing lopinavir incubation period, which would provide a more precise understanding of the 
exact time scale of proteasomal inhibition in SiHa cells exposed to lopinavir. 
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3. Toxicity studies – long and short term effects of lopinavir 
  
3.1.  Introduction 
 
Prior to studying the ability of lopinavir to influence the protein expression profile in HPV 
positive cells, its toxicity was assessed by two means; The effects of continuous short term 
exposure were evaluated by a colourimetric growth assay whereas the long term effects of a brief 
exposure were determined by clonogenic assay. 
 The colourimetric CellTiter 96® AQueous One Solution reagent (Promega, Southampton, UK) 
contains a tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt; MTS) and an electron coupling reagent (phenazine 
ethosulfate, PES). The MTS tetrazolium compound interacts with PES and is bio-reduced by living 
cells to produce a coloured product, formazan. The development of the formazan product is 
therefore directly proportional to the number of proliferating viable cells, and its absorbance can be 
measured at 490 nm. This assay is therefore a quick, efficient alternative to other isotope based 
cell proliferation assays, such as those utilising [3H]-Thymidine incorporation. 
The second assay, the clonogenic assay, is best defined by Nicolaas Franken et al.,(2006) as 
“an in vitro cell survival assay based on the ability of a single cell to grow into a colony. The colony 
is defined to consist of at least 50 cells. The assay essentially tests every cell in the population for 
its ability to undergo ‘unlimited division.” [194]. Consequently, the clonogenic assay is therefore an 
extremely useful tool by which to assess the ability of cells to form viable progeny following a short 
exposure to drug or treatment agent that may limit replicative potential [195]. The first use of the 
clonogenic assay was described by Puck and Marcus, in which they investigated the effects of 
ionizing radiation on the colony forming abilities of HeLa cervical cancer cells [196].  
Interestingly, this type of assay was recently used to investigate the long term effects of 
treatment with low dose cidofovir, a viral DNA polymerase inhibitor licensed for the treatment of 
cytomegalovirus infections. This drug is currently being used off-license to treat HPV related 
recurrent respiratory papillomatosis (RRP). Infection with HPV types 6 and 11 has been implicated 
in respiratory tract head and neck squamous cell carcinomas (HNSCC), specifically the 
development of squamous papillomas of the larynx, a condition known as recurrent respiratory 
papillomatosis (RRP) [197-202]. Reviewed in Stamataki et al. (2006), RRP has a bimodal age 
distribution with cases observed in adults in later life, but the more problematic cases are those that 
occur in juvenile patients (≤ 5 years of age) [203]. The current treatment of choice is surgical 
excision which aims to maintain an open airway preventing asphyxiation and also to improve 
speech, however recurrence is quite common. Repeated surgical procedures can severely affect 
quality of life in the patient as well as imposing a financial burden [203]. Surprisingly, and rather 
worryingly it was recently shown that cidofovir actually improved the survival and cell growth of 
cells expressing either low or high risk HPV E6 proteins [204]. This data clearly demonstrates the 
importance of correctly controlling dosage, treatment time and treatment interval in the 
management of RRP, and in the implementation of any prospective new drug indication. 
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3.2.  Aims 
3.2.1. Assessment of the short term toxicity of lopinavir in a range of HPV positive and 
HPV negative cell lines using colourimetric cell proliferation assays 
 
3.2.2. Assessment of the effects of lopinavir on long-term cellular replication competency 
by clonogenic cell survival assays  
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3.3.  Methods 
 
3.3.1. Cell culture of Tert cells 
 
3.3.1.1. Thawing Tert Cells 
 
Aliquots of Tert cell line were removed from liquid nitrogen and rapidly but gently thawed in 
a water bath at 37°C. Tert cells are a karyotypical ly normal telomerase-immortalised human 
keratinocyte cell line that demonstrates a down regulation in the expression levels of p16INK4a, a 
cyclin D/cdk inhibitor [205]. E6 Expressing Tert cells, generated previously [206], were also used. 
Whilst C33A and C33AE6 cells provide a model test system for assessing E6-mediated effects of 
lopinavir in cell culture, they are however, a fully transformed cell line. In contrast, parental Tert 
cells are a karyotypically normal non-transformed cell line, and are potentially more representative 
of the intended target cell; non-transformed precancerous cervical lesions. In addition, stable E6-
expressing Tert cells allow for assessment of E6-dependent effects. 
Once thawed, the cells were transferred to a 50 ml falcon tube using a Pasteur pipette. Ten 
millilitres of warmed keratinocyte serum free medium (Invitrogen, Paisley, UK) supplemented with 
100 ng epidermal growth factor (EGF) (Invitrogen, Paisley, UK), 25 µg/ml bovine pituitary extract 
(Invitrogen, Paisley, UK) and 0.3 M calcium chloride, was then added to the cell suspension drop 
wise, whilst gently mixing the cells after which these were pelleted by centrifugation at 528 x g for 5 
min. Following centrifugation the supernatant was aspirated and the pellet thoroughly resuspended 
in 10 ml complete serum free medium before being split equally between two T-75 flasks. Culture 
flasks were made up to a total volume of 20 ml with complete medium and cells were then 
incubated at 37°C in a humidified atmosphere contai ning 5% CO2.   
 
3.3.1.2. Sub culture of Tert Cells 
 
During routine passage, Tert cells were not allowed to exceed 30% confluency as they 
become difficult to detach from the culture flask surface if this occurs. At 30% confluency, the 
growth medium was aspirated and the cells washed once in PBS. Cells were trypsinised with 500 
µl trypsin, and returned to the incubator for 3-4 min to ensure complete cell detachment. Trypsin 
was neutralised and the cells were resuspended in 10 ml neutralising medium, composed of Ham 
F-12 nutrient mix (Invitrogen, Paisley, UK) supplemented with 10% bovine serum, before being 
centrifuged at 528 x g for 5 min. The supernatant was aspirated and the cell pellet resuspended in 
10 ml keratinocyte serum free medium. Cells were counted and new flasks seeded at 0.5 x 106 
cells/T-75 flask in a total volume of 20 ml. 
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3.3.1.3. Freezing Tert cells 
 
Tert cells were frozen in freezing medium consisting of a 50/50 mix of keratinocyte serum 
free medium and Ham F-12 nutrient mixture, supplemented with 10% DMSO and 10% bovine 
serum. Cells were harvested and counted as detailed above in section 3.2.1.2 before being 
pelleted by centrifugation 528 x g for 5 min and the supernatant aspirated. The cells were 
resuspended in an appropriate volume of freezing medium to provide a cell suspension at 0.5 x 106 
cells/ml, and 1ml aliquots frozen overnight at -80°C in an isopropanol freezer gradient pot, before 
being transferred to liquid nitrogen for long term storage. 
 
3.3.2. AQ-96 cell proliferation assay to assess short term toxicity of lopinavir 
 
Prior to studying the long term effects of lopinavir on cell proliferation, the short term effects 
were assessed using a range of untransfected and stable transfected cells.  Samples of SiHa, Tert 
parent, Tert vector and Tert Type 16 E6 were harvested and counted (as detailed in sections 2.3.3 
and 3.3.1.2). Cell proliferation was assessed using the AQ-96 reagent assay (Promega, 
Southampton, UK). 
Cells were seeded at 2 x 103 cells/ well in a total volume of 200 µl, in each well of a 96 well 
plate with one full 96 well plate seeded per cell type. Twenty four hours post-seeding, 20 µl of the 
AQ 96 reagent was added to the first three wells of each row in order to provide a time zero (T0) 
data point, and the plates returned to the incubator. Two hours post-incubation, absorbance at 490 
nm was measured for each triplicate using a Dynex MRX plate reader (Dynex Technologies, West 
Sussex, UK).  
Following this, the growth medium from the remaining wells was aspirated and replaced with 
200 µl RPMI-1640 supplemented with lopinavir at concentrations ranging from 5 µM to 30 µM, with 
DMSO volumes adjusted to remain constant. One full row was used for each drug concentration. 
Untreated and DMSO-only treated cells were included as controls and the plates were then 
returned to the incubator. Assessment of cell proliferation using AQ-96 reagent was repeated at 24, 
48 and 72 hrs following the addition of lopinavir. 
 
3.3.3. Effects of lopinavir on the long term survival of cells 
 
A novel 96-well based clonogenic cell survival assay [207] was used to assess the long 
term survival of cells following short term exposure to lopinavir. Parental Tert and stable HPV 16 
E6 expressing (Tert HPV T16 E6) cells were used to assess the effects of lopinavir treatment on 
their long term survival. Prior to this assay a colourimetric AQ-96 dose response growth assay (as 
described in section 3.3.2) was carried out to determine the susceptibility of all Tert cells to 
lopinavir. 
Triplicate cell culture flasks of parental Tert, Tert HPV T16 E6 cells and Tert cells stably 
transfected with empty vector were cultured for 2 or 4 days in growth medium supplemented with 
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either DMSO control or lopinavir at a concentration of 7 µM (high dose) or 5 µM (low dose) in a 
total volume of 20 ml complete serum free medium. DMSO levels were adjusted to remain 
constant. Treatment time periods were staggered so that all flasks were trypsinised harvested and 
counted simultaneously (as described in section 2.3.3). The cell suspension was diluted using 
complete serum free medium to a concentration of 15 x 103 cells/ml.  
Using a 96 well plate for each cell type, 200 µl cell suspension of untreated, low dose treated 
and high dose treated cells were each added to three wells in row A of the 96 well plate. Two 
hundred microlitres of complete serum free medium without lopinavir was added to the remaining 
wells in rows B to H. Into row B, 100 µl of cell suspension was added and thoroughly mixed. From 
row B, a 1/3 serial dilution was carried out to providing cells from concentrations of 3000 cells/well 
down to 1 cell/well in row H. Cells were returned to the incubator and allowed to proliferate at 37°C/  
5% CO2 for a further 7 days, with one change of growth medium at 72 hrs. After 7 days, viable cells 
were measured by the addition of 20 µl AQ-96 reagent to all wells and optical densities (measured 
at 490nm) were measured using a Dynex MRX plate reader (Dynex Technologies, West Sussex, 
UK) 2 hrs post-incubation.  
A visual appreciation of cell growth was obtained by toluidine blue staining (Sigma Aldrich, 
Dorset, UK). The growth medium was aspirated from all wells, and the cells gently washed once in 
PBS and stained by 10 min incubation with 200 µl toluidine blue, before being gently washed twice 
in PBS and the plates inverted and allowed to air dry. 
 
 
3.3.4. AQ-96 Cell proliferation assay of lopinavir treated E6/E7 immortalised and 
control PHFKs 
 
 
Stable E6/E7 immortalised primary human foreskin keratinocytes (PHFKs) were treated 
with lopinavir at concentrations between 5 µM and 40 µM and cell growth assessed at 72 hours by 
means of the CellTiter 96® AQueous One Solution Cell Proliferation Assay (AQ-96 assay) (Promega, 
Southampton, UK). This work was carried out in the laboratories of Professor Ingeborg Zehbe 
(Lakehead University, Thunder Bay, Ontario, Canada), and the data is provided with kind 
permission of this group (See Batman et al., 2011, accompanying Antiviral Therapy manuscript). 
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3.4.  Results 
 
3.4.1. AQ-96 cell proliferation assay to assess short term toxicity of lopinavir 
 
The effects of an escalating dose of lopinavir on the growth of SiHa cells were assessed 
initially. Figure 3.1 depicts the 72hr AQ-96 data expressed as percentage growth change (mean 
values from triplicate data points) for SiHa. Lopinavir had no noticeable effects on SiHa cell growth 
at the lower concentrations used with concentrations below 15 µM having little effect on cell growth. 
Lopinavir produced a clear dose-dependent inhibition of growth in SiHa cells at concentrations of 
15µM and above (Figure 3.1).  
 
 
Figure 3.1 – 72 hr AQ-96 Cell Proliferation assay in SiHa cells exposed to an escalating dose 
of lopinavir 
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Figure 3.1 – A 72hr cell proliferation assay was carried out using SiHa with an escalating dose of 
lopinavir. Viable cell numbers were measured at the time points indicated using AQ-96 reagent. 
Data is presented as percentage growth change based on triplicate data for each time point, based 
on a single experiment. Lopinavir produced dose-dependent growth inhibition. The growth of SiHa 
cells was unaffected at concentrations below 10µM. Data is presented in terms of percentage 
change in growth and is based on triplicate data from a single experiment. 
 
 
 
The effects of lopinavir on parental Tert cells, vector cells and Tert cells stably expressing 
the HPV T16 E6 protein (Tert-HPV 16 E6) were then assessed. The data from this set of cell 
proliferation represents triplicate data points from one assay, and is shown below in Figure 3.2. 
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Figure 3.2 – 72hr AQ-96 cell proliferation assay using Tert parent, Tert Vector and Tert 
T16E6 cells and an escalating dose of lopinavir 
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A – 72hr growth curve, lopinavir treated Tert Parent cells 
B – 72hr growth curve, lopinavir treated Tert HPV vector control cells 
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Figure 3.2 - A 72hr Cell proliferation assay was carried out using parental Tert cells (panel A) Tert 
vector cells (panel B) and Tert HPV T16 E6 cells (panel C) treated with an escalating dose of 
lopinavir. Viable cell numbers were measured at the time points indicated using AQ-96 reagent. 
Data is presented as percentage growth change based on triplicate data for each time point. In 
comparison to SiHa cells (Figure 3.1) Tert parent cells (panel A) were shown to be much more 
susceptible to lopinavir treatment, with lopinavir concentrations over 5µM inhibiting cell growth. 
Compared to Tert parent (panel A) cells, Tert vector (panel B) and Tert T16E6 (panel C) cells were 
more susceptible to lopinavir. In these cells 5µM lopinavir was shown to also inhibit cell proliferation 
over 72 hrs. Data is representative of triplicate data points from a single experiment. 
 
 
 
 
 
In comparison to SiHa cells (Figure 3.1) the full range of Tert cells (Figure 3.2 A, B & C) 
were shown to be much more susceptible to lopinavir treatment. Lopinavir concentrations as low as 
10 µM was shown to inhibit cell growth in Tert parent cells over 72 hrs. Curiously parental Tert cells 
grown in the presence of 5 µM lopinavir were shown to actually outgrow both DMSO treated control 
and untreated control cells over the 72 hr time period. Whilst this enhancement in growth was not 
shown to be significant based on triplicate data points, it was however indicative of an effect which 
should be further investigated with clonogenic assays.  
In comparison to Tert parent cells, Tert vector cells (panel B) and Tert T16E6 cells (panel 
C) were again, more susceptible to lopinavir with concentrations as low as 5 µM lopinavir also 
noticeably inhibiting cell proliferation over 72 hrs. 
 
 
 
 
C – 72hr growth curve, lopinavir treated Tert HPV T16 E6 cells 
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3.4.2. Long term survivability of Tert cells exposed to lopinavir 
 
The long term survival of cells following a brief exposure to lopinavir was assessed using a 
novel clonogenic assay as described by Donne et al., (2009) [207]. After a visual appraisal of 
toluidine blue staining, DMSO treated cells were shown to have similar growth levels at both 2 day 
and 4 day time points in matched cell lines and at matched cell numbers. Both low and high dose 
lopinavir treatment led to a relatively equal increase in the growth of Tert parent cells following 
exposure for 2 days and 4 days. Tert T16 E6 cells were shown to grow noticeably more than Tert 
parent cells at all time and lopinavir dose points. When looking at Tert T16 E6 cells (wells seeded 
with 333 cells), high dose exposure appeared to induce a greater level of cell growth than low dose 
exposure, at both treatment time points. When compared to the 2 day treatment time point, the 4 
day treatment with low dose lopinavir appeared to inhibit cell growth of Tert T16 E6 cells, when 
compared to DMSO treated control T16 E6 cells. 
Statistical analysis based on data generated by the AQ-96 assay was carried out in section 
3.3.3. 
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Figure 3.3 Toluidine blue staining of Tert parents and Tert T16 E6 cells exposed to short 
term doses of lopinavir and grown for a subsequent 7 days 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 – Tert parent and Tert T16 E6 cells were grown for either 2 (Figure 3.3 (A)) or 4 days 
(Figure 3.3 (B)) in the presence of low and high doses of lopinavir. DMSO treated cells were 
included for control purposes. Cells were harvested and re-seeded at a range of cell numbers and 
allowed to grow for a further 7 days, before being stained with toluidine blue. Images are shown for 
wells seeded with 1000, 333 and 111 cells. DMSO treated cells were shown to have similar growth 
levels at both 2day and 4day time points in both cell lines and at both cell numbers. Both low and 
high dose lopinavir treatment were shown to increase growth of Tert parent cells relatively equally 
following exposure for 2 days and 4 days. Tert T16 E6 cells were shown to grow noticeably more 
than Tert parent cells at all time and lopinavir dose points. When looking at Tert T16 E6 cells (333 
cells seeded), high dose exposure appeared to produce a greater level of cell growth than low dose 
exposure, at both time points. In the 4 day treatment data set, low dose treatment appeared to 
inhibit cell growth in Tert T16 E6 cells. 
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3.4.3. Colourimetric Clonogenic Assay – AQ-96 data 
 
The AQ-96 data is shown in Figure 3.4. Control DMSO Tert T16 E6 cells were shown to 
out grow Tert parents at all levels. In order to account for this variation in starting cell number of 
untreated control cells from each group, a one-way ANOVA was performed to find a point at which 
starting cell numbers provided similar starting densities. The vertical arrows represent the starting 
cell numbers that were optimal for analysis across both cell times and both drug treatment time 
points.  
 For each triplicate, consisting of control, low dose and high dose treated cells, a one-way 
ANOVA was performed followed by Dunnett’s post hoc test to find where, if any, significant 
differences occurred. Dunnett’s post hoc test allows comparison of each experimental test sample 
(low dose and high dose), within each group, to a nominated control group (DMSO treated control). 
P values below 0.05 were considered significant.  
Statistical analysis of the data indicates that 2 days exposure to high dose lopinavir leads 
to a significant improvement in cell survival in both Tert Parent cells (p = 0.005) and Tert type 16 
E6 cells (p = 0.016) when compared to their corresponding DMSO control cells. Low dose 
exposure failed to produce a significant increase in cell survival in either cell type regardless of 
treatment time. No statistically significant increase in cell survival was observed in either cell type 
following 4 day treatment. 
 
  
Figure 3.4 – AQ-96 assay data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 – AQ-96 Data generated from parental Tert cells and Tert T16 E6 cells exposed to lopinavir for either 2days or 4days, at either a high or low 
dose. Cells were then reseeded and allowed to grow for 7 days in lopinavir-free medium. Cell growth at 7 days was assed by means of an AQ-96 Assay. 
Data represents mean values based on triplicate data points. Mean values and standard deviations were calculated using Microsoft Excel. Based on 
statistical analysis by one-way ANOVA, vertical arrows show starting cell numbers that were optimal for comparison across all cell types and time points. 
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3.4.4. Analysis of growth in lopinavir treated E6/E7 immortalised and control 
PHFKs 
 
The data provided by the Zehbe group (Figure 3.5) demonstrated that lopinavir toxicity was 
highly selective, preferentially targeting cells immortalised by stable expression of high risk HPV 
E6/E7. At concentrations up to 25 µM E6/E7 expressing PHFKs and SiHa cells were noticeably 
more susceptible to lopinavir treatment than normal, non-transduced PHFKs, growth of which 
progressed uninhibited in contrast to E6/E7 PHFKs and SiHa cells which demonstrated clear dose-
dependent growth inhibition. Beyond 25 µM the selective toxicity of lopinavir was lost, with normal 
PHFKs now demonstrating dose dependent growth inhibition comparable to both SiHa and E6/E7 
expressing PHFK cell types. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.5 – selective toxicity of lopinavir against E6/E7 expressing immortalised primary human foreskin keratinocytes 
 
 
Figure 3.5 - E6/E7 immortalised PHFKs, normal PHFKs and SiHa cells were treated for 72 hours with lopinavir over a dose range of 5-40µM. Cell 
growth was assessed and expressed in terms of percentage growth change when compared to untreated control cells (KER, control primary human 
foreskin keratinocytes). 
 [83] 
 
3.5. Chapter Summary and Discussion 
 
Prior to assessing the consequences of short term exposure to lopinavir on the long term 
survival of cells, the short term toxicity was assessed in SiHa, Tert parent, Tert vector and Tert T16 
E6 cells. Using lopinavir over a concentration range of 5-30 µM, cell growth over a period of 72 hrs 
was assessed using the cell proliferation assays. Cell growth of parental SiHa cells (Figure 3.1) 
was unaffected at the lopinavir concentrations ≤10 µM. However at concentrations ≥15 µM 
lopinavir produced clear dose-dependent inhibition of growth over 72 hrs. Non-transformed, 
telomerase immortalised cells were noticeably more susceptible to lopinavir over 72hrs (Figure 3.2) 
with all lopinavir concentrations producing marked growth inhibition, with the one exception being 
Tert Parent cells, in which 5 µM lopinavir appeared to improve growth when compared to DMSO 
treated control cells.  
Whilst the SiHa cell line has been widely used for laboratory based studies of HPV and 
cervical carcinoma, it is a fully transformed cell line. If lopinavir is to be used to treat the pre-
cancerous immortalised cells associated with HPV-dependent cervical neoplasia, it is necessary to 
assess its effects in a cell type more representative of the intended target cell. This was carried out 
by using a combination of E6/E7 immortalised primary human foreskin keratinocyte (PHFK) cells 
and control PHFKs exposed to an escalating dose of lopinavir (5-40 µM) over a 72 hr period 
(Figure 3.5). Lopinavir showed much greater toxicity towards E6/E7 expressing cells when 
compared to control PHFKs. Whilst the growth of control PHFKs progressed uninhibited up to 
concentrations of 25 µM the growth of both E6/E7 expressing PHFKs and SiHa cells showed clear 
dose dependent inhibition. Interestingly, beyond 25 µM lopinavir the selective toxicity of lopinavir 
was lost, with control PHFKs exhibiting growth inhibition comparable to E6/E7 expressing cells. 
These data suggest that lopinavir has a relatively good therapeutic index for E6/E7 expressing 
immortalised cells when compared to mortal PHFK control cells. 
Having assessed the short term toxicity of lopinavir, the ability of cells to produce progeny 
following a short term exposure to lopinavir was assessed using the clonogenic assay detailed in 
section 3.3.2. The data showed that in both Tert parent and Tert T16 E6 cells, exposure to a high 
dose of lopinavir for a 48 hr period lead to a significant improvement in cell growth over the 
following 7 days when compared to DMSO treated control cells. Forty-eight hour low dose 
treatment had no significant effect in cell growth in either cell type. Four day treatment with high 
dose lopinavir also produced no significant change in cell growth. It is hypothesised that the 
improvement in the growth of high dose treated cells may relate to a phenomenon of lopinavir 
induced cellular quiescence which is defined as a reversible state in which cellular proliferation is 
temporarily halted [208]. The clonogenic assay assesses the ability of cells to form progeny 
following exposure to compounds that can cause persistent long-term damage so as to limit their 
replication potential [194, 196]. The clonogenic assays on lopinavir treated Tert cells demonstrated 
a significant improvement of growth only in those cells exposed to a high dose of lopinavir for a 
period of 48 hrs. One possible explanation for this may be that lopinavir has forced the cell into a 
quiescent state of growth arrest, which may reduce the chances of drug induced damage to cellular 
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machinery. Thus, in the subsequent chase period, growth then resumes unaffected. Following the 
drug treatment period, these cells out grew both control DMSO treated and low dose treated cells, 
both of which may have, in theory, accumulated damage following treatment with lopinavir at a 
concentration which failed to produce the state of quiescence observed in high dose treated cells.  
Initially it was thought that the combination of parental Tert, vector control, and HPV T16 E6 
expressing cells would constitute a model test system with which to study the interaction between 
the HPV T16 E6 protein and lopinavir. However, based on our findings, it was decided that these 
cells were not ideal. The data in Figure 3.2 initially suggested that E6 expressing Tert cells 
demonstrated an increased susceptibility to lopinavir, thus potentially suggesting an underlying E6-
mediated effect that would require further study; however, the demonstration that Tert vector cells 
also demonstrated an increased susceptibility to the drug requires explanation. This is discussed 
further in Chapter 7. 
 
 
 
 
3.6.  Further work 
 
Further work to investigate the rationale behind the improvement in cell survival and re-growth 
following lopinavir treatment could be carried out. The protein p130 has been shown to form a 
complex with the E2F transcription factor, a complex which is only found in quiescent G0 cells. This 
interaction is known to decay as cells proceed through cell cycle [209]. As there has been no 
published data linking HIV protease inhibitor treatment with cellular quiescence or p130, assays to 
measure the extent of the E2F-p130 interaction could be performed to assess the ability of high 
dose lopinavir to induce cellular quiescence. 
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4. Effect of lopinavir on Cellular Protein Levels 
 
4.1.  Introduction 
 
4.1.1. Proteomics 
 
‘The proteome’ is a phrase coined by Wilkins et al (1996) to define the full complement of 
proteins expressed within a given cell [210]. This gave rise to the new study of proteomics, which is 
the study of the protein expression pattern within a cell. More specifically, cancer proteomics is the 
study of the alterations in protein expression, or ‘protein signatures’ that are associated with cellular 
transformation and malignant progression. From a clinical point of view, proteomic analysis may 
provide clues as to the ‘protein signature’ or biomarkers associated with a given disease, which can 
therefore be translated into improved and more specific diagnostic tests [211, 212]. 
 
4.1.2. Techniques for Proteomic analysis  
 
4.1.2.1. 2D-Gel electrophoresis 
 
The first approach that allowed the cell proteome to be explored was that of comparative 
2D gel electrophoresis. Using this method, proteins are first separated based on their isoelectric 
properties by use of a tube gel [213], termed isoelectric focussing (IEF). Following separation, 
proteins are then separated at 90° by molecular mas s using a gel containing sodium dodecyl 
sulphate (SDS) and proteins are visualised either by silver staining or coomassie blue staining. As 
proteins very rarely have the same isoelectric point and molecular mass the number of proteins 
that can be separated by 2D gel electrophoresis is in theory only limited by the size of the gel [213]. 
2D gel electrophoresis is however quite cumbersome and provides no information as to the identity 
of the protein in question. 2D also have a relatively poor dynamic range, and are biased towards 
extremely large proteins [213]. 
 
4.1.2.2. Mass Spectrometry 
 
Another approach to proteomic analysis is that of mass spectrometry (MS), which can be 
coupled with liquid chromatography, LC-MS. Along with basic MS, the development of time-of-flight 
MS (TOF) and matrix assisted laser desorption ionization (MALDI-TOF) [213], greatly improved 
proteomic analysis capabilities. These techniques still rely on an initial comparative separation of 
proteins by 2D gel electrophoresis, followed by isolation and protease digestion of unique signals 
with a protease such as trypsin. From this point MS can be performed directly, or for MALDI-TOF 
analysis, proteins are immobilised within an acidic matrix which absorbs energy in the UV range 
and rapidly emits this in the thermal range. This rapid change in energy vaporises the proteins into 
the gaseous phase where they acquire a charge. The presence of an electrical charge between the 
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MALDI apparatus and the MS equipment rapidly separates proteins based on their mass to charge 
ratio.  
Whilst representing an improvement compared to either lone 2D gel or MS analysis, the 
data provided is still relatively limited in terms of protein identification. In order to identify proteins, 
the indicated mass of the analytes must then be compared to predicted product sizes based on 
previous empirical data. Another weakness of such an approach is set up costs, since MS 
equipment can be extremely expensive. 
 
4.1.2.3. DNA Arrays 
 
For several decades, DNA arrays (such as the Affymetrix genechip) have been used 
successfully to measure gene expression at the mRNA level [212]. Whilst providing a relatively 
quick, high-throughput technique, DNA arrays do have their limitations; The human genome 
contains 20-25,000 genes, which due to alternative splicing and post-translational modification, can 
give rise to 500,000 proteins [214]. As such, analysis at the mRNA level provides limited insight, 
providing only a suggested rather than defined mode of action for any given protein. Furthermore, it 
gives no clues as to sub cellular location or the presence of any interacting proteins [215] and there 
is not always a direct correlation between mRNA and protein expression levels, [216].  
 
 
4.1.2.4. Antibody Microarrays 
 
Antibody microarrays are a relatively recent technology which overcome some of the limitations 
of the preceding approaches. They are a cost effective method which allow rapid comparative 
analysis of the expression of a wide range of proteins whilst in their native state [217]. They permit 
direct effects of pharmacological treatments on the levels of a given protein to be compared to 
control untreated cells. 
Previous work has shown that lopinavir causes proteasomal inhibition and can selectively kill 
E6-dependent cervical cancer cells in vitro [98]. This work demonstrated that lopinavir induced 
inhibition of the proteasome was associated with a stabilisation of the p53 protein which is 
inappropriately targeted by HPV E6 for degradation by the proteasome. Thus, it was hypothesised 
that lopinavir treatment may also alter expression levels of a number of other cellular proteins that 
could be involved in the anti-HPV toxicity of lopinavir. 
The Panorama Xpress profiler725 antibody microarray (Sigma Aldrich, Dorset, UK) was used 
to assess the changes in the proteome between lopinavir treated and untreated SiHa cells (section 
2.1). The array contains 725 different antibodies immobilised in duplicate addresses on a 
nitrocellulose-coated glass slide. The antibodies are against proteins involved in a wide range of 
diverse biological pathways. Non-denaturing protein extracts are from the test system; in this case, 
lopinavir or DMSO treated SiHa cells. These are fluorescently labelled by use of Cy3 or Cy5 
fluorophore [218], and then incubated with the antibody array as shown in Figure 4.1. The 
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fluorescent signal associated with binding to a particular address is captured by means of a 
fluorescent scanner, and is directly proportional to the quantity of bound protein in the sample 
(Figure 4.1).  
In contrast to the Affymetrix gene chip full expression profile microarrays which require 
multiple-comparison statistical analysis, the Panorama XPRESS Profiler-725 antibody microarray 
compares protein expression levels using duplicate antibody spots, combined with a variety of 
antibodies against house keeping protein for signal normalisation. The accompanying Perkin Elmer 
ProScanArray fluorescent scanner software converts scan intensities into numerical values and 
treated versus control cell values are plotted for each protein. This analysis produces a ratio 
rendering the data semi-quantitative. More traditional protein quantitation techniques, such as 
western blotting can then be used to validate antibody array results. 
 
 
   Figure 4.1 – Antibody microarray schematic  
 
 
 
Figure 4.1 – The Panorama Xpress 725profiler antibody microarray contains 725 antibodies 
immobilised on a nitrocellulose coated glass slide. Antibodies are spotted in duplicate, and for ease 
of analysis are arranged into 32 sub-arrays, each including a positive and negative control. Protein 
lysate samples from control DMSO treated and lopinavir treated SiHa cells were labelled with either 
a Cy3 or Cy5 fluorophore before being used to immunoprobe the array slide. Fluorescently labelled 
proteins bind to their specific antibodies. The fluorophore emissions are measured by means of a 
fluorescence scanner, and are directly proportional to the amount of bound protein. The pink 
protein/antibody interaction remains constant following lopinavir treatment, and is therefore 
unaffected by lopinavir treatment. In contrast, lopinavir has caused a marked increase in the 
expression of the blue protein in this diagram. This suggests this protein may be of importance in 
explaining HPV specific toxicity of lopinavir and therefore requires further investigation. 
Control cell 
protein extracts 
Fluorescent tag 
Treated cell 
protein extracts 
Fluorescent tag 
Array slide 1 Array slide 2 
Antibodies specific for two differing proteins 
Proteins specific for two differing array antibodies 
Cy3 or Cy5 fluorescence emission 
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The Panorama Xpress profiler725 antibody array does however, also have limitations. Clearly, 
with coverage of only 725 proteins, it does not equate to the coverage offered by Affymetrix gene 
chip arrays. Furthermore, the efficiency of the antibody microarrays is wholly dependent on the 
specificity of the antibodies immobilised on the array surface, and on the quality of the array in use. 
Another problem is that fluorophore labelling efficiencies may vary between the Cy3 and Cy5 
fluorophores used to label the proteins. In order to circumvent the latter of these potential 
problems, antibody arrays are generally performed under dye swap conditions, in which samples of 
treated lysates are labelled with both Cy3 and Cy5 dyes separately and used to immunoprobe 
duplicate array slides (Dye swap schematic shown in Figure 4.2). 
 
 
 
Figure 4.2 – Normalising antibody microarray data by dye swap analysis 
 
 
 
 
 
 
Figure 4.2 – lopinavir treated lysates were labelled with both a Cy3 and Cy5 fluorophore. The same 
strategy is used to label the control protein lysate samples, and two array slides were incubated 
with opposing dye mixes. Normalising data this way prevents variations in protein/ fluorophore 
binding efficiency between Cy3 and Cy5 from adversely affecting results. The dotted arrowed lines 
represent the points of internal control: Slide 1 contains control lysates labelled with Cy5 and 
treated lysates labelled with Cy3, whilst slide 2 contains control lysates with Cy3 probe, and treated 
lysates with Cy5 fluorophore. An alteration in protein levels observed on slide 1, should also be 
observed on slide 2, if it is a true result rather than a variation due to fluorophore binding. 
 
Lopinavir Treated Lysates 
Control Lysates 
Cy5 
Cy5 Cy3 
Cy3 
Slide 1 Slide 2 
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The same labelling strategy is employed with the control protein lysates. By using this 
arrangement of sample labelling, duplicate array slides can be probed simultaneously, thus 
allowing for internal normalisation of data. This strategy is depicted in Figure 4.2. Slide 1 contains 
control lysates labelled with Cy5 and lopinavir treated lysates labelled with Cy3, whilst slide 2 
contains control lysates with Cy3 probe, and lopinavir treated lysates with Cy5. Thus, a genuine 
signal difference should be observed on both slide 1 and slide 2, whereas this will not be the case if 
it is due to a variation in fluorophore binding efficiency. 
As discussed, the main limitation of the antibody array related to the antibodies 
represented on the array. The antibodies immobilised on the Panorama Xpress profiler725 
antibody array represent only a small fraction of the proteins expressed within a eukaryotic cell. 
The proteins represented by the array are involved with a range of pathways involved with cell 
regulation, proliferation and apoptosis, proteins that could conceivably be involved with lopinavir 
induced toxicity. However, with current technology it is not possible to analyse the full proteome on 
such a platform. As such the use of this type of array should be regarded as an initial investigation 
into the proteomic effects of lopinavir. Any observed alterations in protein expression will be 
subsequently confirmed by the use of more established techniques, such as western blot analysis. 
Should lopinavir be shown to alter the expression of any proteins, bioinformatics and literature 
searches will be carried out in order to provide a clue as to which may be proteins of interest and 
may be worthy of further investigations. 
 
 
 
4.2.  Aims 
 
4.2.1. The Sigma Aldrich panorama Xpress profiler-725 protein-antibody microarray will 
be used to assess alterations in protein levels that occur in lopinavir treated cells 
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4.3. Methods 
 
4.3.1. Preparation for Panorama XPress Profiler 725 antibody microarray 
 
The panorama Xpress profiler-725 antibody array (Sigma-Aldrich, Dorset, UK) was used 
according to the manufacturers’ instructions. In brief, protease inhibitor cocktail was reconstituted 
with sdH2O and stored at room temperature. PBS/Tween-20 (pH 7.4), also supplied with the kit, 
was reconstituted using sdH2O filter sterilised using a 0.45 µm filter and stored at 4°C until use. A 
working stock of 20 mM lopinavir was made up in DMSO. Benzonase working solution was made 
up by adding 2 µl benzonase ultrapure solution to 18 µl of extraction/ labelling buffer and stored on 
ice until use. Buffer A was made up; 10 µl of the reconstituted protease inhibitor, 100 µl of the 
phosphatase inhibitor cocktail II and 1.2 µl of the benzonase working solution was added to 10 ml 
extraction/ labelling buffer. 
Whilst both the C33A/C33AE6 and Tert/TertE6 cell systems have been used in previous 
chapters, the main advantage being the ability to assess E6-dependent effects, the decision was 
made to assess the proteomic effects of lopinavir in SiHa cells. As discussed, SiHa cells, whilst a 
fully transformed cell line, contain a fully integrated HPV genome. It was thought that the anti-HPV 
effects of lopinavir may involve more of the HPV arsenal than simply E6, so to fully ascertain the 
effects of toxic effects of lopinavir against HPV-infected cells, a fully integrated genome is 
essential. SiHa cells were seeded into T-75 culture flasks and cultured as described in section 
2.3.1 to a confluency of 80% whereupon the growth medium was aspirated from all culture flasks 
and replaced with fresh complete medium supplemented with lopinavir at a final concentration of 
25 µM or an equal volume of DMSO. All flasks were returned to the incubator for 6 hrs. In order to 
obtain a sufficient amount of protein for the antibody array, all cells from two lopinavir or two DMSO 
treated flasks were pooled and processed. Remaining flasks were lysed with 2 x Laemmle sample 
buffer and used for western blotting, as described in section 5.3.2.4. 
 
 
4.3.2. Protein extraction from cells 
 
Six hours post-incubation with lopinavir, the growth medium was aspirated and the cells were 
washed twice in PBS/Tween-20 (pH 7.4) and 1.25 ml of ice cold buffer A (prepared in section 
4.3.1) was then added to one T-75 flask from each pair, and this incubated on ice for 5 min. 
Following this, cells were detached from the flask surface using a sterile cell scraper, and the cell 
lysate transferred to a second lopinavir treated T-75 flask as above. This was again incubated for 5 
min on ice and the cells detached. The total cell lysate solution, now containing the pooled contents 
of 2 x T-75 lopinavir treated cells was transferred to a sterile 1.5 ml eppendorf. This extraction 
process was also repeated with two DMSO treated control T-75 flasks.  
The lysates were centrifuged at 10,000 x g for 10 seconds, and the pellet dislodged before 
being centrifuged once more at 10,000 x g for 10 seconds. The supernatant was then transferred to 
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a fresh labelled eppendorf tube. Before proceeding, the protein concentration was determined 
using the Bradford Assay (section 4.3.4). 
 
4.3.3. Preparation of protein lysates for western blot 
 
Cells grown in T-75 flasks were harvested and counted as detailed in section 2.2.3.  The 
cells were then pelleted by centrifugation for 5 min at 528 x g and the supernatant aspirated. The 
cell pellet was then resuspended in 500 µl PBS and transferred to a 1.5 ml eppendorf, before being 
centrifuged at 10,000 x g for 5 min. Cells were then resuspended in a volume of PBS calculated to 
give a final concentration of 1.0 x 106 cells in 20 µl and an equal volume of 2x Laemmle sample 
buffer [219] added to this (Final concentration of 0.5 x 106 cell/20 µl volume). Samples were then 
subjected to three cycles of heating to 95°C for 5 min, before being snap frozen in liquid nitrogen. 
Finally, the samples were stored at -20°C until use . 
 
4.3.4. Estimation of protein content by Bradford Assay 
 
Protein content was estimated using the Bradford assay kit (Thermo Fisher Scientific, 
Northumberland, UK) carried out according to the manufacturer’s instructions. Plates were 
incubated in the dark for 15 min, after which, the absorbance was read at 490 nm using a Dynex 
MRX plate reader (Dynex technologies Ltd., West Sussex, UK). 
 
4.3.5. Protein Labelling 
 
For protein labelling, Cy3 and Cy5 fluorophores were used (GE Healthcare (Amersham), 
Buckinghamshire, UK). Vials of Cy3 and Cy5 protein labelling dye were each resuspended in 20 µl 
fresh DMSO and 10 µl of Cy3 protein labelling dye placed into 2 labelled eppendorfs. Five hundred 
microlitres of lopinavir treated and DMSO control lysates (prepared in section 4.3.2) were each 
added separately to the Cy3 and Cy5 labelling dyes. These were then thoroughly mixed and 
incubated, in the dark at room temperature, for 30 min, with inversion mixing every 10 min. 
 Free Cy3/ Cy5 dye was removed from the protein sample using Sigma Aldrich spin 
columns (Sigma Aldrich, Dorset, UK) according to manufacturers’ instructions. The spin columns 
were centrifuged at 750 x g for 2 min, and the eluate from each tube discarded. The spin columns 
were then placed into fresh eppendorf tubes, and 150 µl of the lysates/ dye mixes pipetted directly 
onto the centre of the membrane of a separate spin column. The remaining cell lysates were stored 
at -80°C. Columns were then centrifuged again at 75 0 x g for 2 min and the eluate retained. The 
protein concentration of each fluorophore labelled sample was then determined using the Bradford 
assay as described in section 4.3.4. 
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4.3.6. Determination of Dye/ Protein molar ratio  
 
The Cy3 and Cy5 absorbencies were read at 552nm and 650nm respectively, using a 
Nandrop-8000 machine (Thermo Scientific, Nanodrop products, Delaware, USA). In brief, the 
machine was initialised by placing 2 µl ultra pure sdH20 on each absorbance reading head in use. 
Following this, 2 µl buffer A (prepared in section 4.3.1) was placed on each of the absorbance 
reading heads to zero the machine. Following this the absorbance of each sample was read and 
recorded. The dye/ protein ratio (D/P) was calculated based on the following formulae: 
   
µM coefficient (ε µM) calculations: 
 
• Cy3 ε µM(552nm) = 0.15µM-1 cm-1 
• Cy5 ε µM(650nm) = 0.25µM-1 cm-1 
 
Therefore the Cy3/ Cy5 concentrations were calculated as follows: 
 
• Cy3 concentration (µM) = A552/0.15 
• Cy5 concentration (µM) = A650/0.25 
 
Protein (µM) concentration: 
 
• [Y(mg/ml)/60,000] x 106  
 
(Where Y represents protein concentration estimated with the Bradford assay) 
 
Finally the D/P ration was calculated: 
 
D/P = 
Cy3 or Cy5 concentration 
Protein concentration of sample 
 
 
 
4.3.7. Sample incubation on the array 
 
One hundred nanograms (100 ng) of each labelled protein lysate sample was used to label 
duplicate array slides. To allow for a dye swap controlled experiment, slide A was probed with Cy5 
labelled untreated (UT) lysates and Cy3 labelled treated (T) lysates. Slide B was probed with the 
reverse. Two separate 5ml aliquots of the array incubation buffer were made up containing 100 ng 
Cy5 untreated and 100 ng Cy3 treated or 100 ng Cy3 untreated and 100 ng Cy5 treated. These 
were mixed gently without vortexing, placed in separate wells of the slide incubation trays, and the 
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two slides immersed fully into two separate protein lysates mix. The trays were then covered in foil 
and incubated at room temperature for 30 min on a rotary shaker with gentle shaking. Following 
this, the slides were removed from the labelled protein mixture and washed with three 5 minute 
washes in the wash buffer provided. Slides were then air dried completely at room temperature, in 
the dark, before being scanned using a Perkin-Elmer Pro ScanArray fluorescent scanner (Perkin-
Elmer, Massachusetts, USA) according to the manufacturers’ instructions. 
 
4.3.8. Data analysis of antibody microarray results 
 
Each protein is represented in duplicate on the array arranged in 32 sub arrays including 
positive and negative controls. Protein differences could be determined between treated and 
untreated samples based on the visual scan results. However, to calculate numerical differences in 
protein levels, mean intensities were calculated for each spot pair, with the mean spot background 
level subtracted. Protein intensities were then plotted graphically with average intensities and 
standard deviations calculated using Microsoft Excel 2003. 
Antibody arrays are specific for a qualitative measurement of protein expression for tissue 
or cell extracts. By determining relative changes in protein expression, it is possible to compare 
control DMSO treated samples to its matched lopinavir treated sample. This analysis produces a 
ratio rendering the data semi-quantitative. The use of an antibody microarray is a rather speculative 
approach by which to identify those proteins altered following exposure to lopinavir. As the array 
represents 725 different proteins, it was decided to utilise a two-stage approach in order to identify 
potentially interesting proteins requiring future studies: 
 
A. Proteins in which upper/lower extremities of error bars did not overlap were considered 
‘proteins of interest’. Extremely low expression proteins and array spots suffering from slide 
manufacturing inaccuracies were disregarded. 
 
B. Bioinformatic searches to identify function(s) of highlighted ‘proteins of interest’ were 
subsequently carried out. Prior to obtaining array data, it was anticipated that the most 
likely protein of interest, with regards to lopinavir toxicity, would be a protein which was 
elevated/stabilised in the presence of lopinavir. In addition, the protein of interest would 
also ideally possess functions relating to cell growth, apoptosis or the antiviral response of 
the cell. Proteins possessing these attributes would be prioritised for future investigations 
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4.4. Results 
 
4.4.1. Fluorescent scan data 
 
Equal amounts of Cy3 and Cy5 labelled protein samples were used to immunoprobe the 
Sigma-Aldrich panorama XPress725 antibody microarray (section 4.3). In order to rule out the 
possibility of misinterpreting the antibody microarray due to differences in Cy3/ Cy5 fluorophore 
labelling efficiencies, it was initially planned on processing the antibody array under dye swap 
conditions. This was done by labelling duplicate samples of DMSO control and lopinavir treated 
protein lysates with both Cy3 and Cy5 fluorophores and immunoprobing duplicate antibody arrays. 
Protein levels are colour coded from blue, representing a low protein level, through to white 
representing high level protein expression. Figure 4.3 below shows the results from the first 
fluorescent scan showing the full array slide, and demonstrates a problem encountered with the 
Cy5 fluorophore, preventing a full dye swap analysis. 
 
 
Figure 4.3 - Failure of Cy5 fluorophore to scan effectively 
 
 
 
Figure 4.3 – Cy3 and Cy5 fluorophore labelled cell proteins were used to immunoprobe the 
Panorama Xpress-725 profiler antibody microarray. The Cy5 fluorophore was scanned using the 
Perkin-Elmer ProScanArray fluorescent scanner according to the manufacturers’ instructions. The 
scan was carried out using several scan settings, the results of which are shown above in 3 
separate panels, each representing one full array image taken under a range of laser setting. 
Regardless of the scanning parameters used, it was not possible to get a scan image that was 
suitable for further analysis. 
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Based on these findings, it was decided that a full dye swap analysis was not possible, and 
subsequent analysis would be based on the Cy3 fluorophore signal. The scan image results shown 
below in Figure 4.4 demonstrate the clear difference in image quality between the Cy3 and Cy5 
fluorophores. 
 
 
 
Figure 4.4 – Fluorescent scan images obtained from Cy3 fluorophores 
 
 
 
Figure 4.4 – Lopinavir treated (6hrs, 25 µM) and DMSO control treated SiHa cells were harvested 
and labelled with a Cy3 fluorophore. Cy3 dye-labelled protein samples were used to immunoprobe 
two Panorama XPRESS profiler725 antibody microarray slides. Fluorescent scans were carried out 
using a Perkin-Elmer ProScanArray fluorescent scanner. Yellow box represents one sub array 
containing 24 proteins spotted in duplicate including positive and negative control spots. 
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Figure 4.4 shows the Cy3 fluorescence scan data for the panorama antibody microarray. 
The 725 antibodies are arranged into 32 sub-arrays, each including 22 separate proteins in 
duplicate addresses, along with positive and negative controls. The yellow boxed area represents a 
single sub array, a close-up of which is shown below in Figure 4.5.  
 
 
 
Figure 4.5 – Close up an a single sub array - Cy3 fluorescent scan data 
 
 
 
 
 
Figure 4.5 – Close up on a single sub-array for the Cy3 fluorophore. The left panel represents the 
untreated protein lysates and the right panel represents the lopinavir treated protein lysates. The 
red boxed pair, on each panel, represents an internal negative control in duplicate, whilst the green 
boxes represent the Cy3/Cy5 positive control. The yellow boxed pairs represent a single protein in 
duplicate, namely Ribonuclease L, levels of which have increased following lopinavir treatment. 
 
 
 
 
 
The background signal was subtracted from each spot and mean intensities were plotted for 
each duplicate signal. Of the 725 proteins covered by the antibody microarray 51 proteins were 
shown to have altered expression levels in the lopinavir treated protein lysates. The raw data signal 
strengths for these 51 proteins are shown below in Figures 4.6 and 4.7, with the colour coded 
signal intensities shown above converted to numerical values using the software package 
accompanying the Perkin Elmer Scanner. Of these 51 proteins, 5 proteins, namely Aurora B, bcl-
10, connexin-43 (two variants), GFAP and mTOR had decreased levels following lopinavir 
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treatment. The remaining 46 proteins all exhibited varying increases in expression following 
lopinavir treatment (For details function and fold-changes of  each protein, please refer to table 
7.1). 
Figure 4.8 shows the data from Figures 4.6 and 4.7 represented in terms of log fold change 
compared to matched DMSO treated control values. 
 
The numerical values for each of the 725 proteins represented on the Panorama Xpress 
Profiler-725 antibody microarray can be viewed as an excel file on the accompanying data CD, with 
file name ‘Full Antibody Microarray data set.xlsx’ 
 
 
 
    
Figure 4.6 – Proteins exhibiting alterations in expression levels following lopinavir treatment 
 
 
 
 
Figure 4.6 – Protein expression levels are shown for DMSO treated control proteins and lopinavir treated proteins. Mean values were calculated using 
Microsoft Excel. 
 
 
    
 
Figure 4.7 – Protein expression levels following lopinavir treatment (continued) 
 
 
 
Figure 4.7 – Protein expression levels are shown for DMSO treated control proteins and lopinavir treated proteins. Mean values were calculated using 
Microsoft Excel. 
 
 
    
Figure 4.8 – Protein expression levels following lopinavir treatment – Log fold change 
 
 
 
Figure 4.8 - Lopinavir treated protein expression profile represented in terms of log fold change compared to DMSO control. The red bar represents RNase L 
protein, levels of which were shown to be elevated following lopinavir treatment. As a known antiviral protein, the role of RNase L in lopinavir toxicity was 
assessed in subsequent chapters. 
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4.5. Chapter Summary and Discussion  
 
It is known that lopinavir is able to induce selective inhibition of the 26S proteasome [130, 131]. 
It was hypothesised that inhibition of proteasomal degradation would lead to changes in cell protein 
levels in lopinavir treated cells, which were not apparent in untreated control cells. Further to this, it 
was thought that one or more of the proteins exhibiting altered expression following lopinavir 
treatment could potentially account for the anti-HPV activity of lopinavir. The protein expression 
profiles of lopinavir treated and DMSO control treated HPV positive SiHa cells were compared 
using the Panorama Xpress725 profiler antibody microarray (Sigma Aldrich, Dorset, UK). In total, 
lopinavir was shown to alter the levels of 51 proteins, shown in Figures 4.6 and 4.7 and table 7.1. 
Of these 51 proteins, lopinavir caused an increase in protein expression in 46 proteins, and a 
decrease in 5 proteins. 
 Literature searches were carried out in order to gain an understanding of all the proteins 
shown to be affected by lopinavir treatment. Not surprisingly, lopinavir treatment was shown to up-
regulate several known apoptosis-markers such as Annexin-5 (ANXA5), the active form of 
Caspase-3 (CASP3), Tumour necrosis factor (TNF) and p63, and as previously demonstrated, p53 
[131]. Interestingly the majority of those proteins were shown to be known targets for proteasomal 
degradation, as highlighted in table 5.1.  Since p53 is a known target of the HPV type 16 E6 protein 
the. Virus Molecular INTeraction database was searched in order to identify any other potential 
known E6 and/or E7 interacting proteins affected by lopinavir treatment  
(http://mint.bio.uniroma2.it/virusmint/, reviewed in [220]). However, at this stage, only p53 has 
previously been shown to interact with E6. 
As demonstrated, lopinavir treatment also down-regulated some proteins in SiHa cells, 
although of particular interest was the down regulation of the Mammalian Target of Rapamycin 
(mTOR). Interestingly, mTOR has recently been shown to be constitutively over expressed in 
cervical carcinomas [221], and most importantly, it has been shown that the HPV type 16 E6 
protein activates mTOR signalling resulting in increased protein synthesis [222] (see Chapter 7 for 
a full discussion of mTOR). In addition, it was also significant that lopinavir-induced down 
regulation of Glial Fibrillary Acidic Protein (GFAP), a protein known to be capable of inhibiting the 
proteasome [223].  
However, of most interest was the observation that lopinavir caused a 1.7-fold increase in 
levels of a protein known as Ribonuclease L (referred to as RNase L for the remainder of this 
thesis, whilst the gene name is referred to as RNASEL) since this is a well known interferon-
inducible antiviral protein (Figure 4.7). This increase was later confirmed by western blotting (see 
chapter 5, Figure 5.7). It is true that the anti-HPV effects of lopinavir may be potentially related to 
the synergistic actions of more than one of the differentially regulated proteins identified by the 
antibody array. However, taking into account the well established antiviral function of RNase L 
[224, 225] it was decided to focus further investigations on the effects of lopinavir on this protein in 
particular. 
 
 
 [102] 
 
4.6. Further work 
 
We have access to a range of other HIV protease inhibitors. Thus, based on the previously 
discussed observations it is suggested that additional western blot and/or microarray analysis of PI 
treated SiHa cells could be carried out. This would establish whether these agents produced similar 
effects to those identified for lopinavir and determine whether these were lopinavir-specific or 
whether they are a general consequence of protease inhibitor treatment. 
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5. RNase L and further lopinavir Studies 
 
5.1. Introduction 
 
One aim of this research project was to assess the link between lopinavir and HPV-specific 
toxicity, with a particular aim being to identify potential proteins that could account for this toxicity. 
Previous results from the Panorama Xpress profiler725 antibody array (Chapter 4) demonstrated 
that in SiHa cells, lopinavir caused alterations in the expression of a number of proteins with a wide 
range of functions.  
Many viruses are known to inhibit the function of, or inappropriately degrade, host cell proteins 
detrimental to viral persistence [226-230], some by directly ‘hijacking’ the ubiquitin-proteasome 
system (as reviewed in [231]). Inappropriate proteasomally-mediated degradation of the tumour 
suppressor protein p53, facilitated by the E6 protein of high risk HPV types, is a classic example of 
this adaptive viral response. In removing p53, HPV replication can proceed unhindered. Taking this 
into account, it was thought that the most likely candidate protein(s) of interest would be ones 
which were elevated following lopinavir treatment, as this potentially implies that the protein has 
been suppressed in the untreated HPV-positive cell. When compared to DMSO treated control 
cells, the data showed that, amongst other proteins, lopinavir induced an increase in the levels of a 
protein known as RNase L. RNase L is a known antiviral protein, and is the main effector protein of 
an interferon-induced antiviral pathway, and its role will be investigated in greater detail. 
 
 
5.1.1. RNase L, Interferon and the 2’,5’,-oligoadenylate (2-5A) antiviral Pathway 
 
Interferons (IFN) [107] are a group of multifunctional secreted proteins involved with 
antiviral defence, cell growth regulation and immune activation and can be split into two broad 
categories; the type I IFNs, IFN-α and IFN-β, which are produced as a direct consequence of viral 
infection, and IFN-γ, a type II IFN which is produced following recognition of an infection by 
activated T lymphocytes and natural killer cells [232]. Stimulation of IFN results in an ‘antiviral state’ 
wherein cells become refractory to further infection. Four IFN-regulated antiviral pathways that 
contribute to the antiviral state have previously been described: the Mx GTPase pathway, the 
double stranded RNA dependent protein kinase pathway (PKR), the ISG15 ubiquitin-like pathway 
and the 2’,5’-oligoadenylate (2-5A) pathway (all extensively reviewed in [233]).   
The 2’, 5’-oligoadenylate pathway (Figure 5.1) comprises two main enzymes, 
oligoadenylate synthetases (OAS) and a latent ribonuclease, RNase L. The pleiotropic effects of 
IFN are regulated through binding of IFN to the IFN-α 1 receptor (IFNR1) which initiates a JAK-
STAT signalling cascade resulting in the transcription of more than 300 IFN-stimulated genes (ISG) 
[234]. The majority of ISGs encode protein products which function as pattern recognition 
receptors, indirectly modulating the antiviral response through detection of viral molecules [234]. 
Yet IFN also stimulates a subset of ISGs which are capable of direct modulation of the antiviral 
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response, namely the OAS genes and their OAS protein products. There are 4 human OAS genes, 
which are located on chromosome 12, OAS1, OAS2, OAS3, which through splice variation, give 
rise to 5 functional OAS, and finally OAS-L which encodes a similar protein with two C-terminal 
ubiquitin-like domains, although it does not synthesise 2-5A  (Figure 5.1(B)) [235]. 
 
 
Figure 5.1 – IFN stimulated 2-5A RNase L antiviral pathway 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 – (A) 2-5A/ RNase L antiviral pathway. (B) 2-5A structure (Diagram from [224]). 
A 
IFN 
2-5A 
Synthetases 
(Inactive) 
2-5A 
Synthetases 
(Active) 
Inactive 
RNase L 
2-5A ATP 
RNA cleavage 
RNase L 
ABCE1 
dsRNA 
RNase L 
RNase L 
ABCE1 
B 
 [105] 
 
Double stranded RNA (dsRNA) molecules as small as 15 bp in length are produced by 
many viruses as replicative intermediates, and these stimulate activation of the OAS system [236]. 
This involves polymerisation, with OAS3 products producing active dimeric 2’,5’-oligomers, whilst 
OAS1 and OAS2 produce active trimeric and tetrameric 2’,5’-oligomers respectively [234]. 
Following activation, ATP is converted into a series of short 5’-phosphorylated, 2’, 5’-linked 
oligoadenylates jointly referred to as 2-5A (Figure 5.1 B). RNase L is constitutively expressed as an 
inactive monomer. Binding of 2-5A within the regulatory region binding pocket of RNase L, which 
requires a 1:1 molar ratio between RNase L and 2-5A, induces a conformational change in the 
ankyrin repeat region (Figure 5.3), which unmasks the nuclease domain of RNase L. As a 
consequence of this ‘unmasking’ homodimerisation of RNase L monomers occurs, resulting in 
activated RNase L dimers [237]. Following this, RNase L cleaves within single stranded regions of 
both cellular and viral RNA, preferentially at the 3’ side of UpAp and UpUp dinucleotides [237]. In the 
absence of 2-5A, the regulatory domain suppresses this ribonuclease activity. The antiviral effects 
of RNA degradation by RNase L are summarised in Figure 5.2. 
 
 
 
Figure 5.2 Antiviral effects of RNase L mediated degradation of RNA 
 
 
 
 
Figure 5.2 – Antiviral effects of RNase L-mediated degradation of cellular and viral RNA substrates 
(diagram adapted from [238]). 
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5.1.2. RNase L Structure 
 
RNase L is a 741-amino acid protein with a molecular mass of approximately 83 kDa 
composed of three domains (Figure 5.3) (as reviewed in [224, 239]): The N-terminal regulatory 
domain, the kinase-like domain and the nuclease domain. 
 
 
Figure 5.3 – Domain locations of RNase L 
 
 
 
 
 
 
Figure 5.3 – The RNase L protein is 741 amino acids in length and is composed of three domains: 
the N-terminal regulatory domain contains 9 ankyrin repeat motifs and is associated with 2-5A 
binding, a protein kinase-like domain, and a C-terminal domain that contains the active 
ribonuclease region. 
 
 
 
5.1.2.1. N-terminal regulatory domain 
 
The N-terminal regulatory domain of RNase L is composed of 8 complete and 1 partial 
ankyrin repeat motifs (R1-R9). These each consist of 30-34 amino acid residues and mediate 
protein-protein interactions [240, 241]. Both ankyrin repeats 7 & 8 contain a GXXXXGKT sequence 
(where X can be any amino acid). This is commonly referred to as a Walker A motif, which 
mediates nucleotide binding in ATP-dependent enzymes [224, 242]. Work on the crystal structure 
of RNase L demonstrated that ankyrin repeats 2 – 4 constitute a 2-5A binding pocket and that 
ankyrin repeats 7 and 9 are involved with protein structural integrity rather than 2-5A binding [243]. 
Upon binding, 2-5A induces a conformational change in the ankyrin repeat domain of RNase L 
which unmasks the C-terminal nuclease domain allowing homodimerisation to occur leading to the 
generation of active RNase L homodimers [237].  
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5.1.2.2. Kinase-like domain & Nuclease domain 
 
The kinase-like and nuclease domain of RNase L are structurally homologous to IRE1p 
[224]. This is a kinase/ribonuclease that functions in the unfolded protein response in 
Saccharomyces cerevisiae [244], which is a process essential for chromosome maintenance [245]. 
Unlike IRE1p, the kinase-like domain of RNase L is less well researched and has been shown to 
lack several residues that are highly conserved amongst other protein kinases [246, 247].  Whilst 
there has been no demonstrable kinase-like functions of RNase L, studies have shown that 
mutations at nucleotide position 392 lead to an extensive (>100-fold) reduction in ribonuclease 
activity, relating to an inability of RNase L to fully dimerise [247]. 
 
 
5.1.3. Endogenous regulation of RNase L  
 
RNase L activity is regulated in a number of ways. For example, 2-5A molecules are 
relatively unstable, short lived proteins, which are rapidly degraded by a combination of 2’-
phosphodiesterases and 5’-phosphatases [225]. Following the successful cloning of RNase L [239], 
Bisbal et al (1995) described the cloning and characterisation of an endogenous polypeptide 
inhibitor of the 2-5A-dependent RNase L antiviral pathway [248], labelling it RLI or RNase L 
inhibitor. RLI, later termed ABCE1 (ATP-Binding Cassette, subgroup E), is a 599 amino acid 
protein with a molecular weight of approximately 68 kDa. Inhibition of RNase L activity does not 
occur through ABCE1-mediated degradation of 2-5A or irreversible inactivation of RNase L [224]. 
Instead, ABCE1 reversibly binds to the ankyrin repeat region of RNase L antagonising the binding 
of endogenous 2-5A and thus preventing the activation of RNase L [248].  
 
 
5.1.4. The RNase L pathway and viral evasion strategies 
 
As a consequence of co-evolution, host-virus interactions are highly dynamic and complex 
with both organisms constantly adapting and developing strategies against the other. Clearly there 
are highly sophisticated innate and adaptive host immune responses which provide both fast acting 
‘first-line’ and longer lasting pathogen-specific defences. However, it is not surprising that there are 
a plethora of equally sophisticated and efficient strategies employed by viruses to circumvent 
cellular defences to allow viral replication and dissemination. As mentioned previously, a classic 
example of virally-mediated host defence evasion is that of high risk HPV E6 & E7-mediated 
degradation of p53 and Rb respectively. However, the RNase L/ 2’, 5’-oligoadenylate pathway is 
also an important antiviral pathway and as such, is targeted by a number of DNA and RNA viruses 
using a range of strategies (summarised in Figure 5.4). 
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Figure 5.4 – Viral intervention strategies targeting the RNase L pathway 
 
 
 
 
 
Figure 5.4 – The 2-5A Oligoadenylate/ RNase L system is a key antiviral defence pathway. 
However, many viruses have strategies by which they can circumvent the antiviral effects of the 
pathway allowing complete viral replication to proceed unhindered (target points are shown in red). 
(Diagram adapted from [224, 249].  
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5.1.4.1. Viral 2-5A homologues 
 
The Herpes Simplex viruses I/II (HSV I/II) employ a multi-faceted approach to disabling the 
RNase L pathway utilising virally encoded proteins. Initially, early in its productive phase of 
replication, HSV is capable of inhibiting the accumulation of interferon stimulated gene (ISG) 
transcripts through the actions of virally encoded proteins. For example, ICP0, an immediate-early 
protein inhibits IRF3-mediated transcriptional activation of ISGs, and virion host shutoff protein 
(vhs), an endonuclease that associates with the translation initiation factor eIF4F, resulting in 
cellular degradation of cellular mRNA and shut-off of host cell protein synthesis (reviewed in [250] 
and [251]). However, these activities do not explain the ability of HSV to replicate in vitro in cells 
previously primed with IFN treatment, which indicates alternative mechanisms [250]. It was noticed 
that much higher doses of α or β IFNs (100-1000 reference units/ml) were required to inhibit the 
growth of HSV I/II infected Chang cells than the same cells infected with encephalomyocarditis 
virus (ECMV) (10-100 reference units/ml) [252]. It was also demonstrated that the levels of 2-5A 
dependent rRNA cleavage products in HSV I/II infected Chang cells were noticeably lower than 
those found in ECMV-infected cells, signifying a drop in RNase L/ 2’, 5’-oligoadenylate activity. 
Interestingly, these authors went on to demonstrate the presence of virally synthesised 2-5A 
homologues in HSV infected cells which, unlike endogenous 2-5A, possessed only weak RNase L-
activating capabilities, providing an explanation as to the higher IFN dosage required to 
successfully treat HSV I/II infections [252].  
 
 
5.1.4.2. dsRNA binding proteins 
 
Double stranded RNA-binding proteins (DRBPs) (reviewed in [253]) are a family of 
prokaryotic, eukaryotic and virally encoded proteins containing an evolutionarily conserved dsRNA 
binding domain (DRBD) of approximately 65-68 amino acids [253]. DRBPs carry out many 
essential physiological roles, helping to regulate signalling pathways and gene expression [253]. 
For example, DICER, an RNase-III endonuclease is involved with RNA interference-mediated gene 
silencing (reviewed in [254]) whilst the NFARs (Nuclear Factors Associated with RNA) NF-90, 
MMP4 and DRB76 are associated with mRNA post-transcriptional regulation, mRNA stability, 
export and translation [253, 255]. 
DRBPs also play a role in host defence pathways, as exemplified by the IFN-dependent 
double-stranded RNA-dependent protein kinase R (PKR) (reviewed in [234]) which along with its C-
terminal catalytic domain, contains two DRBDs in its N-terminal domain. PKR is constitutively 
expressed at low level however, its expression is up-regulated in the presence of IFN [234]. The 
antiviral effects of PKR are mediated through phosphorylation of eIF2α, which arrests eIF2α in the 
translation pre-initiation complex, preventing future rounds of translation from occurring [249]. 
The use of virally encoded dsRNA-binding proteins to interfere with IFN-dependent host 
defence mechanisms is a technique employed by several viruses. For example Vaccinia virus 
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(DRBP - E3L protein), HSV (Us11) Epstein-Barr virus (EB2), Influenza A (NS1), Reovirus (σ3) and 
Ebola virus (VP35) (as reviewed in [249]) subvert the IFN-dependent PKR/ RNase L pathways 
through a combination of sequestering dsRNA preventing IFN activation or by directly binding to 
the DRBD regions of PKR preventing its activation . 
 
 
 
5.1.4.3. Inhibition of 2-5A oligoadenylate synthetase and selection of resistant 
strains 
 
Hepatitis C virus (HCV) is the leading cause of both chronic liver disease and 
hepatocellular carcinoma (HCC) in western countries, and combination therapy consisting of 
Interferon and ribavarin is the most effective treatment strategy (reviewed in [256]). HCV, like HSV, 
has also developed a multi-faceted approach to subvert the host antiviral response utilising two 
distinct strategies: selection of IFN-resistant strains and inhibition of 2’,5’-oligoadenylate synthetase 
mediated by the viral protein ‘non-structural protein 5A’ (NS5A). Reviewed in [257] the NS5A 
protein is localised to the cytoplasmic perinuclear region and is considered an extremely pleiotropic 
protein with key roles in viral RNA replication and modulation of the host cell physiology. Early work 
by Enomoto et al (1995) in patients chronically infected with HCV-1b identified mutations within a 
discreet central region of the HCV NS5A protein that correlated with response to IFN treatment. 
This was labelled the ‘interferon sensitivity-determining region (ISDR)’ [258, 259]. Identification of 
the ISDR suggested that NS5A plays a role in HCV resistance to IFN, which was later confirmed by 
Gale et al (1997). These authors demonstrated that PKR repression and IFN resistance were 
mediated through direct binding between NS5A and the PKR ISDR, therefore preventing the 
dimerisation and resultant activation of PKR [260, 261].  
Subsequent work demonstrated that NS5A could also inhibit the effects of IFN in an ISDR 
and PKA-independent manner, indicating the existence of previously unknown mechanisms of 
immune evasion by HCV [262]. The work of Taguchi et al (2004) concluded that the exact nature of 
these mechanisms were due to inhibition of 2’,5’-oligoadenylate synthetase, with subsequent 
inactivation of RNase L. NS5A was shown to physically interact with 2’,5’-oligoadenylate 
synthetase, with the interaction requiring an N-terminal region (aa 1-148) of NS5A, which does not 
contain the ISDR, and two regions of 2’,5’-oligoadenylate synthetase (aa 52-104 and 184-275) 
[257]. Interestingly the NS5A binding points within 2’,5’-oligoadenylate synthetase are known to 
contain several regions important for enzymatic activity, suggesting inhibition of 2’,5’-oligoadenylate 
synthetase function  is mediated through binding within the active site [257]. 
Chronic HCV infections are a significant cause of worldwide morbidity and mortality and 
Interferon-α2b treatment, in conjunction with the pro-drug ribavarin, eliminates HCV from patients 
infected with HCV genotypes 2 and 3 (HCV 2a, 2b, 3a & 3b) much more efficiently than those 
infected with a HCV genotype 1 virus (HCV 1a & 1b) [263]. Han and Barton (2002) demonstrated 
that in HCV-1 genotypes, the RNase L sensitive UU/UA sequences occurred much less frequently 
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than in the more interferon-sensitive genotypes [263]. This data suggests that during the course of 
IFN treatment mutations could possibly accumulate in HCV-1 mRNA’s that result in the escape of 
HCV from the antiviral effects of RNase L with subsequent positive selection of resistant strains 
[224]. 
 
 
 
5.1.4.4. Increased ABCE expression 
 
HIV-1 virion formation requires the assembly of ~5,000 Gag polypeptides into an immature 
spherical capsid structure. This process occurs in an ATP-dependent, multistep process and 
requires a host protein of 68 kDa, identified as ABCE1, the endogenous inhibitor of RNase L [264, 
265]. RNase L has been shown to degrade HIV-1 transcripts during the early stages of HIV 
infection and HIV-1 transcript accumulation coincides with a reduction in RNase L activity [266]. 
Based on these observations, Martinand et al (1999), used an in vitro system based on human T-
cell H9 cells infected with HIV-1, to demonstrate that a decrease in RNase L activity coincided with 
an increase in the HIV-induced expression of the ABCE1 endogenous inhibitor of RNase L [266]. 
 
 
5.1.5. RNase L and human disease 
 
Whilst the antiviral properties of RNase L are now well documented, it has become 
apparent that defects within the 2’,5’-oligoadenylate (2-5A) pathway are now implicated in a range 
of human pathologies such as prostate cancer and chronic fatigue syndrome (CFS).  
 
 
5.1.5.1. Familial Prostate cancer 
 
The prostate is a walnut-sized gland which is a component of the male reproductive 
system. It is located below the bladder, in front of the rectum, and produces and stores seminal 
fluid [267]. Prostate cancer is the most common cancer of men in the UK, accounting for almost a 
quarter of new cancer diagnoses. The risk of developing prostate cancer increases with age and 
more than half of cases arise in men over the age of 70. Worldwide, approximately 913,000 men 
were diagnosed with prostate cancer in 2008, leading to approximately 258,000 deaths (data from 
http://www.cancerhelp.org.uk/type/prostate-cancer/). Whilst age, environmental and hormonal 
factors are known to play key roles in prostate cancer pathogenesis more recently, host genetics 
has been shown to play a role in a subset of prostate cancers termed hereditary prostate cancer 
(HPC). As demonstrated in a case-controlled study by Steinberg et al (1990), men with a father or 
brother affected with prostate cancer were twice as likely to develop prostate cancer when 
compared to men with no affected relatives. Interestingly, the risk was shown to increase with 
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increasing number of first-degree family members affected (a 5 and 11-fold increased risk for two 
and three first degree relatives affected respectively) [268]. 
Early linkage analysis studies of families affected by HPC identified several loci that could 
potentially be harbouring prostate cancer susceptibility gene(s) namely HPC1 (1q24-25) [269] and 
subsequently HPCX (Xq27-q28), PCAP (1q42), CAPB (1p36), HPC20 (20q13) and HPC2/ELAC 
(17p) (reviewed in [270, 271]). The proposed HPC gene(s) were predicted to account for ~43% of 
early-onset prostate cancer cases (≤55 years of age) and ~9% of all cases [267] whilst further work 
demonstrated HPC1 linkage was most common amongst those families in which prostate cancers 
cases were considered more severe [272]. The proposed link between prostate cancer and RNase 
L was firmly established with the discovery of germline mutations in RNASEL that segregated 
within prostate cancer families showing linkage to HPC1 [273] and mutations in RNASEL are now 
unequivocally linked with prostate cancer [274-278]. Several key mutations (reviewed in [279]) 
have since been identified, the three most extensively studied being: 
 
 E265X – A 795G→T transition resulting in conversion of a glutamic acid residue 
with in the 2-5A binding domain to a stop codon. 
 M1L – A 3G→A transition resulting in a methionine to isoleucine transition in the 
translational start codon producing a missense mutation. 
 R462Q – A missense mutation located within the kinase-like domain. A G→A 
transition at nucleotide position 1385 results in an amino acid change of arginine 
to glutamine at position 462. 
 
Both the E265X and M1L variants produce an RNase L with an activity level 50% below 
that of the wild type protein. The R462Q transition, located within the kinase like domain (Figure 
5.1) produces a three-fold reduction in catalytic activity. This was shown to be due to an impaired 
ability of RNase L to fully dimerise, with a subsequent failure of the protein to induce RNA 
degradation and apoptosis [224]. Males heterozygous for this variant carry a 1.5-fold increased 
risk, whilst homozygous males carry a 2-fold increased risk of developing prostate cancer, in fact, 
R462Q variant is now implicated in up to 13% of prostate cancer cases [280]. 
 
 
5.1.5.2. Chronic fatigue Syndrome (CFS) 
 
CFS (reviewed in [281]) is a debilitating syndrome, predominantly affecting women, 
thought to affect 240,000 people in the UK. It is characterised by unexplained and extreme fatigue 
lasting for a period of at least 6 months. Additional symptoms include memory loss/ poor 
concentration, sore throat, lymphadenopathy, muscle pain and extreme exhaustion after physical 
exertion, non of which are resolved with bed rest [281]. Both neuroendocrinological and 
immunological causes have been put forward to explain CFS, although there is also thought to be a 
link between infection and the disorder. Epstein Bar virus (EBV), Candida Albicans, Borellia 
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Burgdorferi, Enterovirus, Cytomegalovirus, Coxsackie B virus and Hepatitis C virus have all been 
linked to CFS; however no conclusive link between any of these infectious agents and CFS has 
been demonstrated [282]. Studies have shown chronic immune activation [281] and dysregulation 
of the 2',5'-oligoadenylate (2-5A) synthetase/RNase L antiviral pathway occurs in CFS patients 
[283, 284] potentially indicating a viral aetiology for both CFS and prostate cancer. This prompted 
research, from several independent groups, into the possibility of viral involvement and led to the 
identification of a potentially novel gammaretrovirus pathogen.  
 
 
5.1.5.3. Xenotropic Murine leukaemia virus-Related Virus  
 
5.1.5.3.1. Discovery and potential association with disease 
 
As discussed, RNase L is a key protein in the antiviral response. Thus, rather than reduced 
apoptosis of aberrant cells being responsible for the development of prostate cancer, it was 
hypothesised that a mutation-related reduction in the RNase L-dependent antiviral response could 
enhance cellular susceptibility to infection with an as yet unknown tumour virus (in genetically 
susceptible individuals). Urisman et al (2006), used a viral detection DNA microarray composed of 
highly conserved viral sequences, to detect novel gammaretroviral sequences in 7/11 (63%) cDNA 
samples derived from R462Q-homozygous prostate cancer cases in comparison to 1/8 (12.5%) 
homozygous (RR)/ heterozygous (RQ) prostate cancer cases [285]. Following on from these initial 
findings, specific RT-PCR analysis of 86 prostate tumours demonstrated the same gammaretroviral 
sequences in 8/20 (40%) cases, in comparison to 1/66 (1.5%) RR/RQ cases [285]. The novel virus 
demonstrated a high degree of sequence homology to known murine leukaemia viruses carried by 
most mouse strains as endogenous integrated viral genomes yet was shown to be a distinct virus 
and was named Xenotropic Murine leukaemia virus-Related Virus or XMRV [286]. Having 
produced a replication-competent viral clone, Dong et al (2007) demonstrated successful XMRV 
replication in the prostate cancer cell lines DU145 and LNCaP, along with an ovarian cancer cell 
type (Hey1b) and a cervical carcinoma cell line (HeLa) [287]. Interestingly, XMRV replication in 
DU145 cells was inhibited by IFN-β treatment [287]. Conversely, LNCaP cells, previously shown to 
be deficient in JAK1 [288], an integral protein required for IFN signalling, and partially deficient in 
RNase L [289], were resistant to IFN-mediated inhibition of XMRV replication [287]. This illustrates 
the importance of a fully functioning RNase L pathway against XMRV. XMRV was also shown to 
have no sequence homology with known human endogenous retroviruses (HERVs) potentially 
making XMRV the third extant retrovirus known to infect humans, the other two being HIV and the 
HTLV-family, which belong to the lenti- and δ-retrovirus genera respectively. Sequencing data on 
full-length XMRV virus cloned from three separate RNase L QQ variant tumours indicated infection 
had occurred with the same type of virus, however, sequence variation within gag and pol regions 
were also suggestive of independent acquisition of the virus in each case [285]. These findings 
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suggest XMRV is transmitted by an exogenous route [290], and recent work suggests sexual 
transmission as a possible route of infection [291]. 
Whilst the original study [285] demonstrated that the presence of XMRV was restricted to 
prostate stromal fibroblasts, subsequent work have since detected XMRV in epithelial cells of 
prostate cancer cases [292] and in the prostate epithelial cell line 22Rv1 [293]. However, 
regardless of tropism, the requirement of the Xenotropic and polytropic retrovirus receptor 1 
(XPR1) for viral entry, a cellular receptor thought to be ubiquitously expressed in human cells is a 
common link [287]. 
The potential link between XMRV and CFS (5.1.1.5.2) was originally suggested by 
Lombardi et al (2009) who demonstrated the presence of XMRV DNA in peripheral blood 
mononuclear cells (PBMCs) from 67% (68 out of 101) CFS patients in comparison to 3.6% (5 out of 
218) healthy controls [294]. More recent data from the same research group, using the same 
sample set, has since demonstrated XMRV DNA in 85% of the original 101 CFS patient samples 
tested [295] demonstrating the problems faced by researchers due to the lack of standardised 
assays for XMRV detection. 
 
5.1.5.3.2. Potential mechanism of XMRV oncogenesis 
 
Although work has demonstrated that XMRV possesses no direct transforming abilities in 
cell culture models, it is capable of causing rare transformations, possibly indicative of indirect 
activation of endogenous oncogenes [296]. Also, XMRV possesses no oncogenes however the 
Env protein of other retroviruses has previously been shown to cause transformation in susceptible 
cells [297-301] and it is thought that XMRV may induce oncogenesis through low level insertional 
activation of oncogene(s) [302]. 
 
  
5.1.5.3.3. XMRV: A new gammaretrovirus or laboratory contamination? 
 
Despite early studies implicating XMRV in human disease, many recent studies have failed 
to reproduce the findings. In particular, the presence of XMRV in CFS patients [294] has been 
contested by a number of independent research groups, each failing to identify XMRV specific 
sequences [303-306]. Indeed, many recent studies have since gone on to suggest that XMRV is 
merely a result of laboratory contamination with known murine leukaemia viruses (MLVs) [307-
310]. Whilst the findings are inconclusive at this stage XMRV research is still on-going.  
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5.2. Aims 
 
5.2.1. RNase L was identified as a protein of interest based on results from the 
Panorama Xpress profiler-725 array. The lopinavir induced increase in protein 
expression will be confirmed initially by western blot using protein lysates isolated 
from lopinavir treated cells as described in Chapter 4 
 
5.2.2. The relationship between lopinavir concentration/ length of incubation time and 
RNase L expression in SiHa cells will be assessed by western blot analysis 
 
 
5.2.3. The expression of the endogenous inhibitor of RNase L (ABCE1) following 
lopinavir treatment in SiHa cells will be assessed by western blot analysis 
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5.3. Methods 
 
5.3.1. Analysis of RNase L mRNA expression in lopinavir treated cells 
 
SiHa, CaSKi, C33A parent, C33A E6 (section 2.3.1) and all Tert cell types (section 3.3.1.1) 
were thawed and cultured, as described in sections 2.3.2 & 2.3.3, at 37°C/ 5% CO 2 to a confluency 
of 80%. Having identified lopinavir-mediated alterations in the proteome of SiHa cells, highlighting 
an increase in RNase L, it was important to confirm this finding using more longstanding and robust 
methods. However as a matter of interest, prior to subsequent work, the endogenous expression 
levels the endogenous expression of RNase L in a range of cell types was also assessed. 
Furthermore, to highlight, if any, the association(s) between E6 and RNase L the C33A test system 
will be utilised as it provides a suitable non-E6 expressing control cell type, a factor lacking when 
solely using SiHa cells.  Should E6 subsequently be found to modulate the activities of RNase L 
and/or the antiviral properties of lopinavir, CaSKi cells will be a useful cell line with which to confirm 
these findings; Like SiHa cells, CaSKi cells contain fully integrated HPV. However, in contrast to 
SiHa cells which contain 1-2 copies per cell [186], CaSKi cells are known to contain 400 – 600 
HPV16 copies per cell [311], so in theory, any E6-dependent effects will be much more pronounced 
in the CaSKi cell system. 
Upon reaching 80% confluency, cells were treated with lopinavir or an equal volume of 
DMSO. All cells were treated with lopinavir at a final concentration of 25 µM with the exception of 
Tert cells, which, due to their increased sensitivity to lopinavir (demonstrated in chapter 3), were 
treated at 5 µM final concentration. Cells were returned to the incubator at 37°C/ 5% CO 2 and at 6 
hrs, cells were harvested and 1 x 105 cells counted and washed twice in PBS. RT-PCR analysis 
was carried out as described in section 2.3.18.2 using RNase L and PLA specific primer pairs 
(detailed in Appendix 3). 
 
 
5.3.2. Western blot analysis of RNase L and ABCE1 protein levels in SiHa cells  
 
5.3.2.1. Dose response sample preparation 
 
SiHa cells were cultured (as described in section 2.3.3) to a confluency of 80% whereupon 
they were treated with DMSO or an increasing dose of lopinavir over a range of 5 - 30 µM, in 5 µM 
increments with DMSO levels adjusted to remain constant throughout. Cells were incubated at 
37°C/ 5% CO 2 and harvested 6 hrs post-incubation with lopinavir by trypsinisation and counted (as 
described in section 2.3.3) prior to centrifugation at 528 x g for 5 min, after which, the supernatant 
was aspirated and discarded. Cells were resuspended in 500 µl PBS and transferred to a sterile 
eppendorf, and centrifuged at 295 x g for 5 min after which, the PBS was aspirated and the cells 
resuspended in a sufficient volume of a 1:1 mix of PBS and 2 x Laemmle buffer (see Appendix 2) 
to ensure a lysate with 0.5 x 106 cells/ 20 µl. All samples were then subjected to three flash 
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freeze/thaw cycles with heating to 95°C before bein g stored at -20°C. Proteins were separated 
using a 12% SDS-PAGE gel as described in section 5.3.2.4, and then transferred onto an Hybond-
C nitrocellulose membrane and a western blot carried out, including a GAPDH loading control as 
described in section 5.3.2.5.  
 
5.3.2.2. Time course sample preparation 
 
SiHa cells were cultured to a confluency of 80% whereupon the growth medium was 
aspirated and replaced with complete RPMI supplemented with lopinavir at a final concentration of 
25 µM or an equal volume of DMSO. Cells were then harvested at 2, 4, 6, 8, 12 and 24 hrs post-
incubation and prepared for SDS-PAGE analysis as described in section 5.3.2.1.  
 
5.3.2.3. Effects of 25 µM lopinavir on E6/E7 Immortalised PHFKs 
 
In collaboration with Professor Ingeborg Zehbe (Lakehead University, Thunder Bay, Canada) 
the effects of lopinavir on E6/E7 immortalised human keratinocytes were evaluated. Karyoptically 
normal human primary foreskin keratinocytes and immortalised human keratinocytes stably 
expressing HPV E6 and HPV E7 were treated for 72 hrs with lopinavir over a concentration range 
of 5 - 40 µM. Cell pellets from E6/E7 expressing PHFKs treated with 25 µM lopinavir over 72 hrs 
were provided which were thoroughly resuspended in 50 µl CelLytic-MTM cell lysis buffer (Sigma-
Aldrich, Dorset, UK). Protein concentrations were estimated using the Bradford assay (described in 
section 4.3.4) and normalised using CelLytic-MTM cell lysis buffer, to ensure equal loading of 
proteins. Proteins were separated on a 12% SDS-PAGE gel as described in section 5.3.2.4 and 
proteins transferred to Hybond-C nitrocellulose membrane. This was immuno-probed with primary 
rabbit anti-RNase L antibody, followed by primary mouse anti-GAPDH to confirm equal loading 
(section 5.3.2.5). 
 
5.3.2.4. Sodium dodecyl sulphate Polyacrylamide Gel  Electrophoresis  
 
A Whatman minigel twin system (Whatman Biometra, Goettingen, Germany) was used for 
the separation of proteins by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE). In brief, gel casting moulds were assembled according to the manufacturers’ instructions. 
A 12% separating gel was prepared (5 ml sdH20, 6 ml 30% acrylamide solution, 3.8 ml 1.5M Tris-
HCL (pH 8.8), 150 µl 10% SDS solution, 150 µl 10% ammonium persulphate (APS) solution 
(Sigma Aldrich, Dorset, UK) and 6 µl N, N, N’, N’-tetramethylethylenediame (TEMED) (Sigma 
Aldrich, Dorset, UK)), poured and overlaid with sdH20 to prevent drying out and to ensure a smooth 
interface between gels. After complete polymerisation, a stacking gel was prepared and poured 
(2.7 ml sdH20, 670 µl 30% acrylamide solution, 500 µl 1M Tris-HCL (pH 6.8), 40 µl 10% SDS, 40 µl 
10% APS and 4 µl TEMED) allowing a depth of 1 cm between the bottom of the sample well and 
the separating gel. An appropriate sample well comb was put in place and the stacking gel allowed 
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to fully polymerise. Proteins from 0.5 x 106 cells (20 µl) were loaded along side 10 µl Novex sharp 
prestained protein standards (Invitrogen, Paisley, UK) and were separated in 1 x Laemmle running 
buffer at 20 mA.  
 
 
5.3.2.5. Western blot 
 
Protein transfer and western blotting was carried out using the method originally described 
by Towbin et al (1979) [312]. Proteins were transferred onto Hybond-C nitrocellulose membrane 
(Amersham Biosciences, Bucks, UK) soaked in 1 x transfer buffer containing methanol using a 
Whatman Biometra semidry blotter (Whatman Biometra, Goettingen, Germany) for 40 min at 10 V.  
The membrane was air dried prior to blocking in PBS containing 5% non-fat milk powder and 0.1% 
Tween-20 (Sigma Aldrich, Dorset, UK) for 2 hrs at room temperature with gentle shaking. After 
three PBS washes, membranes were incubated overnight at 4 °C with primary rabbit anti-RNase L 
antibody (ab32307, Abcam, Cambridge, UK) at a concentration of 1/500 in PBS with gentle 
shaking. Following three 5 min PBS washes membranes were incubated for 2 hrs at room 
temperature with swine anti-rabbit horse radish peroxidise (HRP) conjugated secondary antibody 
(Dako, Cambridge, UK) at a concentration of 1/2000 in PBS containing 5% non fat milk powder 
with gentle shaking. Following three further 5 min PBS washes, proteins were visualised using ECL 
(Amersham Biosciences, Bucks, UK) and exposure to hyperfilm (Amersham Biosciences, Bucks, 
UK) according to the manufacturer’s recommendations. 
Membranes were re-probed with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
housekeeping protein antibody to confirm equal protein loading. Following a brief PBS wash, the 
membrane was incubated for 1 hr at room temperature in 5% non-fat milk powder in PBS with 
gentle shaking. Membranes were incubated for 2 hrs at room temperature with primary mouse anti-
GAPDH (ab9484, Abcam, Cambridge, UK) at a concentration of 1/1500 with gentle shaking. These 
were given three 5 min PBS washes then incubated for 2 hrs at room temperature with rabbit anti-
mouse HRP conjugated secondary antibody (Dako, Cambridge, UK) at a concentration of 1/2000 in 
PBS containing 5% non-fat milk powder. Proteins were visualised using ECL and exposure to 
hyperfilm (Amersham Biosciences, Bucks, UK) according to the manufacturers’ instructions. 
 
 
 
5.3.3. Analysis of the endogenous inhibitor of RNase L (ABCE1) protein levels in 
SiHa cells in response to increasing lopinavir concentration and increasing 
incubation time 
 
 
Using the protein lysates samples produced in section 5.3.2.1, proteins were again 
separated using a 12% SDS-PAGE gel and transferred to Hybond-C nitrocellulose membrane as 
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described in sections 5.3.2.4 and 5.3.2.5 respectively. Primary rabbit anti-ABCE1 antibody (Abcam, 
Cambridge, UK, ab32270) was used at a concentration of 1/200 in PBS containing 0.1% BSA, and 
the membranes incubated for 2 hrs at room temperature with shaking. Membranes where then 
rinsed with three 5 min incubations in PBS and incubated with swine anti-rabbit HRP conjugated 
secondary antibody (Dako, Cambridge, UK) as described in section 5.3.2.4, before being visualised 
with ECL and Hyperfilm. A GAPDH loading control western blot was carried out as described 
above. 
 
 
 
 
 
5.3.4. Analysis of RNase L expression in lopinavir treated E6/E7 immortalised 
PHFKs 
 
Having previously demonstrated the increased susceptibility of E6/E7 immortalised PHFK 
cells to lopinavir when compared to non-transduced PHFK cells (Chapter 3, Figure 3.5) the 
expression of RNase L protein in E6/E7 immortalised PHFK cells exposed to 25 µM lopinavir for 72 
hrs was assessed by western blotting, using the techniques described in sections 5.3.2.4 and 
5.3.2.5.  
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5.4. Results 
 
5.4.1. Analysis of mRNA expression levels following lopinavir treatment 
 
The Sigma Panorama XPRESS-profiler 725 antibody microarray demonstrated that 
lopinavir treatment caused an up-regulation in RNase L in HPV positive SiHa cells. However, this 
accumulation of RNase L protein levels could have arisen through several possible mechanisms; 
lopinavir could be stimulating an up regulation in RNase L mRNA transcription, increasing the rate 
of protein translation or inhibiting protein breakdown. RT-PCR analysis (section 5.3.1) was used for 
semi-quantitative comparison of RNase L mRNA levels between lopinavir and DMSO control 
treated in a range of HPV positive and negative cell lines (Figure 5.5). This confirmed the presence 
of RNase L mRNA PCR product at the expected size of 194 bp in Caski, SiHa and the full range of 
Tert cells. These data also demonstrated the absence of RNase L transcripts in C33A vector and 
E6 cells, which is the subject of further investigated in Chapter 6. Significantly, lopinavir produced 
no significant changes in the mRNA levels of RNase L when compared to DMSO treated control 
cells.  
 
 
 
Figure 5.5 RNase L mRNA expression levels following lopinavir treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 – RNase L mRNA expression levels were assessed in a range of HPV positive and HPV 
negative cell lines. Cells were treated with 25 µM lopinavir (+) or DMSO (-) untreated control. Cells 
were harvested at 6 hrs and RT-PCR carried out using RNase L specific and PLA control primers. 
Tert cells were treated at a final concentration of 5 µM. Samples were separated along side a 
100bp PCR ladder. No noticeable alteration in mRNA expression was observed. 
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In order to confirm that lopinavir treatment did not alter RNase L mRNA expression in SiHa 
cells, the RT-PCR analysis was carried out in triplicate cultures of SiHa cells following 6 hr 
incubation with 25 µM lopinavir or an equal volume of DMSO (Figure 5.6). Subsequent 
densitometric analysis was carried out using Image J analysis program (http://rsbweb.nih.gov/ij/), 
with mean values and standard deviations calculated using Microsoft Excel (2003). Lopinavir 
treatment was shown to have no effect on RNase L mRNA levels when compared to DMSO treated 
control cDNA (p = 0.244, with values less than 0.05 considered significant). 
 
 
 
 
Figure 5.6 Lopinavir does not significantly alter RNase L mRNA levels 
 
 
 
Figure 5.6 – SiHa cells were grown to 80% confluency at which point they were treated with 25 M 
lopinavir (+) or DMSO control (-) for 6 hrs. Cells were harvested and RT-PCR was repeated in 
triplicate using RNase L and GAPDH control primers. RT-negative control samples (RT-) were 
included for both treated and untreated cells to demonstrate the absence of genomic DNA 
contamination.  
 
 
 
 
 
5.4.2. Lopinavir produces a dose dependent increase in RNase L protein levels in 
SiHa cells. 
 
The lopinavir induced increase in RNase L protein levels (Chapter 4) was confirmed with 
western blot analysis of protein lysates prepared as in section 4.3.2 (Figure 5.7(A)). This 
demonstrated an increase in RNase L protein levels following 6 hr incubation with 25 µM lopinavir 
when compared to a DMSO treated control cell protein lysate. Following on from this, the 
relationship between lopinavir dose and RNase L expression was also assessed by western 
blotting. Lopinavir was shown to produce a clear dose dependent increase in RNase L over the 
concentration range studied (Figure 5.7(B)). RNase L signal strengths are displayed as relative 
intensity compared to matched GAPDH controls, and demonstrate a clear dose-dependent 
increase in RNase L expression Figure 5.7(C). 
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Figure 5.7 - Lopinavir produces a dose-dependent increase in RNase L  
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Figure 5.7 – (A) Western blot analysis on 6hr 25 µM lopinavir treated SiHa cells prepared during 
the antibody microarray analysis. Proteins separated on a 12% SDS-PAGE. A western blot was 
carried out using primary rabbit anti-RNase L and mouse anti-GAPDH antibodies. Confirms the 
induction of RNase L protein in lopinavir treated SiHa cells. (B) Western blot analysis on SiHa cells 
treated with an escalating dose of lopinavir for 6 hrs (C) Image J (available from 
http://rsbweb.nih.gov/ij/) density analysis of protein signals from western blot, shown as a relative 
intensity compared to matched GAPDH signals shows a clear dose dependent increase in RNase 
L protein levels. Analysis based on a single experiment. (D) Full image western blot, RNase L/ 
lopinavir dose response.  
 
 
 
 
 
5.4.3. Lopinavir produces time dependent changes in RNase L protein levels in 
SiHa cells 
 
Having demonstrated the ability of lopinavir to produce a dose dependent increase in 
RNase L protein levels in SiHa cells, the relationship between changes in incubation times at a 
fixed lopinavir concentration of 25 µM was assessed. Western blot analysis demonstrated a clear 
time-dependent increase in RNase L protein level (Figure 5.8(A)). Again, densitometric analysis 
was used to express RNase L signal as a relative intensity based on matched GAPDH control and 
demonstrated an almost linear increase in RNase L over the time points studied (Figure 5.8(B)). 
The peak signal strength occurred 8-12 hrs post-incubation, followed by a reduction in signal 
strength at 24 hrs. 
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Figure 5.8 - Lopinavir produces a time dependent increase in RNase L 
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Figure 5.8 – SiHa cells were treated with lopinavir at 25 µM for 2, 4, 6, 8, 12 and 24 hrs before 
being harvested. (A) Proteins were separated on a 12% SDS-PAGE and transferred to Hybond-C 
nitrocellulose membrane and a western blot carried out using primary rabbit anti-RNase L and 
mouse anti-GAPDH antibodies. (B) Image J (http://rsbweb.nih.gov/ij/) density analysis of protein 
signals from western blot, shown as a relative intensity compared to matched GAPDH signals, 
based on a single experiment. This demonstrates a clear time dependent increase in RNase L 
protein levels, with a peak at 12 hrs, followed by a reduction in levels at 24 hrs. 
 
 
5.4.4. Lopinavir induces a significant increase in RNase L expression 
 
Based on the triplicate RNase L western blot data from Figures 5.7(A) and (B) and Figure 
5.8(A), mean RNase L and GAPDH signal strengths were evaluated for all the 6 hr, 25 µM lopinavir 
data points shown. Using densitometric analysis (Image J) software, mean intensities, mean 
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relative intensities and standard deviations were calculated using Microsoft Excel, and are shown 
below (Figure 5.9). A ‘p’ value below 0.05 was considered significant and a student t-test was 
performed using Microsoft excel (2003) to compare lopinavir and DMSO treated protein lysates. 
Cells exposed to 25 µM lopinavir for 6 hrs showed a very significant 9.5-fold increase in RNase L 
protein (p = 0.005) when comparing DMSO control cells (Figure 5.9). 
 
 
Figure 5.9 – Lopinavir produces a significant increase in RNase L protein levels 
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Figure 5.9 – Using the Image J density analysis program, mean relative intensities were calculated 
based on triplicate data sets of the untreated DMSO control and six hour lopinavir (25 µM) treated 
RNase L signals. Lopinavir treatment was shown to induce a significant 9.5-fold increase in RNase 
L protein levels in SiHa cells, when compared to matched DMSO treated control cells. 
 
 
 
5.4.5. Lopinavir does not effect ABCE-1 protein levels in SiHa cells 
 
Having confirmed a lopinavir induced time and dose dependent increase in RNase L 
protein expression in SiHa cells following lopinavir treatment, the effects of lopinavir on the 
endogenous inhibitor or RNase L (ABCE1) were assessed. Although RNase L protein was 
increased following lopinavir treatment, it was not known what effect this treatment had on ABCE1 
protein levels. Thus, using the dose and time response lysates prepared in section 5.3.2.1 and 
5.3.2.2 respectively, proteins were separated using a 12% SDS-PAGE gel (Section 5.3.2.4) and a 
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western blot was immunoprobed using a primary rabbit anti-ABCE1 antibody (section 5.3.3) with 
GAPDH as a loading control (section 5.3.2.4).  
Figures 5.6 and 5.7 illustrate the western blot data of ABCE1 protein levels in SiHa cells 
treated with an escalating dose of lopinavir or for increasing time period at a fixed concentration of 
lopinavir. In contrast to RNase L protein levels, ABCE1 protein levels remain unchanged regardless 
of lopinavir concentration or incubation time period. This demonstrates that the observed increases 
in RNase L protein were not accompanied by any alteration in the levels of its endogenous 
inhibitor, ABCE1. 
 
 
Figure 5.10 – Lopinavir concentration does not alter ABCE1 protein levels 
 
 
Figure 5.10 - SiHa cells were treated with escalating concentrations of lopinavir. At 6 hrs, cells 
were harvested and proteins separated on a 12% SDS-PAGE. Proteins were transferred on to 
Hybond-C nitrocellulose membrane and a western blot carried out using primary rabbit anti-ABCE1 
and mouse anti-GAPDH antibodies. No dose dependent changes in ABCE1 protein levels were 
observed in HPV positive SiHa cells. 
 
 
Figure 5.11 Lopinavir incubation time does not alter ABCE1 protein levels 
 
 
 
Figure 5.11 - SiHa cells were treated with a fixed dose of 25 µM lopinavir for the incubation periods 
shown. Cells were harvested at these time points and proteins separated on a 12% SDS-PAGE. 
Proteins were transferred on to Hybond-C nitrocellulose membrane and a western blot carried out 
using primary rabbit anti-ABCE1 and mouse anti-GAPDH antibodies. No time dependent changes 
in ABCE1 protein levels were observed in HPV positive SiHa cells. 
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5.4.6. Lopinavir up-regulates RNase L in E6/E7 immortalised PHFK 
 
RNase L protein levels in E6/E7 transduced PHFKs exposed to lopinavir were assessed by 
western blotting. As previously demonstrated for SiHa cells, lopinavir induced an increase in 
RNase L albeit at a slower rate than was observed in SiHa cells (Figure 5.8(A)). While 25 µM 
lopinavir caused a peak RNase L signal in SiHa cells after 8 h with a subsequent drop after 24 hr 
(Figure 5.8), E6/E7 expressing PHFKs peaked at 48 hr followed by a subsequent drop after 72 hr 
(Figure 5.12).  
 
Figure 5.12 - Lopinavir up-regulates RNase L in E6/E7 expressing PHFK 
 
 
Figure 5.12 - E6/E7 immortalised PHFK were exposed to lopinavir (25 µM) over a 72 hr time period 
and harvested at the time points indicated. Proteins were separated on a 12% SDS-PAGE and 
transferred to Hybond-C nitrocellulose membrane and a western blot carried out using primary 
rabbit anti-RNase L and mouse anti-GAPDH antibodies. 
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5.5. Chapter Summary and Discussion 
 
As previously demonstrated, lopinavir treatment of SiHa cells was shown to alter protein 
expression of a number of proteins with a variety of biological functions. Of most interest, was the 
observed increase in the levels of the antiviral protein RNase L following lopinavir treatment 
(Chapter 4).  
These data are the first to demonstrate this effect in HPV positive cervical carcinoma SiHa 
cells and in stable HPV16 E6/E7 transfected human keratinocytes (PHFK). 
In order to further investigate the relationship between lopinavir and RNase L, RT-PCR and 
western blotting was carried out in order to determine both dose and time dependent variations in 
RNase L expression. Lopinavir associated variations in the level of ABCE1 were also investigated 
since it was not known if this would increase in parallel with RNase L, which would effectively limit 
its effectiveness. 
Interestingly, the RT-PCR data (Figure 5.5) demonstrated an absence of RNase L in C33A 
vector and E6 cells implying that the function of RNase L protein may be deleterious to the growth 
of these cells. Thus, as a consequence RNase L expression is down-regulated in these cells. This 
is an interesting finding, and one that is further utilised in Chapter 6.  
RT-PCR also demonstrated no apparent changes in the RNase L mRNA levels in a range 
of HPV positive and negative cell lines following lopinavir treatment (Figure 5.5). Triplicate RT-PCR 
analysis of lopinavir treated SiHa cells demonstrated no significant difference in RNase L mRNA 
levels (Figure 5.2 (B), p = 0.24) indicating that the increase in RNase L protein levels is not related 
to an increase in gene transcription (Figure 5.6). This does not, however, rule out a lopinavir-
induced increase in protein translation. However, by measuring the rate of incorporation of 35S-
Methionine into newly formed proteins as a surrogate marker for protein translation, Pyrko et al., 
demonstrated that the HIV protease inhibitors atazanavir (Reyataz®) and nelfinavir (Viracept®) 
were not associated with an increase in protein translation [313]. Taking these findings into 
account, it is suggested that the observed increase in RNase L protein is related to an 
accumulation of protein as a consequence of lopinavir-induced inhibition of proteolysis. This is due 
to its ability to cause selective inhibition of the chymotryptic-like function of the proteasome [131]. 
The relationship between lopinavir and RNase L in SiHa cells was further investigated by 
assessment of the time and dose dependent response to this drug.  Lopinavir was shown to 
produce a clear dose-dependent increase in RNase L levels over a concentration range of 5 - 30 
µM (Figure 5.7 (B) & (C)) at a fixed incubation time of 6 hrs. It was noticed that lopinavir 
precipitated at concentrations above 30 µM (data not shown), so this was chosen as a maximum 
treatment dose.  
Figure 5.8 demonstrates the clear time dependent increase in RNase L protein levels 
following lopinavir treatment. Time dependent increase in levels of the proteasomally-targeted 
protein p53 following lopinavir treatment of SiHa cells has been previously demonstrated [131]. The 
peak of RNase L expression at 8-12 hrs post-incubation with lopinavir is consistent with this earlier 
data. The drop in RNase L protein levels at 24 hrs lopinavir treatment was associated with a drop in 
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GAPDH loading control protein levels. The explanation for this is most likely due to the previously 
reported apoptotic/ toxic effects of the drug at this time point [131].  
Based on our data, statistical analysis established that in SiHa cells, 6 hr treatment with 
lopinavir at a final concentration of 25 µM produced a significant 9.5-fold increase in RNase L 
levels (p = 0.0053), when assessed by western blot and triplicate densitometric analysis (Figure 
5.9). Interestingly, whilst still exhibiting a lopinavir-dependent increase in RNase L expression, 
E6/E7 immortalised PHFKs demonstrated a much slower accumulation of RNase L (Figure 5.12). 
Whilst SiHa cells demonstrated a peak in signal strength at approximately 8 hrs, the PHFK data 
demonstrated a peak after approximately 48 hrs followed by a reduction at the 72 hr time point, 
which may related to differences in cell growth rates, or perhaps differences in the kinetics 
associated with proteasomal inhibition between these cell types. 
 RNase L protein is regulated by an endogenous inhibitor, ABCE1, and previous studies 
have shown that ABCE1 expression can be induced during HIV-1 infection, with subsequent down 
regulation of the RNase L antiviral pathway [266]; In a similar fashion to HIV, it was hypothesised 
that HPV may also be facilitating an increase in ABCE1 levels in SiHa cells and it was therefore 
suggested that the increase in RNase L protein level could conceivably be related to a fall in 
ABCE1 protein levels as a result of lopinavir treatment. Alternatively, lopinavir may induce an 
increase in ABCE1 levels, which would therefore reduce the pro-apoptotic functions of RNase L. A 
fall in ABCE1 levels would in turn increase availability of functional RNase L monomers that are 
capable of activation. Our data demonstrated no alterations in ABCE1 protein levels, regardless of 
lopinavir concentration or incubation time (Figures 5.10 and 5.11 respectively). Therefore, these 
studies support the concept that lopinavir-induced inhibition of proteasomal degradation is 
responsible for the observed increase in RNase L protein in SiHa cells. The importance of RNase L 
in HPV-specific lopinavir toxicity will be further assessed in Chapter 6.  
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6. RNase L and Lopinavir Toxicity 
 
6.1. Introduction 
 
The results discussed previously demonstrated a dose dependent increase in RNase L protein 
levels over a concentration range of 5-30 µM with a peak occurring 12 hours post treatment in SiHa 
cells. It was also shown that this lopinavir-induced increase in RNase L was not accompanied by 
altered expression of the endogenous inhibitor of RNase L (ABCE1) regardless of concentration or 
incubation time. The following section describes gene silencing, forced expression and co-
immunoprecipitation experiments to assess the contribution of RNase L and its inhibitor ABCE1 to 
toxicity of lopinavir against HPV positive cells. 
 
 
 
6.1.1. Gene silencing 
 
The RNA interference (RNAi) system is an essential pathway through which the expression 
of specific target genes is inhibited (Figure 6.1), with a subsequent reduction in protein levels. It is 
initiated by double stranded RNA (dsRNA) and is involved with natural protein degradation and 
turnover in animals and plants [314, 315]. Most notably, this mechanism can be artificially used to 
silence specific genes of interest, which greatly facilitates ascribing function to their corresponding 
protein. There are two main laboratory-based techniques to bring about targeted gene silencing: 
short hairpin RNA (shRNA) and small interfering RNA (siRNA)  
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Figure 6.1 – Mechanism of siRNA mediated inhibition of protein synthesis 
 
 
Figure 6.1 – Mechanism of siRNA-mediated inhibition of protein synthesis. dsRNA is degraded by 
DICER to produce siRNA complexes with 2nt over hangs at the 3’ ends of each strand. The lead 
siRNA strand binds to target mRNA sequences in a sequence specific manner through interaction 
with the RNA Induced Silencing Complex (RISC) which has the Argonaute-2 (Ago2) protein at its 
core. mRNA degradation prevents protein synthesis of the target protein. 
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6.1.1.1. Advantages and disadvantages of siRNA and shRNA 
 
In order to assess the role of RNase L, small interfering RNA (siRNA) mediated gene 
silencing is one possible option to knock down production of the protein. During siRNA-mediated 
RNA interference (RNAi), mRNA for a given protein is degraded by introduction of corresponding 
double stranded RNA (dsRNA) as reviewed in [254, 316, 317]. An alternative method is that of 
short hairpin RNA interference (shRNA) with the main difference between siRNA and shRNA’s 
relating to the means of delivery and generation of the dsRNA silencing duplexes [318]. Direct 
liposome-mediated siRNA oligonucleotide interference has the advantage of being rapid, but is 
only transient. When using this approach siRNA oligonucleotides are observed within the cell within 
as little as 4hrs of lipofection, producing a peak of activity at 24 hrs. However, as little as 1% of the 
initially introduced siRNA duplex remains by 48hrs, highlighting the ‘hit and run’ nature of siRNA-
based protein knockdown [319]. Short hairpin, shRNA sequences are delivered as DNA encoded 
within an integrated mammalian expression vector which allows constitutive expression of siRNA 
silencing duplexes. Although this approach is considerably more efficient [318], it can introduce 
clonal selection artefacts. Therefore, given the short timescale of the planned growth assays, it was 
decided to use transient siRNA oligonucleotide lipofection to silence RNase L expression. 
 
  
6.1.2. Constitutive expression of RNase L 
 
In a similar fashion to the previously described methods of gene silencing, proteins can 
also be artificially expressed as stable or transient transfectants. However, in order to achieve 
stable expression of a toxic protein it is usually necessary to use an inducible system. Alternatively, 
if the intended assay permits, transient expression of the target protein is a quick alternative for the 
study of toxic proteins; Because a cell death assay provides an ideal means to assess the impact 
of re-introducing RNase L into cells, it was decided that transient expression would be appropriate. 
 
 
6.1.3. Protein-Protein interactions by Co-immunoprecipitation 
 
Protein-protein interaction studies will be performed in order to confirm the role of the 
RNase L/ ABCE1 interaction in the observed toxicity of lopinavir. Co-immunoprecipitation will be 
used to identity or confirm protein-protein interactions and is summarised in Figure 6.2. Briefly a 
target protein (X) specific antibody is firstly incubated with a homogenised cell protein lysate. This 
is then mixed with protein G sepharose beads which bind to the constant region of immunogloblins 
from many species. The antibody plus protein X binds to the protein G beads and unbound proteins 
are removed by washing. Any proteins (Y) which interact either directly or indirectly with protein X 
should remain associated with the beads and will thus be eluted along with protein X. Western 
blots can then be used to analyse protein X immunoprecipitated material for the presence of both 
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protein X and Y. The main advantage of a Co-IP reaction is that it is a quick means to demonstrate 
the association of two or more proteins in a cell lysate, although it does not confirm a direct 
physical association as the interaction may occur as part of a larger multi-protein complex [320].  
Other considerations are the quality of the available primary target antibodies and the strength of 
the interaction between the two ligands (X & Y) – If this is a weak interaction, it is unlikely that the 
Co-IP will be successful. 
 
 
Figure 6.2 – Simplified Co-immunoprecipitation schematic 
 
 
 
 
 
Figure 6.2 – Co-immunoprecipitation (Co-ip) allows protein-protein interactions to be studied. The 
antibody to protein X is immobilised on a solid support such as protein G sepharose beads, before 
binding to protein Y. Should Protein X and protein Y interact in vivo, the interaction can be 
confirmed by western blot analysis using a primary antibody targeting protein Y. This demonstrates 
that Protein X and protein Y are interacting in their native cellular states. 
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6.2.  Aims 
 
6.2.1. Assess the effects of siRNA mediated degradation of RNase L on cell growth in 
untreated cells and also in lopinavir treated cells 
6.2.2. Assess the effects of over expression of RNase L in RNase L-deficient C33A cells 
by transient transfection 
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6.3. Methods 
 
6.3.1. siRNA mediated degradation of RNase L mRNA 
 
6.3.1.1. Pilot study to test siRNA effectiveness 
 
siRNA mediated degradation of RNase L was carried out using Qiagen’s flexitube system 
specific for RNase L (Qiagen, West Sussex, UK) which provided four RNase L specific siRNA (1, 2, 
3 and 4), and were designed to exhibit no off-target effects. ALLSTAR negative and MAP kinase 
positive controls were also used (All siRNA target sequences used are shown in Appendix 4) All 
siRNAs were reconstituted in 100 µl sterile RNase-free water providing a 10 µM stock solution. 
Previous work (Chapters 4 & 5) highlighted a lopinavir-induced alteration in a range of 
protein expression levels. Of most interest was the observed increase in the antiviral protein RNase 
L in SiHa cells exposed to lopinavir. However, whilst an interesting protein, the anti-HPV effects of 
lopinavir may be as a result of synergism between a range of proteins, rather than simply being 
restricted to RNase L-mediated effect. It is therefore essential that the true importance of RNase L 
in mediated HPV-specific toxicity be assessed. Furthermore, the E6 protein of high risk HPV types 
is known to be an extremely pleiotropic protein, mediated a wide range of responses. Based on this 
observation, it is feasible that E6 may in some way interact with RNase L and/or lopinavir. It is 
again essential, that the true significance of E6 be assessed, and again C33A/ C33AE6 cells 
provide a perfect cell culture system by which to assess this. 
Briefly, SiHa cells were seeded at 5 x 104 cells/ well in 6-well plates in a total volume of 2 
ml complete RPMI-1640 growth medium and allowed to reach 80% confluency at 37°C/ 5% CO 2. 
Cells were transfected using the lipofectamine-2000 reagent according to the manufacturers’ 
recommendations (Invitrogen, Paisley UK). In a round-bottomed cryovial a 6 µl aliquot of siRNA 
was combined with a 250 µl aliquot of OptiMem (serum free medium, (Invitrogen, Paisley UK)). In a 
separate round bottomed cryovial, a 25 µl aliquot of lipofectamine-2000 (Invitrogen, Paisley, UK) 
was combined with 250 µl of OptiMem. Both tubes were then incubated at room temperature for 5 
min. The contents of both tubes were then combined, incubated for a further 20 min at room 
temperature and 106.2 µl of transfection mix was added drop wise to each well as detailed in 
Figure 6.3. 
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Figure 6.3 – 6-well plate layout for pilot siRNA study 
 
 
 
 
Figure 6.3 - 6 well plate layouts for siRNA transfection. In order to provide sufficient cell numbers 
for analysis, cells were seeded into all wells of four plates, allowing duplicate wells for each siRNA/ 
control samples to be harvested at both 24 hrs and 48 hrs to identify time dependent differences in 
protein knockdown. Four wells were transfected for each of the four siRNAs and two control 
siRNAs (1, 2, 3, 4 – Test siRNA; MAPK, Map Kinase negative control; All Stars, Negative control). 
 
 
Six hours prior to harvesting, cells were exposed to 25 µM lopinavir as a means to 
artificially elevate low levels of endogenous RNase L. Twenty-four hours post-transfection, the 
growth medium was aspirated and each well washed with 2 ml PBS. 100 µl of trypsin was added 
and the plates returned to the incubator for 2-3 min, or until complete cell detachment had 
occurred. Addition of 1ml complete RPMI-1640 was then used to neutralise the trypsin and 
resuspend the cells and appropriate duplicates pooled. Cell numbers were determined using a 
haemocytometer (as detailed in section 2.3.3) and protein lysates prepared for SDS-PAGE/ 
western blot analysis (as detailed in section 5.3.2.1) which were stored at -20°C until use. These 
were separated on a 12% SDS-PAGE gel as detailed in section 5.3.2.4 and a western blot carried 
out as described in section 5.3.2.5 immuno-probing the membrane with primary rabbit anti-RNase 
L antibody and GAPDH as a loading control.  
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6.3.1.2. AQ-96 Cell Proliferation assay in siRNA transfected SiHa +/- Lopinavir 
 
Two thousand cells were seeded per well in a 96-well plate in a total volume of 200 µl 
complete RPMI-1640. Twenty-four hours later the cells were transfected with RNase L (siRNA-1), 
MAPK or ALLSTAR control siRNA using the same transfection mixture detailed above in section 
6.3.1.1 with volumes adjusted for the different well size. Twenty-four hours later the growth medium 
was aspirated from all wells and replaced with 200 µl complete RPMI-1640 growth medium 
supplemented with lopinavir at final concentrations of 20, 25 and 30 µM. A 72hr AQ-96 cell 
proliferation assay was then carried out as described in section 3.3.2. 
 
 
 
6.3.2. Lopinavir does not up-regulate RNase L in lopinavir resistant CaSKi cells 
 
CaSKi cells were cultured (as described in section 2.3.3) to a confluency of 80% 
whereupon they were treated with DMSO or an increasing dose of lopinavir over a range of 5 - 30 
µM, in 5 µM increments with DMSO levels adjusted to remain constant throughout. Six hours post 
incubation with lopinavir cells were harvested and prepared and separated by SDS-PAGE as 
described in sections 5.3.2.1 and 5.3.2.4 and a western blot immunoprobed with RNase L and 
GAPDH loading control as described in section 5.3.2.5.  
 
 
6.3.3. Over expression of RNase L in C33A parent and C33AE6 cells 
  
6.3.3.1. Maxi prep of RNase L vector 
 
An RNase L mammalian expression vector (EX-U1047-M02 Vector GeneCopoeia, MD, 
USA – See Appendix 1 for vector map) was used for studies involving the over expression of 
RNase L and was reconstituted using 50 µl 1 x Tris-EDTA (TE) buffer, and incubated at room 
temperature for 60 min. A 6.5 µl aliquot was then used to transform a 50 µl aliquot of chemically 
competent XL-1 Blue E.coli cells, and plated onto LB agar plates as detailed in section 2.3.8. 
Laboratory stocks of the RNase L expression vector were prepared using the Qiagen Maxi plasmid 
purification kit according to the manufacturer’s instructions (Qiagen, West Sussex, UK) and the 
sample adjusted to 1 µg/µl using 1 x TE buffer and stored at -20°C until further use. 
 
 
6.3.3.2. Transient transfection of C33A parent and C33AE6 cells with RNase L  
 
The RNase L vector prepared in section 6.3.3.1 was used to transiently transfect C33A 
parent and C33AE6 cells. Cells were grown in T-25 culture flasks to a confluency of 80%, 
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whereupon they were each transiently transfected with the RNase L vector DNA as follows. 
Plasmid DNA (3.33 µl from 1 µg/µl stock solution) was combined with 116.7 µl OptiMem serum free 
medium whilst 15 µl of lipofectamine-2000 was combined with 116.7 µl of OptiMem aliquoted into a 
separate tube and incubated at room temperature for 5 min. Both solutions were then combined 
and incubated at room temperature for a further 20 min prior to drop wise addition to the culture 
flask. A lipofectamine-2000 only control transfection mix was also set up as above. Transfection 
efficiency was assessed by co-transfection of RNase L expression vector with the β-galactosidase 
expression vector pCDNA 3.1 V5-HIS lacZ at a ratio of 4:1. Shortly prior to the transfection, growth 
medium containing free floating viable cells was removed from each of the T-25 culture flasks and 
placed in a labelled 50 ml falcon tube and the cells pelleted by centrifugation, at 528 x g for 5 min. 
The supernatant was aspirated and the cell pellets resuspended in 10 ml complete RPMI-1640 and 
returned to the correct T-25 culture flask. All flasks were incubated at 37°C/ 5% CO 2. 
 
  
6.3.3.3. Twenty-four hour Live/Dead cell count 
 
Twenty four hours post-transfection, the growth medium containing free floating cells was 
removed from the culture flasks and transferred to a 50 ml falcon tube. Cell monolayers were 
washed with PBS and 230 µl of pre-warmed trypsin added and the flasks returned to the incubator 
for 3 min until complete cell detachment had occurred. The trypsin was then neutralised by addition 
of the complete growth medium previously removed from each specific flask, thoroughly 
resuspending the cells. A haemocytometer live/dead cell count was then performed using trypan 
blue exclusion (Sigma Aldrich, Dorset, UK) and number of blue cells expressed as a percentage of 
the total number of cells counted. Duplicate cell counts were performed for each culture flask. 
Subsequently, the lacZ expressing cells were fixed and stained for ß-Galactosidase activity 
as described in section 2.3.10 and the transfection efficiencies for both C33A parent and C33AE6 
cells calculated as detailed in section 2.3.11. Transient transfection and 24 hr live/dead counts 
were repeated in triplicate.  
 
 
6.3.4. The effect of the HPV type 16 E6 protein on RNase L and its endogenous 
inhibitor of RNase L (ABCE1) 
 
6.3.4.1. Transient Transfection and cell harvesting 
 
C33A parent and C33AE6 cells were transiently transfected with RNase L as previously 
described and protein extracts harvested at 4, 8, 12 and 24 hrs post transfection (described in 
section 6.3.3.2). Protein lysate was also prepared from lipofectamine-only untransfected control 
cells. All samples were subjected to three cycles of freeze/thaw, with heating to 95°C. 
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6.3.4.2. SDS-PAGE and Western Blot 
 
Protein samples were then separated using a 12% SDS-PAGE gel as described in section 
5.3.2.4 and a western blot carried out as detailed in section 5.3.2.5. The membrane was probed 
using primary rabbit anti-RNase L antibody and also rabbit anti-ABCE1 antibody, as described in 
sections 5.3.2.5 and 5.3.3 respectively. GAPDH was used as a loading control as described 
previously. 
 
 
6.3.5. Effect of HPV E6 protein and/or lopinavir on the Nuclear/ Cytoplasmic shift of 
RNase L 
 
6.3.5.1. Immunohistochemistry staining of RNase L 
 
SiHa cells were seeded at 2 x 104 cells per well in two 8-well slide flasks (BD Falcon 
Biosciences, Oxford, UK) in a total volume of 500 µl complete RPMI-1640 and incubated at 37°C 
5% CO2. Upon reaching 80% confluency the growth medium was aspirated and replaced with 500 
µl fresh complete RPMI-1640 supplemented with either 25 µM lopinavir or an equal volume of 
DMSO. The flasks were returned to the incubator for 6 hrs after which the growth medium was 
aspirated and all cells rinsed twice in 500 µl PBS before being fixed for 10 min with 500 µl 2% 
paraformaldehyde. Cells were washed twice in 500µl PBS and permeabilised with 200µl PBS/0.1% 
Triton solution (Sigma-Aldrich, Dorset, UK) for 5 min at room temperature followed by treatment 
with 200 µl peroxidase inhibitor for 15 min at room temperature. These were then incubated with 
200 µl blocking solution (3% BSA in 1 x PBS) at room temperature for 45 min. The cells were 
washed with PBS and a 200 µl aliquot of each antibody dilution in PBS/ 0.015% triton added per 
well (Sigma-Aldrich mouse anti-RNase L (antibody R3529), 1:100 & 1:500, Abcam rabbit anti-
RNase L (antibody 32307), 1:50 & 1:250, and mouse anti-β-Actin loading control, 1:500 (Sigma 
Aldrich A1978)). DAB and all secondary-only antibody controls were treated with an equal volume 
of PBS/0.0.15% Triton and the slides were placed in a humidified chamber and incubated overnight 
at +4°C. 
Following washing with PBS, a 200 µl aliquot of a 1:500 dilution of the appropriate biotin 
conjugated secondary antibody was added in PBS/3% BSA. At this stage, PBS/3% BSA was 
added to the DAB only control wells and the slides were then incubated at room temperature for 45 
min. Following washing with PBS, cells were incubated with 200 µl Streptavidin-HRP conjugate 
(made up at a dilution of 3 µl/ml in PBS) for 30 min at room temperature then washed with PBS. All 
the wells were then incubated with 200 µl DAB solution for 10 min (DAB reagent diluted 1:10 with 
DAB kit buffer). The reaction was quenched with PBS and the cells dehydrated through an ethanol 
gradient prior to two 5 min xlyene incubations and mounting. 
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6.3.5.2. Nuclear/ cytoplasmic Fractionation 
 
C33A and C33AE6 cells were transiently transfected with RNase L as described in section 
6.3.3.2. Eight hours post-transfection, the growth medium was aspirated and replaced with 10 ml 
complete RPMI-1640 supplemented with 25 µM lopinavir or an equal volume of DMSO and all 
flasks returned to the incubator at 37°C/ 5% CO 2 for 6 hrs. The growth medium was then removed 
from the culture flasks and the cells detached with 230 µl trypsin which was subsequently 
neutralised by the addition of the complete medium previously removed from the flask. An aliquot 
containing 5 x 106 cells was then pelleted by centrifugation at 528 x g for 5 min after which the 
supernatant was then aspirated and discarded. The resulting cell pellet was washed with PBS and 
re-pelleted by centrifugation. 
Cell fractionation was carried out using the nuclear/ cytoplasmic fractionation kit from 
Thermo-Fisher Scientific (Fisher Scientific UK Ltd., Leicestershire, UK) according to the 
manufacturer’s directions. In brief, cytoplasmic extraction reagent-1 (CER1) and nuclear extraction 
reagent-1 (NER1) buffers were prepared with protease inhibitor cocktail (20 µl inhibitor cocktail/ml 
buffer) and 500 µl of ice cold CER1 buffer was added to each cell pellet, which was then vortexed 
for 15 sec. The sample was then incubated on ice for 10 min after which, 27.5 µl of ice cold 
cytoplasmic extraction reagent-2 (CER2) buffer was added, the sample vortexed for a further 5 sec 
and incubated on ice for 1 min. This was then centrifuged for 5 min at 16,000 x g after which the 
supernatant containing the cytoplasmic fraction was immediately transferred to a chilled eppendorf 
and stored at -80°C. The remaining cell pellet was re-suspended in 250 µl of ice cold NER1 buffer 
and vortexed for 15 sec placed on ice and vortexed for 15 sec every 10 min for a total of 40 min. 
The sample was subsequently centrifuged at 16,000 x g for 10 min and the supernatant containing 
the nuclear fraction transferred to a chilled eppendorf, before being stored at -80°C. 
In order to ensure equal loading of proteins, a Bradford assay was carried out as described 
in section 4.3.4. Cytoplasmic and nuclear samples were each normalised in CERI or NERI buffer 
respectively and the cell samples prepared for western blot analysis as described in section 5.3.2.1 
using 4 x Laemmle lysis buffer. A 15% SDS-PAGE gel (3.5ml sdH20, 7,5ml 30% acrylamide mix, 
3.8ml 1.5M Tris (pH 8.8), 150µl 10% SDS, 150 µl 10% APS and 6 µl TEMED) was prepared and 
overlaid with a stacking gel as detailed in section 5.3.2.4. Prior to loading, 1 µl ß-mercaptoethanol 
was added to each sample and proteins then separated as described in 5.3.2.4 and a western blot 
carried out as described in section 5.3.2.5 immuno-probing the membrane using primary rabbit 
anti-RNase L antibody as described in section 5.3.2.5. Efficient sub fractionation of nuclear and 
cytoplasmic proteins was confirmed by immunoprobing the extracts with mouse anti-GAPDH 
(section 5.3.2.5) and rabbit anti-HDAC1 (New England Biolabs, Herts., UK) used at a concentration 
of 1/800 in PBS. Subsequent washes and detection were carried out as described in section 
5.3.2.5. 
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6.3.6. Co-Immunoprecipitation of RNase L and ABCE1 from RNase L transiently 
transfected C33A parent and E6 cells 
 
C33A and C33A6 cells were transiently transfected with RNase L as described in section 
6.3.3.2. Eight hours post-transient transfection, the growth medium was aspirated from all culture 
flasks and replaced with 20 ml fresh complete RPMI-1640 supplemented with 25 µM lopinavir or an 
equal volume of DMSO. Six hours following the addition of lopinavir or DMSO control the growth 
medium was aspirated, cells washed with PBS and 500 µl ice cold CelLytic-MTM cell lysis buffer 
was added (Sigma Aldrich, Dorset, UK). The flasks were then incubated on ice for 5 min after 
which cells were detached using a sterile cell scraper, transferred to chilled eppendorf tubes and 
incubated at 4°C for 15 min with gentle vertical ro tation. Extracts were subsequently centrifuged at 
10,000 x g for 15 min at 4°C after which the supern atant was transferred to a chilled eppendorf and 
a Bradford protein assay carried out to determine protein levels as described in section 4.3.4. 
Equivalent protein concentrations were achieved by adding Cellytic-MTM cell lysis buffer. 
A uniform suspension of protein-G sepharose beads (Sigma Aldrich, Dorset, UK) was 
transferred to an eppendorf, and pelleted by centrifugation at 5,000 x g for 1 min, washed twice 
with 500 µl PBS, pelleted by centrifugation as above before finally being resuspended in 500 µl ice 
cold CelLytic-MTM cell lysis buffer (Sigma Aldrich, Dorset, UK). In order to minimise non-specific 
binding due to IgG contamination the samples were then incubated with 30 µl of the protein-G 
sepharose bead suspension for 2 hrs at 4°C on a ver tical rotator followed by centrifugation at 
10,000 x g for 1 min, and the supernatant transferred to a chilled eppendorf.  
Extracts were incubated overnight at 4°C with 1.5 µ g anti-ABCE-1 antibody and 75 µl of the 
protein-G sepharose suspension with gentle vertical rotation. The beads were pelleted by 
centrifugation at 10,000 x g for 2 min at room temperature, the supernatant containing unbound 
protein discarded and the protein-G sepharose beads washed once with 200 µl ice cold CelLytic-
MTM buffer. The beads were then pelleted by centrifugation at 5,000 x g for 1 min, the CelLytic-MTM 
cell lysis buffer aspirated and the samples resuspended in 80 µl 2 x Laemmle sample buffer prior to 
heating to 95°C for 5 min. These extracts were then  separated using a 12% SDS-PAGE gel as 
described in section 5.3.2.4 and a western blot carried immunoprobed with primary rabbit anti-
RNase L as described in section 5.3.2.5.  
In order to further assess the association between lopinavir and the ABCE1/RNase L complex, 
the co-immunoprecipitation reaction was repeated to include duplicate flasks grown with complete 
RPMI medium supplemented with 25 µM lopinavir or an equal volume of DMSO, and extracts 
harvested at 6, 12 and 24 hrs and processed as detailed above. 
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6.4. Results 
 
 
6.4.1. siRNA mediated protein knock down of RNase L 
 
6.4.1.1.  mRNA degradation efficiencies of available siRNA 
 
Figures 6.4(A) & (B) show the western blots of siRNA transiently transfected SiHa cells 
harvested at 24 hrs and 48 hrs respectively. In comparison to two separate controls, a MAP Kinase 
specific siRNA and an ALLSTAR negative siRNA, the RNase L specific siRNA’s have significantly 
reduced the RNase L protein signal at 24 hrs. A MAP kinase-specific siRNA transfection was 
carried out in order to demonstrate that RNase L knockdown was a specific consequence of the 
RNase L specific siRNA, as opposed to a general consequence of siRNA transfection of SiHa cells 
in culture. In comparison to the 24 hr transfection results, 48 hrs post transfection RNase L levels 
appeared elevated, appearing as a small double band.  
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Figure 6.4 - RNase L protein knock down assessed 24 & 48 hrs post siRNA 
transfection 
 
 
 
 
 
 
 
 
Figure 6.4 – SiHa cells were grown to 80% confluency before being transfected, using 
lipofectamine-2000, with either siRNA targeting RNase L (1-4) or one of two controls siRNA. 
Duplicate cell samples were harvested at 24 hrs (panel A) and 48 hrs (panel B) following 
transfection and proteins separated using a 12% SDS-PAGE gel. A western blot was carried out 
probing with primary rabbit anti-RNase L antibody and a GAPDH loading control. Proteins were 
visualised with ECL and exposure to hyperfilm. 24hr transfection with siRNA appears to produce 
the most efficient degradation of RNase L. In comparison to 24 hr transfection results, at 48 hrs 
post transfection, RNase L levels appear slightly elevated, appearing as a small double band.  
 
 
 
 
 
 
 
 
80kDa 
37kDa 
RNase L 
GAPDH 
1           2          3         4      MAPK ALLSTAR 
siRNA RNase L 
80kDa 
37kDa 
RNase L 
GAPDH 
1           2          3         4      MAPK ALLSTAR 
siRNA RNase L 
B – siRNA silencing of RNase L – 48 hr Harvest 
A – siRNA silencing of RNase L – 24 hr harvest 
 [144] 
 
 In order to quantify the degree of RNase L protein knockdown at 24 hrs densitometric 
analysis of western blot signals was carried out using the Image J analysis program 
(http://rsbweb.nih.gov/ij/). Figure 6.5(A) shows relative intensities for each sample compared to 
matched GAPDH loading controls. All siRNAs were shown to produce high levels of RNase L 
protein knockdown, when compared to ALLSTAR or MAPK siRNA transfected control cells. Figure 
6.5(B) shows the data from Figure 6.5(A) presented as a percentage down-regulation when 
compared to the ALLSTAR transfected controls, assuming the ALLSTAR signal represents 100% 
protein expression. Whilst all were very effective, siRNA-1 proved to be the most efficient, reducing 
the detectable levels of RNase L by 98.1% when compared to the ALLSTAR transfected cells. 
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Figure 6.5 - Densitometric analysis of RNase L protein level 24hrs post-siRNA transfection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5 – (A) Image J density analysis software was used to plot signal intensities for each 
siRNA treated cell sample harvested at 24hrs. Signals are expressed as relative intensity 
compared to the matched GAPDH signal, and are based on a single experiment. Clearly 
demonstrate a high level of protein knockdown in RNase L siRNA treated cells. (B) For each siRNA 
protein levels are expressed as a percentage knockdown compared to ALLSTAR siRNA. All four 
siRNA demonstrated high level of protein knockdown, with siRNA-1 being the most efficient, 
producing 98.1% protein knockdown. 
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Curiously, a double RNase L band was observed in the 48 hr post siRNA transfection 
proteins (Figure 6.4B) which complicated the Image J quantification analysis. However, it was clear 
that the RNase L signal intensity was slightly higher for each siRNA at 48 hrs than at 24hrs 
indicating a restoration of RNase L protein synthesis. 
 
 
6.4.1.2. Effect of siRNA mediated inhibition of RNase L on  cell growth in SiHa 
cells 
 
All the siRNA sequences tested were capable of inducing transient reduction in the 
expression of the RNase L protein, although siRNA 1 was clearly the most efficient. Thus, 72 hr 
colorimetric cell proliferation assays were carried out (section 6.3.1.2) in cells transfected with 
either siRNA 1 or the ALLSTARS negative control, both with and without lopinavir. 
 Figure 6.6 shows cell proliferation assay for siRNA1, ALLSTAR and lipofectamine-only 
control transfected cells in the absence of lopinavir. The data are presented as percentage change 
from the starting density at T = 0. Statistical analysis was carried out using Microsoft excel, with 
student T-tests carried out comparing siRNA-1 cells to ALLSTAR control cells based on triplicate 
data sets - p-values below 0.05 were considered significant. When comparing siRNA-1 transfected 
cells to ALLSTAR transfected cells the growth rate in siRNA-1 transfected cells was significantly 
higher at all data time points (24hrs p = 0.005, 48hrs, p = 0.0004, and 72hrs p = 0.003).  
 The growth of cells exposed to lipofectamine-2000 only did not significantly differ from 
ALLSTAR control transfected cells. 
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Figure 6.6 – 72hrs AQ-96 growth proliferation assay following siRNA mediated inhibition of 
RNase L 
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Figure 6.6 – 72hr AQ-96 cell proliferation growth curve. Data represented as percentage growth 
change. SiHa cells were transfected with siRNA targeting RNase L or an ALLSTAR control siRNA. 
Lipofectamine only transfected control cells were also included. Based on OD490 data, when 
compared to ALLSTAR controls RNase L degradation with siRNA-1 produced a significant (p<0.05) 
improvement in cell growth at each data point over 72hrs. Data based on triplicate data points from 
a single experiment  
 
 
 
6.4.1.3. Effect of siRNA mediated inhibition of RNase L following lopinavir 
treatment 
 
The results shown in Figure 6.7 are the cell proliferation assays carried out on siRNA 1 and 
ALLSTAR control transfected cells treated with an escalating dose range of lopinavir (20, 25 and 
30 µM). The data are presented as percentage growth change based on triplicate data points 
(Figure 6.7A-D).  
 
 
Figure 6.7 (subsequent pages) – 72hr growth assays following siRNA transfection and 
lopinavir treatment 
 
SiHa cells were transiently transfected with either siRNA-1 or ALLSTAR negative control before 
being subsequently grown in RPMI-1640 supplemented with either DMSO or lopinavir at the 
concentrations shown. Growth was monitored over 72hrs and shown percentage growth change 
(panels A-D). Findings based on triplicate data points from a single experiment. 
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A – DMSO Control 
B – 20 µM lopinavir treated 
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C – 25 µM lopinavir treated 
D – 30 µM lopinavir treated  
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Consistent with the results obtained in untreated transfected cells (Figure 6.6) DMSO-only 
treated siRNA transfected cells (panel A) showed steady growth over the 72 hr period. It was also 
noticed that siRNA 1 transfected cells had a modest growth advantage over ALLSTAR control 
cells. Significantly, a divergence in the growth characteristics of these cells occurred when they 
were grown in the presence of lopinavir over a relatively small dose range of 20 - 30 µM. In the 
presence of 20 µM, cell growth was inhibited when compared to DMSO treated cells, yet after an 
initial drop in cell number, both siRNA-1 and control cells demonstrated growth recovery at the 48 
hr and 72 hr time points. At this concentration of lopinavir, no statistically significant variation in 
growth was observed between siRNA 1 and control transfected cells. With 25 µM lopinavir (panel 
C) both siRNA-1 and ALLSTAR transfected cells again demonstrated an initial drop in cell number 
after the first 24 hrs, although this was much more pronounced in the ALLSTAR cells. After 48 hrs 
the siRNA-1 transfected cells showed a marked recovery in growth, in contrast to the ALLSTAR 
cells, in which growth appeared to plateau producing a statistically significant difference in growth 
at 72 hrs (p<0.05). At 30 µM lopinavir this selective toxicity was lost with all cells showing 
pronounced growth arrest irrespective of the transfection procedure (Figure 6.7, panel D). It is 
significant that the difference in selective toxicity observed between 25 and 30 µM lopinavir is 
entirely consistent with the previously shown growth assays carried out on E6/E7 immortalised 
keratinocytes (Figure 3.5). E6/E7 expressing keratinocytes demonstrated a time dependent 
increase in RNase L protein expression in cells treated with 25 µM lopinavir, and were markedly 
growth inhibited when compared to control treated keratinocytes. However, most significantly, this 
growth selectivity was lost at concentrations of lopinavir greater than 25 µM. 
 
 
6.4.2. Lopinavir does not up regulate RNase L in lopinavir-resistant CaSKi cells 
 
Figure 6.8 demonstrates western blot analysis of RNase L protein in CaSKi cells exposed to an 
escalating dose of lopinavir. In contrast to SiHa cells, no lopinavir-dependent increase in RNase L 
protein expression was observed. CaSKi cells were used as they have previously shown to be 
resistant to lopinavir treatment [131]. The CaSKi cell line is a fully transformed HPV positive 
cervical carcinoma cell line. However, in contrast to SiHa which contains 1-2 integrated copies of 
HPV type 16 [186] it is known that CaSKi cells contain several hundred copies of HPV type 16 
(Figure 6.8(B)). 
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Figure 6.8 – Lopinavir does not up-regulate RNase L in resistant CaSKi cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8 – (A) CaSKi cells were exposed to an escalating dose of lopinavir. Cells were harvested 
6 hrs post incubation and separated by SDS-PAGE. A western blot was immunoprobed with 
RNase L and GAPDH loading control. No increase in RNase L was observed based on a single 
experiment. (B) RT-PCR data reproduced with permission from Dr Xiaotong He. RT-PCR 
demonstrates the increased levels of E6 protein in CaSKi cells when compared to SiHa cells. 
 
 
 
 
6.4.3. Over expression of RNase L in an RNase L-deficient cell line 
 
6.4.3.1. Effect of reintroducing RNase  L into C33A parent and C33AE6  
 
Figure 6.9(A) shows the results from the live/dead cell counts taken 24 hrs post-
transfection with an RNase L expression vector in C33A parent and C33AE6 cells. Statistical 
analysis showed no significant difference in percentage background cell death when comparing 
control untransfected C33A parent and C33AE6 cells (p = 0.50) (Figure 6.9(A)). Test values with 
background death removed are shown in Figure 6.9(B). 
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Figure 6.9 – Assessment of cell death 24 hr post-transfection of RNase L into C33A parents 
and C33AE6 cells 
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Figure 6.9 – (A) C33A Parent and C33AE6 cells were transfected with an RNase L expression 
vector using Lipofectamine-2000. The number of dead cells was assessed at 24 hrs using trypan 
blue exclusion and control Lipofectamine-2000 treated control cells were also included. (B) The 
percentage of dead cells observed at 24 hrs minus the background cell death. Data presented 
based on triplicate data points from a single experiment. 
 
A – Percentage dead cells 24hrs post-transfection with RNase L 
 
B – Percentage dead cells, background death subtracted 
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In order to account for potentially differing transfection efficiencies between C33AE6 and 
C33A parent cells, triplicate flasks were stained for ß-Galactosidase activity, demonstrating 
transfection efficiencies of 8.4 % ± 0.53 and 9.07 % ± 0.46 for C33A parent and C33AE6 
respectively. In order to fully account for this slight variation in transfection efficiency, the observed 
dead cells were expressed as a percentage of the transfected cells based on the ß-Galactosidase 
staining data, as shown in Figure 6.10. Based on this analysis, the data suggests that transient 
transfection of the RNase L expression vector produced a significant (p<0.01) 4.7 fold increase in 
cell death in the C33A parent cells when compared to C33AE6 cells. 
 
 
Figure 6.10 – Percentage dead cells observed at 24hrs post transfection with RNase L, 
expressed as a percentage of successfully transfected cells 
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Figure 6.10 – Percentage of dead cells observed 24hrs following transfection of RNase L into C33A 
Parent and C33AE6 cells expressed as a percentage of those cells successfully transfected based 
on ß-Galactosidase staining. Transient transfection of the RNase L expression vector produced a 
highly significant 4.7 fold increase (p < 0.01) in cell death in C33A parent cells when compared to 
C33AE6. Data based on Triplicate data points. 
 
Percentage dead cells 24hrs post-transfection with RNase L 
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6.4.3.2. Effect of HPV E6 protein on RNase L and ABCE1 
 
The preceding results indicate that the presence of the HPV Type 16 E6 protein appeared 
to confer a survival advantage on C33A cells transiently transfected with RNase L. Based on these 
findings, it was initially hypothesised that E6 may be facilitating the degradation of RNase L in vitro. 
In order to address this issue, flasks of C33A parent and C33AE6 cells were again transiently 
transfected with RNase L (section 6.3.3.2). Protein lysates were prepared from cells harvested at 4, 
8, 12 and 24 hrs post-transfection, and separated by SDS-PAGE, and RNase L and ABCE1 
expression was assessed by western blot analysis (section 6.3.4.2) shown in Figures 6.11 (A) & 
(B) respectively. Figure 6.11(A) demonstrates the lack of endogenous RNase L expression in 
untransfected C33A parent and C33AE6 cells and also demonstrates that following transient 
transfection, an incubation period of approximately 8 hrs is required before RNase L protein 
detected. It is also clear that the E6 protein has no effect on RNase L protein levels, regardless of 
harvest time point, up to and including 24 hrs. Figures 6.11 (A) & (B) also confirm the presence of 
equivalent levels of endogenous ABCE1 protein in both C33A parent and E6 cells. It is also 
apparent that the presence of the HPV type 16 E6 protein does not exert any effect on ABCE1 
levels, regardless of harvest time (Figure 6.11B). 
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Figure 6.11 – Effect of the HPV E6 protein on RNase L and ABCE1 protein levels in 
C33A parent and C33AE6 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.11 – C33A Parent and C33AE6 were transfected with equal amounts of RNase L 
expression vector using the Lipofectamine-2000 reagent. Cell lysates were prepared at the time 
points indicated and proteins were separated on a 12% SDS-PAGE gel. A western blot was carried 
out with membranes probed for RNase L (panel A) levels along with ABCE1 levels (panel B). 
GAPDH control blots were also carried out. The HPV type 16 E6 protein appears to have little 
effect on the levels of RNase L protein or ABCE1, regardless of transfection time, with levels 
remaining constant. Panel A also demonstrates a transfection time of approximately 8 hrs is 
required for RNase L expression.  
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6.4.3.3. Effect of the HPV E6 protein on the  nuclear/cytoplasmic localisation of 
RNase L 
 
6.4.3.3.1. Immunohistochemistry staining 
 
Having demonstrated that the HPV type 16 E6 protein does not facilitate the degradation of 
RNase L, it was decided to evaluate E6 mediated alterations in nuclear/cytoplasmic localisation by 
immunohistochemistry. Immunostaining with anti-Actin was included as a positive control, with the 
results shown in Figure 6.12.  
 
 
Figure 6.12 – Immunohistochemistry staining – β-Actin controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.12 – SiHa cells were grown using slide flasks. At a confluency of 80% cells were treated 
with lopinavir at a final concentration of 25µM. Control untreated cells were treated with an equal 
volume of DMSO. Following 6 hrs incubation with lopinavir, cells were fixed and stained using a 
positive control anti-Actin antibody at a concentration of 1:500 and an appropriate biotinylated 
secondary antibody. Cells were visualised using DAB staining, and staining is based on a single 
experiment. 
 
 
 
 
Figure 6.13 demonstrates the staining obtained using a Sigma Aldrich mouse primary anti-
RNase L antibody (Sigma-Aldrich antibody R3529), at concentrations of 1:100 and 1:500. RNase L 
expression was predominantly cytoplasmic, and lopinavir did not alter RNase L localisation, 
regardless of the primary antibody concentration used to assess protein levels. 
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Figure 6.13 – Immunohistochemistry staining of RNase L in lopinavir treated SiHa cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.13 – Immunohistochemistry staining. SiHa cells were grown using slide flasks to a 
confluency of 80% whereupon cells were treated with lopinavir at a final concentration of 25µM or 
an equal volume of DMSO. Following 6hrs incubation with lopinavir, cells were fixed and stained 
using a Sigma Aldrich mouse anti-RNase L antibody at a concentration of 1:500 and 1:100, and an 
appropriate biotinylated secondary antibody. Cells were visualised using DAB staining. RNase L 
expression was predominantly cytoplasmic, and the localisation or RNase L intensity did not alter 
following treatment with lopinavir, based on a single experiment with over a range of primary 
antibody dilutions. 
 
 
Figure 6.14 demonstrates the RNase L staining obtained using the Abcam rabbit anti-
RNase L antibody (Abcam antibody 32307) at concentrations of 1:50 and 1:250. Looking first at 
cells stained at a primary antibody concentration of 1:50, the RNase L expression pattern appears 
similar to the results obtained using the Sigma Aldrich antibody (Figure 6.13). RNase L appears 
predominantly restricted to the cytoplasm, and lopinavir does not produce any widespread changes 
in RNase L localisation. Treatment did however appear to have increased nuclear expression of 
RNase L in a small number of cells (arrowed), which presumably is a consequence of the 
extremely pleomorphic morphology of SiHa cells. In contrast to this, in cells stained using primary 
anti-RNase L at a concentration of 1:250, RNase L expression has demonstrated a dramatic 
Untreated Treated 
Sigma Anti-RNase L 1:500 
100 microns 
Sigma Anti-RNase L 1:500 
Sigma Anti-RNase L 1:100 Sigma Anti-RNase L 1:100 
100 microns 
100 microns 100 microns 
 [158] 
 
nuclear to cytoplasmic shift in localisation. In the DMSO treated cells, RNase L expression is 
predominantly nuclear, with very little cytoplasmic staining observed, however, following lopinavir 
treatment, the expression of RNase L in the cytoplasm is much more intense, with an apparent 
drop in nuclear staining levels. 
 
 
Figure 6.14 – Immunohistochemistry staining of RNase L in lopinavir treated SiHa cells 
 
 
 
Figure 6.14 – Immunohistochemistry staining of RNase L in control DMSO treated and lopinavir 
treated SiHa cells. SiHa cells were grown using slide flasks. At a confluency of 80% cells were 
treated with lopinavir at a final concentration of 25 µM. Control untreated cells were treated with an 
equal volume of DMSO. Following 6 hrs incubation with lopinavir, cells were fixed and stained 
using an Abcam rabbit anti-RNase L antibody at a concentration of 1:50 and 1:1250, and an 
appropriate biotinylated secondary antibody. Cells were visualised using DAB staining. At a 1:50 
concentration, RNase L appears predominantly restricted to the cytoplasm, and lopinavir does not 
produce any widespread changes in RNase L localisation. However, lopinavir treatment does 
appear to have increased nuclear expression of RNase L in a small number of cells (arrowed). In 
comparison, in cells stained with primary antibody at a concentration of 1:250, RNase L was shown 
to exist predominantly in the nucleus. In these cells, lopinavir appeared to produce a nuclear to 
cytoplasmic shift in RNase L expression based on a single experiment. 
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6.4.3.3.2. Nuclear/ Cytoplasmic Fractionation 
 
The preceding Immunohistochemistry results (section 6.4.3.3.1), do not convincingly 
demonstrate lopinavir-induced alterations in RNase L localisation. Since it was concluded this 
could be due to the pleomorphic nature of SiHa cells, it was decided to use an alternative cell 
system. Nuclear/cytoplasmic fractionation of transiently RNase L transfected C33A and C33AE6 
cells treated with lopinavir was used to further assess the ability of the drug to effect nuclear/ 
cytoplasmic localisation in the presence and absence of E6.  
Figure 6.15 shows the western blot result from the RNase L transfected cells. The GAPDH 
and HDAC1 signals demonstrate that a successful fractionation has taken place. Cytoplasmic 
fractions from each pair tended to contain higher levels of RNase L than nuclear fractions, in both 
parent and E6 cells.  
Neither the presence of the E6 protein or treatment with lopinavir altered the detectable 
levels of RNase L in either cellular compartment. 
 
 
 
 
Figure 6.15 – Effect of the HPV E6 protein and lopinavir on the nuclear/ cytoplasmic 
localisation of RNase L 
 
 
 
 
Figure 6.15 – C33A parent and C33AE6 cells were transfected with RNase L. Duplicate samples 
were also treated with 25 µM lopinavir for 6 hrs. Cell samples were separated into nuclear and 
cytoplasmic fractions, and proteins separated on a 12% SDS-PAGE gel. A western blot was carried 
out and probed with primary rabbit anti-RNase L and GAPDH loading control (C, cytoplasmic. N, 
nuclear). Based on a single experiment. 
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6.4.4. Co-immunoprecipitation of RNase L and ABCE1 
 
Since no convincing difference in lopinavir-induced sub-cellular localisation of RNase L 
was observed, it was decided to use co-immunoprecipitation to investigate whether the drug could 
alter the physical association between RNase L and its endogenous inhibitor ABCE1. Anti-ABCE1 
immunoprecipitates were prepared from transiently RNase L transfected C33A and C33AE6 cells 
treated with lopinavir or DMSO control. These were western blotted and sequentially 
immunoprobed with anti-ABCE1 and anti-RNase L antibodies (Figure 6.16(A)). These data 
confirmed that lysates from RNase L transfected C33A and C33AE6 showed a signal at the 
predicted molecular weight. This confirms the interaction between the transfected RNase L proteins 
and its endogenous inhibitor ABCE1 in C33A parent and C33AE6 cells. 
 Image J density analysis of RNase L signals was carried out and the results shown in 
Figure 6.16(B) are represented as a relative intensity compared to matched-ABCE1 protein levels. 
Based on these observations, C33AE6 cells had 1.9-fold more RNase L associated with ABCE1 
than equivalent C33A control cells. Significantly, lopinavir was shown to produce a modest drop in 
RNase L protein levels in RNase L transfected C33AE6 cells. 
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Figure 6.16 - Co-immunoprecipitation of RNase L and ABCE1 in RNase L transfected C33A 
parent and C33AE6 cells 
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Figure 6.16 - (A) western blot analysis following co-immunoprecipitation of RNase L with ABCE1 in 
RNase L transfected C33A parent and C33AE6 cells. Duplicate untransfected controls (C) were 
included along with 25µM 6hr lopinavir (+/- lop) treated RNase L transfected C33AE6 cells. Data 
confirms the physical interaction of ABCE1, and also that the interaction appears stronger in E6 
expressing cells. (B) Image J density analysis of signal strength following western blot based on a 
single representative western blot. Signals are represented as a relative intensity compared to 
ABCE1 signal strengths. When compared to C33A Parent cells, C33AE6 transfected cells exhibited 
a 1.9-fold increase in RNase L/ ABCE1 binding, which was slightly reduced following lopinavir 
treatment. 
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To further assess the effects of lopinavir on the RNase L/ ABCE1 interaction, the previous 
co-immunoprecipitation reaction was repeated including samples treated with lopinavir for 6, 12 
and 24 hrs. The results of this western blot are shown in Figure 6.17(A) with relative intensities 
calculated using image J shown in Figure 6.17(B). As expected, neither control untransfected cell 
types demonstrated a signal. The interaction between RNase L and ABCE1 was again confirmed 
as being stronger in C33AE6 cells than in parent C33A cells (a 1.4-fold increase). Further to this, 
treatment for 6, 12 and 24 hrs subsequently produced a linear decrease in signal intensity with 24 
hrs lopinavir treatment producing a signal a third of the intensity of the DMSO treated RNase L 
transfected cells. 
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Figure 6.17 – Repeat Co-immunoprecipitation of RNase L and ABCE1 in RNase L transfected 
C33A parent and C33AE6 cells followed by a lopinavir time course 
 
 
 
Figure 6.17 - (A) western blot analysis following co-immunoprecipitation of RNase L with ABCE1 in 
RNase L transfected C33A parent and C33AE6 cells. Duplicate untransfected controls (C) were 
included along with 25µM lopinavir treated RNase L transfected C33AE6 cells, treated for the time 
indicated. Data confirms the physical interaction between RNase L and ABCE1, and also that the 
interaction appears stronger in E6 expressing cells. (B) Image J density analysis of signal strength 
following western blot based on a single representative western blot image. Signals are 
represented as a relative intensity compared to ABCE1 signal strengths. When compared to C33A 
Parent cells, C33AE6 transfected cells exhibited a 1.4-fold increase in RNase L/ ABCE1 complex 
signal. In contrast to Figure 6.18, lopinavir produced a marked decrease in RNase L/ABCE1signal 
at 6hrs, and over the remaining time points produced a linear decrease in RNase L/ ABCE1 signal 
strength. 
 
 
A – Co-Immunoprecipitation following lopinavir time course 
B – Image J density analysis 
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6.5. Chapter Summary and Discussion 
 
As previously discussed it has been demonstrated that lopinavir produces a dose 
dependent growth inhibition of growth in SiHa cells (Figure 3.1(A)) with a dose dependent increase 
in the levels of the RNase L protein. This effect was observed over a dose range of 5 - 30 µM, with 
a peak intensity occurring at 12 hrs. In order to assess the role of RNase L in the toxicity of 
lopinavir against cells expressing HPV oncoproteins, siRNA mediated degradation of RNase L was 
used. 
The work carried out in collaboration with Professor Zehbe demonstrated that lopinavir 
induced an increase in RNase L in E6/E7 immortalised PHFKs (Figure 5.12). These data clearly 
support our observation of a lopinavir induced increase in RNase L expression in SiHa cells. 
Furthermore, cell proliferation assays demonstrated pronounced differences in the growth rates of 
E6/E7 expressing PHFKs when compared to control PHFKs exposed to lopinavir. The E6/E7 
expressing cell lines were shown to be much more susceptible to lopinavir growth inhibition than 
the corresponding control cells (Figure 3.5). These studies also demonstrated the importance the 
dose range of lopinavir – when used at concentrations approaching 25 µM, normal PHFKs showed 
steady growth, whereas the growth of E6/E7 immortalised PHFKs was dramatically reduced. At 
concentrations >25 µM the selective toxicity was lost and cell proliferation was inhibited equally in 
both cell types. 
It was of interest that siRNA 1 mediated silencing of RNase L in untreated SiHa cells 
induced a significant improvement in cell growth over 72 hrs, when compared to control ALLSTAR 
siRNA transfected cells (Figure 6.7). What is the potential explanation of this result? Although 
endogenous RNase L is known to exert anti-proliferative effects in virally infected cells, it is also 
considered to a potential tumour suppressor [267]. Since untreated SiHa cells express RNase L, 
albeit at low levels (see Figures 5.7 & 5.8), it is possible that siRNA silencing of the expression of 
this product may lead to an improvement in the growth of these cells. As stated previously, siRNA 
achieves peak silencing within 24 hrs of transfection which is subsequently followed by a rapid 
decline in effectiveness and concomitant restoration of protein synthesis by 48 hrs. This ‘hit and 
run’ nature of siRNA-mediated silencing provides an effective, yet very small window of opportunity 
to study the true effects of RNase L silencing on cell proliferation. This is in contrast to shRNA 
which would provide constitutive stable knockdown of RNase L. Whilst the AQ-96 cell proliferation 
assay indicates metabolic activity, cell proliferation can be assessed with a number of techniques; 
Assays for proliferating cell nuclear antigen (PCNA) (reviewed in [321]) and DNA synthesis by 5’-
2’-bromodeoxyuridine incorporation in conjunction with flow cytometric analysis of apoptotic 
markers would provide a multifaceted approach to assessing the implications of endogenous 
RNase L knockdown on cell proliferation. 
In order to determine whether RNase L plays a role in lopinavir-induced toxicity, a 72hr cell 
proliferation assay was carried out following siRNA silencing of RNase L in lopinavir treated SiHa 
cells. The data shown in Figure 6.7 demonstrated that in those cells with reduced RNase L 
expression, lopinavir had less of an impact on cell growth, implying a reduction in lopinavir toxicity. 
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This effect was found to be optimal at 25 µM lopinavir, and was lost at concentrations higher than 
this. It is significant that these data are consistent with the growth differential observed between 
E6/E7 immortalised PHFKs and control PHFKs which was also seen to be maximal at 25 µM 
lopinavir (Figure 3.5). 
Taking all these observations together, our results support a functional link between RNase 
L and lopinavir toxicity in HPV infected cells. It is of note that the 25 µM optimum drug 
concentration for these effects is much higher (>15 fold) than that which is achieved in the 
cervico/vaginal fluid in HIV patients taking oral Kaletra [322], a factor which has been previously 
discussed [131].  
The data shown in Figure 6.8(A) demonstrates the absence of RNase L induction in CaSKi 
cells exposed to lopinavir. This data is potentially indicative of a functional interaction between 
RNase L and E6. We have demonstrated the importance of RNase L in lopinavir toxicity in SiHa 
cells, suggesting that the increased expression of E6 protein in CaSKi cells (shown in Figure 
6.8(B)) may be limiting the effects of RNase L by promoting the association with ABCE1, which 
would in turn account for the increased resistance of CaSKi cells to lopinavir treatment. 
These data raise the question of how does HPV compromise the function of RNase L? It is 
known that the high risk HPV E6 protein inappropriately activates the cellular E3 ubiquitin ligase, 
E6AP, which leads to the uquitination and degradation of the p53 tumour suppressor protein by the 
proteasome [56]. Thus, we hypothesised that the HPV E6 protein could also facilitate the 
inappropriate degradation of RNase L in order to suppress its antiviral/ anti-proliferative functions in 
the HPV infected cell. In order to further investigate this hypothesis, HPV negative C33A cells and 
stable HPV type 16 E6 transfected cells were used since it was found that these cells lack 
endogenous RNase L expression (Figure 5.5), therefore overcoming the limitation of a lack of a 
suitable control cell when using SiHa model systems. Transient transfection of both of these cells 
with an RNase L expression vector demonstrated that C33A parent cells exhibited a highly 
significant 4.7-fold increase in dead cells compared to C33AE6 cells when observed 24 hrs post-
transfection (Figure 6.10). These data provided a first indication that that the HPV E6 protein was 
potentially capable protecting these cells from RNase L induced cell killing. However, this was not 
found to be due to E6 inducing the degradation of RNase L, since equivalent levels of the RNase L 
protein were observed in transiently transfected C33A and C33AE6. Another possible explanation 
was that E6 could be up-regulating the levels of the endogenous RNase L inhibitor, ABCE1, yet 
this was shown to be unchanged in both cell types, regardless of harvest time point (Figure 
6.11(B)). Although these data provide an initial insight into the association between E6 and RNase 
L they can only be thought of as preliminary data. This particular live/dead assay suffers from 
several flaws which prevent a definitive conclusion from being made. Initially, the cell numbers 
involved in the analysis of this particular assay are extremely low, and are therefore potentially 
open to interpretation when considering relative +/- standard deviation values for both control and 
E6 expressing cells. In addition, before a definitive conclusion could be made, it would be 
necessary to repeat the assay utilising a range of cell types that endogenously express both 
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RNase L and E6, to rule out an RNase L-induced cell death phenomenon that is strictly restricted 
to the C33A cell line.   
What other factors could explain this difference in sensitivity to RNase L? Having ruled out 
E6-mediated degradation of RNase L, the ability of E6 to alter cellular localisation was assessed, 
which provided conflicting results. Based on immunohistochemical staining (Figure 6.14), the 
RNase L expression pattern following lopinavir treatment of SiHa cells was shown to vary 
depending on the primary antibody, and the concentration at which it was used. To clarify these 
findings, western blot analysis of fractionated RNase L transfected cells was carried out (Figure 
6.15). These data from western blot analysis demonstrated that RNase L expression was elevated 
in the cytoplasmic fractions when compared to nuclear fractions however lopinavir did not 
significantly alter its cellular localisation, in either C33A parents of C33AE6 cells, when compared 
to DMSO control cells. 
Having demonstrated that the E6 protein does not facilitate the degradation of RNase L or 
cause an increase in ABCE1 levels, or affect its cellular localisation, the interaction between RNase 
L and its endogenous inhibitor was evaluated (Figure 6.16 & 6.17). Co-immunoprecipitation of 
ABCE1 and RNase L was carried out in C33A parent and C33AE6 cells exposed to lopinavir 
following transient transfection with an RNase L expression vector. These data demonstrated an 
increase in the levels of RNase L associated with ABCE1 in C33AE6 cells, when compared to 
equivalent C33A control cells, of between 1.4 - 1.9-fold. This implies that the E6 protein is in some 
way enhancing or promoting the interaction between ABCE1 and RNase L, thus inhibiting the 
interaction between RNase L and its endogenous activator protein, 2-5A. The net result would be a 
reduction in the activation potential of RNase L followed by a subsequent drop in its antiviral/ 
apoptotic capabilities. This would therefore account for the reduced cell death in C33AE6 cells 
observed 24 hrs post-transfection with RNase L. Six hour lopinavir treatment was initially shown to 
cause a mild reduction in the ABCE1/ RNase L interaction in C33AE6 transfected cells (Figure 
6.17). However, in cells treated with a fixed dose of lopinavir over a 24 hr period, the reduction in 
RNase L associated with ABCE1 was noticeably reduced, demonstrating a linear relationship 
between lopinavir incubation and signal strength. The membrane was re-probed with ABCE1 and 
demonstrated constant ABCE1 protein levels regardless of lopinavir incubation time.   
 
 
6.6.  Further work 
  
The most important result arising from the work in this chapter centres around the observation 
that the presence of the HPV type 16 E6 protein confers a survival advantage on C33A cells 
transiently transfected with RNase L. Furthermore, in addition to the potential weaknesses in this 
assay, highlighted in section 6.5, it is also important to further characterise the cell death induced 
following the re-introduction of RNase L into the C33A test cells. The ‘ApoAlert’ Annexin-V-FITC 
apoptosis detection kit available from Sigma Aldrich 
(http://www.sigmaaldrich.com/etc/medialib/docs/Sigma/Bulletin/apoafbul.Par.0001.File.tmp/apoafbu
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l.pdf) would be utilised to assess RNase L induced cell death. However, in contrast to classical 
TUNEL staining (reviewed in [323]), the ApoAlert kit will allow for detection of apoptosis at an 
earlier stage than in addition to allowing differentiation of apoptotic cells from viable and necrotic 
cells.  
Further to this, it was demonstrated that in E6 expressing cells, the interaction between RNase 
L and its endogenous inhibitor ABCE1 was noticeably stronger (Figure 6.16 and Figure 6.17), and 
was destabilised in the presence of lopinavir. Co-immunoprecipitation reactions would be repeated 
using cell samples in which RNase L is expressed endogenously, namely SiHa and Caski cells, 
both of which express full HPV genomes, along with endogenous RNase L protein, as 
demonstrated previously. CaSKi cells, derived from a small bowel mesentery metastasis originating 
from an epidermoid carcinoma in a 40 yr old Caucasian female [324] also contain integrated 
HPV16. However, in contrast to SiHa cells which contain 1-2 copies per cell [186], CaSKi cells are 
known to contain 400 – 600 HPV16 copies per cell [311]. Previous work has demonstrated that 
CaSKi cells are relatively resistant to lopinavir treatment [131] and if, as suggested by the current 
findings, E6 plays a role in augmenting the RNase L/ ABCE1 interaction leading to a reduction in 
lopinavir toxicity, the increased E6 expression in CaSKi cells will in theory explain the decreased 
sensitivity to lopinavir. 
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Chapter 7 – Discussion, Conclusions and Future Work 
 
7. Discussion  
 
 
Of the estimated 529,409 new cases of cervical cancer occurring worldwide in 2008, more than 
80% were shown to occur in developing countries. Those developing countries within Africa, in 
particular, suffer a disproportionately high burden [10]. In a region where HIV and poverty 
exacerbate the problems associated with cervical malignancy, and where HPV vaccination and 
effective cervical screening programmes are both limited and potentially ineffective, it is clear that a 
low-cost, low-technology, preferably self-applied alternative therapy for the management of HPV-
related cervical malignancy is essential. We provide evidence to suggest that lopinavir, an HIV-
specific antiretroviral, possesses anti-cancer activities that would make it suitable for use in the 
management of HPV-related pre-cancerous lesions of the cervix. 
 
 
7.1. Lopinavir alters protein expression in HPV positive SiHa cells  
 
Many viruses are known to inhibit the function of, or inappropriately degrade host cell proteins 
detrimental to viral persistence [226-230]. More specifically, through the synergistic actions of the 
viral E6 and E7 proteins, HPV is able to directly ‘hijack’ the ubiquitin-proteasome system (reviewed 
in [231]) resulting in the degradation of the p53 and Rb tumour suppressor proteins, facilitating 
unhindered viral replication and oncogenesis. The HIV-specific protease inhibitor lopinavir has 
been shown to specifically inhibit the chymotryptic-like activity of the 26S proteasome [73, 325]. It is 
now thought that, in conjunction with inhibition of protease function, inhibition of the proteasome 
plays a significant role in the anti-HIV activity of lopinavir and related compounds [326]. 
Proteasomal inhibition with lopinavir has been shown to limit E6-dependent degradation of p53, 
stabilising protein levels and selective killing of HPV type 16 E6-dependent cervical carcinoma cells 
in vitro [98]. Thus, it was hypothesised that, in addition to p53, inhibition of proteasomal 
degradation would lead to changes in expression levels of a range of cell proteins regulated by the 
proteasome. Furthermore, it was postulated that one or more of the proteins exhibiting altered 
expression following lopinavir treatment could potentially account for the anti-HPV activity of 
lopinavir. In order to address this, the protein expression profiles of lopinavir-treated and DMSO-
control treated HPV positive SiHa cells were compared using the Panorama Xpress725 profiler-725 
antibody microarray (Chapter 4). Lopinavir treatment of HPV positive SiHa cells lead to alterations 
in expression levels of 51 proteins responsible for a wide range of biological functions. It was not 
surprising that several known apoptosis-markers, including Annexin-5, activated Caspase-3, p63, 
TNF and p53 were elevated (Figures 4.6 and 4.7) since previous work demonstrated lopinavir-
induced apoptosis in SiHa cells [98]. Interestingly, many of the altered proteins were shown to be 
targets for proteasomal degradation (Highlighted (*) in Table 7.1) indicating that lopinavir can inhibit 
proteasomal function to such an extent so as to allow accumulation of proteins that would 
otherwise be degraded. Bioinformatic analysis of all the proteins in Table 7.1 was carried out, 
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including a search of the Virus Molecular INTeraction (Virus MINT) database [327] for known E6 
and/or E7 interacting proteins. Curiously, only p53 has previously been shown to be degraded by 
the action of E6. 
Clearly, there are limitations to using an array such as the Panorama Xpress725 profiler-725. 
Whilst this allows comparative analysis of expression levels of over 700 proteins this is only a small 
fraction of the total number of proteins comprising the complete proteome of a mammalian cell. As 
such, the possibility remains that lopinavir may still alter the expression of other virally dis-regulated 
proteins which are not represented on the array.  
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Table 7.1 –Proteins with altered expression levels following exposure of SiHa cells to 
lopinavir 
 
Gene Protein name Function/Association Fold change 
ANXA5 Annexin 5 Calcium binding protein 2.15 
CTBP1 (C-terminal) * C-Terminal binding protein 1 Transcription regulatory protein 1.87 
CHEK2 * CHK2 checkpoint homolog Serine/Threonine kinase 1.84 
RAB5A Ras related protein Rab 5A GTPase 1.84 
RNASEL * Ribonuclease L Ribonuclease 1.76 
ACTR3 Actin related protein 3 Cytoskeletal protein 1.73 
GRB2 Growth factor receptor bound protein 2 Adapter molecule 1.73 
SYNPO Synaptopodin Cytoskeletal associated protein 1.72 
CASP3 Caspase 3 (active) Cysteine Protease 1.69 
EGF Epidermal growth factor Growth Factor 1.68 
TP63 * Tumour protein p63 Transcription factor 1.68 
BIRC5 * Survivin Adapter molecule 1.67 
ILK * Integrin-linked kinase Serine/Threonine kinase 1.59 
ERK2 Mitogen activated protein kinase 1 Serine/Threonine kinase 1.56 
SYNPO Synaptopodin Cytoskeletal associated protein 1.56 
SNCA α-Synuclein Chaperone protein 1.56 
PADI4 Peptidylarginine deiminase 4 Enzyme: Hydrolase 1.52 
CHEK1 * Cell cycle checkpoint kinase Serine/Threonine kinase 1.52 
TUB Tubulin/ Tyrosine Cytoskeletal associated protein 1.50 
NOS1 * Nitric oxide synthase 1 Enzyme: Synthase 1.50 
CTBP1 (N-terminal) * C-Terminal binding protein 1 Transcription regulatory protein 1.49 
TNF Tumour necrosis factor-α Ligand 1.48 
H2AFX H2A Histone Family, member X DNA binding protein 1.47 
AKT1 * Protein Kinase B-alpha Serine/Threonine kinase 1.47 
CHEK2 * CHK2 checkpoint homolog Serine/Threonine kinase 1.47 
FANCD2 * Fanconi anemia, complementation group D2 Cell cycle control protein 1.47 
DIABLO * SMAC protein Cell cycle control protein 1.46 
PAWR PRKC, apoptosis, WT1, regulator Transcription regulatory protein 1.45 
ILK * Integrin-linked kinase Serine/Threonine kinase 1.45 
MC3R Melanocortin 3 receptor Cell surface receptor 1.44 
APP Amyloid Precursor Protein Receptor activity 1.43 
MKI67 * MKI67 (FHA domain) interacting 
nucleolar phosphoprotein RNA binding protein 1.43 
CFL2 * Cofilin 2 Cytoskeletal associated protein 1.38 
DMD * Dystrophin Structural protein 1.37 
CENPE Centromeric protein E DNA binding protein 1.36 
PTK2(pp125) Focal adhesion kinase 2 (pp125) Tyrosine kinase 1.35 
TP53 * Tumour protein p53 Transcription factor 1.28 
DMD * Dystrophin Structural protein 1.25 
TP53 * Tumour protein p53 Transcription factor 1.18 
GJA1 * Connexin 43 Membrane transport protein 0.76 
GFAP Glial fibrillary acidic protein Structural protein 0.63 
GJA1 * Connexin 43 Membrane transport protein 0.60 
MTOR Mammalian Target of Rapamycin Kinase 0.53 
(Note:- Proteins marked with * are known to be substrates for proteasomal degradation) 
 [171] 
 
Of significant interest was the lopinavir-induced up regulation of RNase L, which is a major 
cellular antiviral protein. Based on western blot analysis, lopinavir (25 µM, 6 hrs) was shown to 
induce a significant (p<0.05) 9.5-fold increase in RNase L protein levels when compared to DMSO 
treated control cells (Figure 5.9). Both dose and time dependent increases in RNase L expression 
in lopinavir treated SiHa cells (Figures 5.7 & 5.8) were confirmed by western blot analysis. RT-PCR 
was then used to successfully demonstrate that this up regulation was related to an accumulation 
of protein, as a result of proteasomal inhibition, rather than lopinavir-induced increases in gene 
translation and protein synthesis (Figure 5.6).  
 
 
7.2.  RNase L plays a key role in the toxicity of lopinavir in SiHa cells 
 
It has previously been demonstrated that lopinavir exerts dose dependent growth-limiting 
effects of lopinavir in SiHa cells ([98] and Figure 3.1 in this report), however there has been no 
investigation as to how this correlates with RNase L expression, or indeed, no demonstration of the 
true importance of RNase L in this HPV-specific toxicity. In order to ascertain the significance of 
RNase L in lopinavir-dependent HPV-specific toxicity, the effects of transient siRNA-mediated gene 
silencing of RNase L in SiHa cells in the presence of lopinavir were assessed (Figure 6.7). 
Interestingly the data demonstrated that lopinavir exerted comparable levels of toxicity at lower (20 
µM) concentrations, regardless of siRNA treatment. In contrast to this, when exposed to 25 µM 
lopinavir, siRNA transfected SiHa cells demonstrated a significant growth advantage over non-
transfected cells, signifying a drop in lopinavir toxicity in the absence of RNase L. This indicates 
that RNase L plays a key role in facilitating the toxic effects of lopinavir in this HPV positive cell 
system. Interestingly however, beyond 25 µM lopinavir, the selective nature was lost, with both test 
and control cells demonstrating comparable growth inhibition, indicating, that whilst effective, 
lopinavir may have a very narrow optimal therapeutic window. Significantly, these data are 
consistent with the growth differential observed between E6/E7 immortalised and control primary 
human foreskin keratinocytes (PHFKs), which was shown to be optimal at 25 µM lopinavir (Figure 
3.5). Interestingly, it was also demonstrated using clonogenic analysis (Chapter 3) of control and 
stable E6-expressing karyotypically normal hTert-immortalised keratinocytes that lopinavir could 
actually promote the growth of these cells (Chapter 3). Together, these observations support a 
functional link between RNase L and lopinavir toxicity in HPV infected cells, and indicate that 
lopinavir may have an effective yet narrow therapeutic optimal concentration, which will clearly 
have implications for dosing practices should lopinavir be shown to be an effective HPV therapeutic 
in vivo.  
 
 
 
 
7.3. A Novel mechanism of HPV-specific lopinavir toxicity 
 
We have demonstrated that at least part of the toxicity of lopinavir in HPV positive SiHa cells is 
reliant on an increased expression of the antiviral protein RNase L. This implies that HPV disables 
the RNase L pathway in virus infected cells. Indeed, several viruses have developed strategies by 
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which they can circumvent the RNase L pathway [328]. For example, previous work has 
demonstrated that HIV-1 is able to induce the expression of ABCE1 [329], the endogenous inhibitor 
of RNase L, and in doing so, is able to down-regulate the activity of the RNase L antiviral pathway 
(RNase L pathway shown in Figure 5.1). However, at this stage, the details of mechanism by which 
HPV alters the RNase L pathway are unknown. In addition, the mechanism by which lopinavir 
restores RNase L function, inducing lopinavir-dependent toxicity, is also unknown.  
As a possible explanation, it was hypothesised that HPV, like HIV, may also up-regulate 
ABCE1 as a means of inhibiting the RNase L pathway.  Although this is an interesting concept, the 
current data demonstrates that lopinavir does not appear to affect ABCE1 protein levels, regardless 
of concentration or incubation time. This clearly indicates that HPV may be utilising an alternative 
mechanism(s) by which to subvert normal RNase L function. Interestingly, CaSKi cells have been 
shown to contain several hundred-fold greater levels of HPV type 16 E6 protein than SiHa cells. 
This is interesting in light of the fact that they have previously been shown to be refractory to 
lopinavir treatment [98]. In addition we have since demonstrated that lopinavir fails to induce an up 
regulation of RNase L in CaSKi cells (Figure 6.8). This suggests that the E6 protein may be directly 
responsible for limiting RNase L function, hence impeding lopinavir toxicity in CaSKi cells.  
In order to assess the interaction between RNase L and E6, we utilised the HPV negative 
parental C33A cells in addition to C33A cells stably expressing the HPV type 16 E6 protein (C33A 
E6), as we had previously demonstrated that these cells lacked endogenous RNase L mRNA and 
protein (Figures 5.5 and 6.11 respectively). We demonstrated that transient re-introduction of 
RNase L in these cells resulted in a highly significant 4.7-fold increase in cell death in parental cells 
when compared to E6 expressing cells. This raised the question of how does E6 curtail RNase L-
mediated cell death and confer a protective effect on C33A E6 cells? Surprisingly, western blot 
analysis, immunohistochemical staining and nuclear/cytoplasmic fractionation ruled out E6-
mediated degradation of RNase L, E6-mediated up-regulation of ABCE1 and E6-dependent 
alterations in nuclear/cytoplasmic localisation of RNase L. However, co-immunoprecipitation 
reactions with ABCE1 and RNase L were carried out in C33A parent and E6 expressing cells 
following transient transfection with RNase L. Western blot analysis demonstrated that HPV type 
16 E6 appeared to enhance or promote the interaction between ABCE1 and RNase L.  
How would this confer a protective effect on E6 expressing cells? In theory, an enhancement of 
the interaction between RNase L and its endogenous inhibitor, ABCE1 would result in a reduction 
in the potential for interaction between RNase L and 2-5A activating molecules (see section 5.1.1). 
The net result would be a reduction in the activation of RNase L, limiting its antiviral and apoptotic 
capabilities. Indeed, this is a strategy employed by HIV-1, which is known to up regulate ABCE1 as 
a means to down-regulate the RNase L pathway [329]. More importantly, it was subsequently 
demonstrated that lopinavir was able to de-stabilise the ABCE1/RNase L interaction in E6 
expressing cells (Figure 6.17), which should in theory remove the steric hindrance preventing the 
activation of RNase L, with subsequent enhancement of antiviral/apoptotic activities in these E6-
expressing, lopinavir treated cells. 
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The current data support the conclusion that HPV does compromise the activity of RNase L. 
We demonstrate, for the first time, a prospective new mode of action of lopinavir against HPV 
infected cells unrelated to protease inhibition. These data suggest that, in association with the 
stabilisation of p53 demonstrated previously [98], the effects are partly related to an induction/ 
stabilisation of the antiviral protein RNase L and the ability of lopinavir to modulate the E6-mediated 
enhancement of the interaction between RNase L and ABCE1. Importantly, the data has also 
unexpectedly demonstrated the ability of lopinavir to preferentially target immortalised cells, as 
discussed below. 
 
7.4. Lopinavir targets Immortalised cells regardless of immortalisation technique 
 
Whilst a useful tool for molecular studies of HPV, SiHa cells are a fully transformed cell line, 
and it was intended to evaluate the potential use of lopinavir for the treatment of pre-cancerous 
cervical lesions, it was essential to also use a test system more representative of the intended 
target cell. Working in collaboration with Professor Ingeborg Zehbe, the effects of lopinavir (0-40 
µM) on control and E6/E7 immortalised primary human foreskin keratinocytes (PHFKs) were 
assessed by cell proliferation assays (Figure 3.5) and western blot analysis of RNase L expression 
(Figure 5.12). Interestingly, whilst the growth of normal PHFKs progressed relatively uninhibited up 
to concentrations of 25 µM, both SiHa and E6/E7-immortalised PHFKs showed markedly reduced 
growth. Beyond 25 µM control cells demonstrated growth inhibition comparable to E6/E7 
immortalised cells, again highlighting the narrow therapeutic window of lopinavir. Furthermore, 
lopinavir treatment was also shown to increase RNase L protein levels in E6/E7 transduced 
PHFKs, albeit over a much longer time scale than demonstrated in SiHa cells, which may reflect 
differences in cell growth rates, or differences in the kinetics of the lopinavir/ proteasome 
interaction in these particular cells. As discussed previously, the timescale of proteasomal inhibition 
in these cells, following exposure to lopinavir, is currently unknown. This has raised several 
questions: 
• Is there a gradual decline in proteasomal activity?  
• Does lopinavir produce a simply on/off switch in proteasome function?  
• Do the kinetics of lopinavir-mediated inhibition of the proteasome differ 
between cell types?  
We have generated SiHa cells stably expressing the pZsProSensor-1 proteasome sensor 
vector which uses GFP expression and detection as a surrogate marker for proteasomal activity 
(Chapter 2). Facilities permitting, live fluorescent imaging of these cells, in the presence of 
lopinavir, would provide a much more detailed overview of the lopinavir/ proteasome interaction in 
SiHa cells, and the system could easily be replicated using a range of cell types. 
The data initially suggested that lopinavir was preferentially targeting E6-immortalised cells 
over mortal cells. However, in addition to the PHFK system, it was thought that the combination of 
parental Tert, vector control, and HPV type 16 E6 expressing cells would also constitute a model 
test system with which to study the interaction(s) between the E6 protein and lopinavir. Tert cells 
are an HPV-negative karyotypically normal telomerase-immortalised human keratinocyte cell line 
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that demonstrates a down regulation in the expression levels of p16INK4a, a cyclin D/cdk inhibitor 
[205]. Cell proliferation assays demonstrated that in addition to E6-expressing Tert cells, both 
vector control and parental cells, with no E6 content, also demonstrated lopinavir dose-dependent 
growth inhibition (Figure 3.2) indicating that immortalised cells were specifically targeted by 
lopinavir. In addition,  as mentioned previously, C33A cells are an HPV-negative cervical 
carcinoma cell line and these cells are also susceptible to lopinavir treatment [98]. Significantly, this 
suggests that lopinavir preferentially targets immortalised cells, regardless of the immortalisation 
procedure, rather than specifically targeting E6 or E6/E7 immortalised cells.  
This observation was also confirmed by recent work in the laboratories of our collaborator 
Professor Ingeborg Zehbe. HPV type 16 E6 is an extremely multi-functional protein and is able to 
target a wide range of host proteins (detailed in Table 1.1). Accordingly, the E6 protein is an 
attractive target for HPV-specific antiviral drugs. The zinc finger domains of E6 play an important 
role in cell transformation and mutations in this region have been shown to inhibit the interaction 
between E6 and cellular targets such as E6AP and the E6 binding endoplasmic reticulum calcium-
binding protein (E6BP/ERC55) (As discussed in Zehbe et al, Manuscript in preparation). Thus, it is 
thought that targeting the E6 zinc finger motifs may eliminate HPV positive cells and several 
compounds have since been developed which eject zinc atoms from the zinc finger domains, thus 
altering E6 protein structure and function (Zehbe et al, Manuscript in preparation). In an on-going 
collaboration with Professor Ingeborg Zehbe (Thunder Bay Regional Research Institute, Thunder 
Bay, Ontario, Canada), the anti-HPV activities of lopinavir were recently compared to known zinc 
finger ejector (ZFE) compounds using mortal and E6/E7-immortalised PHFK in addition to the 
cancer cell lines SiHa, CaSKi, HeLa, ME180 and C33A, all with differing HPV/ E6 content; SiHa 
and CaSKi are HPV type 16 positive, HeLa are HPV type 18 positive, ME180 cells are HPV type 39 
positive whilst C33A are an HPV-negative cervical carcinoma cell line with no E6 content (Zehbe et 
al, Manuscript in preparation). Interestingly, while the ZFE compounds were uniformly toxic to both 
PHFK and cancer cell lines, lopinavir again demonstrated selective toxicity. While primary mortal 
PHFKs were highly resistant to lopinavir treatment as expected, all cancer and E6/E7-immortalised 
PHFK cell lines, with the exception of CaSKi cells, were susceptible to lopinavir treatment.  
These data support the hypothesis that the specificity of lopinavir for immortalised cells is not 
restricted to those specifically immortalised through E6/E7 expression. Indeed our Tert cell 
lopinavir-toxicity data from this research project (Chapter 3) support this conclusion and has been 
included in this manuscript, which is currently in preparation for submission to the journal of 
Antiviral Research.  It is again interesting that the Zehbe laboratory demonstrated that CaSKi cells 
were refractory to lopinavir treatment. As we have discussed previously, a possible explanation of 
this is related to the E6 content of these cells. In comparison to SiHa cells, CaSKi express several 
hundred fold more HPV type 16 E6 protein. Our data has indicated that E6 may play a role in 
down-regulating the RNase L pathway through enhancing the ABCE1/RNase L interaction which 
may offer some explanation as to the resistance observed in CaSKi cells. However, the Zehbe 
paper also speculates that the resistance of mortal PHFK and CaSKi cells may also be related to 
differences in the apoptotic pathways occurring in different cell types. Specifically, they speculate 
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that cell type specific differences in the activity of the pro-apoptotic c-Jun NH2-Terminal Kinase 
(JNK) may play a role in lopinavir-resistance (Zehbe et al, Manuscript in preparation). Significantly, 
it has recently been shown that apoptotic responses differed when comparing doxorubicin treated 
C33A (lopinavir-sensitive) cells and CaSKi cells (lopinavir-resistant). Doxorubicin treated CaSKi 
cells demonstrated decreased JNK expression when compared to C33A cells [330]. In light of this 
observation, it may be interesting to carry out western blot analysis of JNK protein expression 
levels in drug treated versus DMSO treated lopinavir-resistant cells and lopinavir-susceptible cells. 
The importance of JNK expression in lopinavir treated cells could be further assessed by siRNA-
mediated gene silencing of JNK or exposure to JNK-specific kinase inhibitors 
(http://www.agscientific.com/sp600125.html) which would demonstrate, if any, the role of JNK-
expression in lopinavir resistance/ toxicity. In addition to the E6 protein level differences discussed 
previously, variation in JNK expression will undoubtedly explain some of the lopinavir-specific 
resistance seen in CaSKi cells. These findings suggest that lopinavir-resistance is a multifaceted 
response requiring further research.  
It is clear from our results that RNase L is responsible for at least part of the toxicity of lopinavir in 
HPV positive cells however it is obviously not the only mechanism involved. Lopinavir preferentially 
targets immortalised cells, regardless of the immortalisation technique, indicative of alternative 
mechanisms, that are, at this stage unknown. However, our data does provide further evidence 
strongly supporting the use of lopinavir as a treatment of pre-cancerous HPV-related lesions of the 
cervix. In order to expand on these findings, it may be interesting to assess the ability of lopinavir to 
target a range of immortalised cell lines, for example SV40-immortalised cells, which will provide a 
more complete picture of lopinavir activity. 
 
7.5. Treatment of HPV-related pre-cancerous lesions of the cervix with lopinavir 
 
 
As discussed, in addition to inhibition of HIV protease, protease inhibitors demonstrate anti-
angiogenic, anti-inflammatory, anti-proliferative and anti-cancer actions (see Section 1.7.2.1) 
mediated through inhibition of the cellular 26S proteasome, in addition to modification of the 
functions of MMP2, VEGF and bFGF. Protease inhibitors are, therefore, an extremely versatile 
group of drugs. Indeed, lopinavir and ritonavir (Kaletra) have since been shown to be effective for 
the treatment of Coronavirus-related Severe Acute Respiratory Syndrome (SARS) [331, 332]. 
There are several on-going clinical trials investigating the use of protease inhibitors against a range 
of tumour types (Table 7.2), however, to date, there are no clinical trials specifically evaluating 
lopinavir, either as a single agent or co-formulated with ritonavir, as a means to target HPV-related 
pre-cancerous lesions of the cervix 
Following the introduction of HAART, it was anticipated that the fall in HIV viral load and 
restoration of the host immune system would lead to a reduction in opportunistic infections 
associated with HIV. Whereas this was true for HIV-related Kaposi’s sarcoma, with incidence rates 
dramatically falling during the HAART era, HAART was shown to have little impact on HPV-related 
cervical carcinoma. What could account for this apparent difference in clinical response? I now 
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believe that the anti-HPV effects of lopinavir are unrelated to immune restoration, occurring 
instead, as a result of a targeted interaction between lopinavir and the HPV infected cell. It is 
known that Lopinavir stabilises the p53 protein and can induce apoptosis of HPV positive cervical 
carcinoma cells in-vitro, and we now also demonstrate an up regulation of RNase L. However, 
these responses were shown to occur at drug concentrations approximately 15-fold higher than 
those generally found in cervico-vaginal secretions of women taking oral Kaletra [333]. This 
indicates that oral administration of HAART-PI compounds does not achieve the cervical drug 
concentrations required to induce the anti-HPV effects of lopinavir.    
Having identified a prospective new mode of action of lopinavir against HPV infected cells, 
related to modification of the innate RNase L cellular antiviral pathway, we propose that lopinavir 
may be suitable for use in the management of HPV-related cervical carcinoma. However, we have 
also demonstrated the importance of lopinavir concentration in achieving these responses, and as 
such we propose that lopinavir will be of greatest use when used as a topically applied agent.
  
Table 7.2 Clinical trials investigating the use of protease inhibitors as anti-cancer agents 
 
Trial ID Cancer type and stage Trial Phase Institution Treatment and Schedule 
NCT01095094 Progressive or Recurrent High Grade Glioma II 
Cleveland Clinic Taussig Institute, 
Case 
Comprehensive Cancer Center, 
Ohio, USA 
Oral ritonavir and lopinavir twice daily in the absence of 
disease progression or unacceptable toxicity 
NCT00233948 Recurrent liposarcoma I/II City of Hope, Duarte, CA, USA Nelfinavir orally, twice daily every 28 days 
NCT00436735 Solid tumours I National Cancer Institute, Bethesda, MD, USA Nelfinavir orally, twice daily every 21 days 
NCT00589056 Stage IIII NSCLC I/II University of Pennsylvania, PA, USA 
Nelfinavir orally, twice daily beginning 1-2 weeks before 
initiation of chemoradiotherapy and continuing until 
completion of radiotherapy 5 days per week for 7-8 
weeks; with intravenous cisplatin intravenously on days 
1, 8, 29 and 36 and etoposide intravenously days 1-5 and 
29-33 
NCT00705393  Locally advanced pancreatic cancer I 
University of Nebraska, Omaha, 
NE, USA 
Nelfinavir orally twice daily concurrent with stereotactic 
radiotherapy after neoadjuvant gemcitabine, fl uorouracil, 
and calcium folinate chemotherapy,followed by surgery 
and adjuvant chemotherapy 
NCT00704600 Rectal cancer I/II Maastro Clinic, Maastricht, Netherlands 
Nelfinavir orally twice daily beginning 7 days before 
chemoradiotherapy with capecitabine 825 mg/m2 twice 
daily 
NCT00694837 Glioblastoma I/II Maastricht University, Maastricht, Netherlands 
Nelfinavir orally twice daily beginning 7 days before 
chemoradiotherapy with temozolomide 
 
(Table Adapted from [167]).
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7.5.1. Topical application of lopinavir 
 
We have demonstrated extensive in vitro evidence indicating that lopinavir specifically 
targets and can induce apoptosis in both HPV-infected cells and non-HPV infected immortalised 
cells. Furthermore the data suggests that a final drug concentration of ≥25 µM is required, 
effectively precluding the use of oral lopinavir, instead suggesting that a topical application may be 
required. 
The use of topical agents for application to the cervix is not a new concept. The small 
molecule terameprocol (tetra-O-methyl nordihyrdoguaiaretic acid, M4N, EM1421) was recently 
evaluated in a phase I/II dose-escalation clinical trial for use as a topically applied agent in women 
with HPV-associated CIN. The trial aimed to define the maximum tolerated dose, dose-limiting 
toxicities and pharmacokinetic properties [334] of terameprocol vaginal ointment. Terameprocol, 
derived from the plant Larrea tridentata demonstrates several anti-viral and anti-cancer abilities 
[334]: 
• It selectively interferes with transcription of viral genes with Sp-1-dependent 
promoters, including HPV E6 and E7. 
• Inhibits Sp-1-dependent Cdc2 (p34) gene expression inhibition causing G2 cell 
cycle arrest. 
• Stimulates apoptosis by reducing mRNA levels and subsequent protein 
production of the cyclin-dependent kinase CDC2, resulting in the inactivation of 
the CDC2/cyclin B complex.  
• Down regulation of the production and activation of survivin, a member of the 
Inhibitor of Apoptosis (IAP) family of proteins, which down regulates apoptosis 
through inhibition of the function of caspases [335]. 
 
Terameprocol was applied to the cervix of trial participants in 5 ml aliquots using a 
disposable vaginal applicator. All patients received a total of three doses of terameprocol, 
administered by a physician at intervals of one week. The study demonstrated that terameprocol 
vaginal ointment was well tolerated with a favourable safety profile, with no serious adverse events 
reported and only mild self-limiting adverse events. The authors did however admit some 
limitations to the study; 
• The terameprocol vaginal ointment was formulated with white petroleum jelly, and 
its effects, if any, on drug bioavailability were unknown at the time of the study 
• The duration of drug exposure at the cervix was anticipated to be extremely brief 
since patients were allowed to move around after application. 
• No devices, such as diaphragms or pessaries were used to increase the contact 
time between drug and cervical cells. 
Clearly this phase I/II study has provided sufficient justification to suggest that topical 
application of lopinavir on the cervix is a viable treatment option. Indeed, in the on going studies, 
we aim to assess the usefulness of lopinavir as a topical application, however the studies will also 
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aim to address the limitations highlighted in the terameprocol vaginal ointment study, in particular, 
the short duration of drug exposure at the cervix. As discussed, topical application of a given 
therapeutic agent will generally result in only a brief exposure of the target cells to the agent in 
question. Accordingly with any topically applied agent, improving dose duration is of great 
importance. The principle of direct, targeted, gynaecological drug exposure has been previously 
demonstrated by the NuvaRing® contraceptive drug delivery system, an oestrogen and progestin 
impregnated, slow release delivery system made of flexible ethylene-vinyl acetate copolymer 
(Figure 7.1) (http://www.nuvaring.com/Consumer/index.asp).   
 
 
 
Figure 7.1 – Flexible, slow release gynaecological drug delivery system 
 
Figure 7.1. (Left) NuvaRing® vaginal flexible slow release drug delivery system and (Right) in-situ 
location proximal to the cervical transformation zone (images taken from http://women-health-
info.com/173-NuvaRing.html and [336]). 
 
 
This particular drug delivery system has many attributes that would make it useful for the 
local application of lopinavir to the cervix. Initially, the highly vascularised nature of the vaginal 
mucosa, in combination with the localised slow-release mechanism avoids first-pass metabolism at  
the liver, allowing for sustained drug levels. In addition the NuvaRing® is extremely low-
technology [336]. However, by far the most interesting attribute relates to the dosing schedule. The 
NuvaRing® is inserted manually, and remains in place for a period of 3 weeks, followed by a 7 day 
drug-free period. Subsequently, a fresh ring is inserted and so on. It has been shown that this 
dosing strategy improves patient compliance [336]. As discussed previously, current screening and 
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surgical approaches to managing HPV related cervical malignancy are hampered in low-resource 
regions, Africa in particular,  by the lack of basic health facilities and trained personnel [337]. In a 
region where vaccination is not currently a viable option, and where HIV co-infection exacerbates 
the problems of HPV related malignancy, a low-cost, low-technology therapeutic approach which 
promotes patient compliance and requires minimal dosing may be particularly useful. It is thought 
that the system may be adapted in order to develop a slow-release system for use with lopinavir, 
however, whilst an extremely interesting concept, the reformulation studies of lopinavir that would 
be required to develop such a system will be prohibitively expensive at this stage. Fortunately 
however, there are several formulations of Kaletra currently available, including standard tablets, 
an alcohol based liquid, and a soft-gel capsule (Kaletra Drug Safety Data Sheet available from 
http://www.rxabbott.com/pdf/kaletratabpi.pdf).  
It is anticipated that soft-gel capsules (SGC) will be the most favourable formulation for use 
as a topical application. While the SGC formulation has been shown to be relatively heat stable at 
low ambient temperatures, it has also been shown to lose structural integrity at temperatures over 
35°C, while maintaining pharmacological activity [3 38]. It is anticipated that when inserted into the 
vagina, in close proximity to the cervix, that the combination of body temperature, vaginal 
secretions and patient movement, will lead to the controlled breakdown of the SGC formulation, 
resulting in slow, targeted release of lopinavir, directly targeting the pre-cancerous cells of the 
cervix. Clearly, self-application of the capsule removes both the requirement for extensive health 
care facilities and highly trained personnel.  
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8. Conclusions and Novel findings 
8.1. Conclusion 
 
The aims of this research project were to (1) To identify cellular proteins, in addition to p53, 
degraded by HPV that are stabilised in the presence of lopinavir and (2) To identify potential new 
effectors of lopinavir that account for its anti-HPV activity and to fully characterise the potential 
mechanism(s).  
A range of proteins were stabilised in the presence of lopinavir, of most significance was the 
demonstration that lopinavir leads to a dose and time dependent stabilisation of the antiviral protein 
RNase L. It is proposed that the HPV-specific antiviral effects of lopinavir are as a result of the 
synergistic actions of the lopinavir stabilised proteins p53 and RNase L. The data potentially 
indicates that HPV can inactivate RNase L by enhancing the interaction with its endogenous 
inhibitor protein, ABCE1, an interaction with is subsequently de-stabilised in the presence of 
lopinavir. We believe the data demonstrates a previously unknown mode of action of lopinavir 
against HPV-infected cells that is unrelated to the ability of this compound to inhibit the HIV 
protease. Interestingly, the ability of lopinavir to induce apoptosis of non-HPV related immortalised 
cells merits further investigation since this indicates this drug may be useful for the treatment of 
other non HPV related pre-malignant conditions. 
 
In view of the observation that infection with HPV can enhance the sexual transmission of HIV 
in both men and women, a low cost, low technology, non-surgical alternative for the management 
of HPV-related pre-cancerous cervical lesions will not only reduce the burden of HPV-related 
disease but may also reduce the health burden associated with HIV infection. 
 
The findings support the conclusion that lopinavir may be a suitable, low-cost, self-applied 
topical alternative for the management of HPV-related pre-cancerous lesions of the cervix. 
Furthermore, it is anticipated that this agent will be of particular benefit in low-resource countries, in 
particular sub-Saharan Africa, which currently bears a disproportionate burden of world wide HPV-
related cervical cancer cases.  
 
8.2. Novel Findings  
 
 Lopinavir up-regulates RNase L in HPV positive SiHa cells. 
 
 RNase L protein is a key protein in the regulating anti-HPV activity of lopinavir. 
 
 HPV type 16 E6 protein produces a protective effect in C33A cervical carcinoma cells, 
inhibiting RNase L-mediated cell death. 
 
 HPV Type 16 E6 protein does not degrade RNase L, effect its sub-cellular localisation 
or up-regulate ABCE1 (RNase L inhibitor). 
 
 The HPV type 16 E6 protein enhances the association between RNase L and ABCE1, 
whilst lopinavir appears to destabilise the association. 
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9. Future Work 
 
9.1. Analysis of the effects of lopinavir on mTOR 
 
The Mammalian Target Of Rapamycin (mTOR) (Figure 9.2) is the target of the drug rapamycin 
which, together with its derivatives, has been shown to have prolonged antitumour activity in a 
variety of cancers [339]. The antibody micro array analysis indicated that lopinavir induces a down-
regulation of mTOR in SiHa cells (figure 4.7 & 4.8). Interestingly it has recently been shown that 
the mTOR pathway is constitutively activated in CIN and invasive cervical carcinoma [221] and 
indeed it has also been shown that HPV type 16 E6 protein activates mTORC1 signalling pathways 
resulting in increased protein synthesis [222]. In light of these observations we will initially treat 
SiHa and other cervical carcinoma cell lines (HeLa & CaSKi) with a range of concentrations and 
durations of exposure to lopinavir. Proteins will be extracted and the effects of this treatment on 
mTOR levels examined by western blotting.  
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Figure 9.2 – mTOR signalling pathway 
 
 
 
 
Figure 7.2 – mTOR signalling pathway. The mammalian target of rapamycin protein is an 
intracellular kinase that controls protein synthesis and cell cycle progression. The pathway is 
stimulated by growth signals and exposure to nutrients. Activation of the pathway results in active 
mTOR, which phosphorylates S6K and also 4E-BP. Active S6K, promotes formation of translation 
initiation complexes, whilst phosphorylation of 4E-BP releases eIF4F which binds to the 5’ cap of 
mRNA, initiating cap dependent translation. 
(PI3K, phosphatidylinositol 3’-kinase; PDK1, phosphoinositide-dependent kinase-1; AKT, also 
known as protein kinase B, PKB; TSC1 & TSC2, tuberous sclerosis complex 1 & 2, also referred to 
as hamartin and tuberin respectively; Rheb, Ras-homolog enriched in brain, GTP bound; GβL, also 
known as mLST8, Gβ-like protein; Raptor, regulatory associated protein of TOR; S6K, p70S6 
kinase). 
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If these results confirm the lopinavir-induced down regulation of mTOR, the ability of lopinavir 
to synergise with rapamycin to induce apoptosis of abnormal cells will be assessed. The effects of 
these compounds will also be evaluated in the organotypic culture systems described in section 
9.3.1. Notably in recent phase II clinical trials of endometrial cancer, mTOR inhibitors have shown 
promising results [340] synergising with platinum and taxane based drugs [341]. Depending of the 
extent of the synergism observed between lopinavir and rapamycin in the preceding experiments, 
the levels of lopinavir achievable by oral administration may be sufficient to attain synergistic 
effects with rapamycin. These data would thus support a prospective new use for this combination 
of drugs in the treatment of premalignant and invasive cervical carcinoma. 
 
 
9.2. High Risk HPV E7 protein and lopinavir 
 
While the current findings support a role for HPV type 16 E6 in the inhibition of RNase L-
dependent cell death (Figure 6.6), the data has not yet ruled out the possibility of E7 contributing to 
this effect.  In addition to C33A E6 cells, E7 expressing cells are available. It is planned to repeat 
transient RNase L transfection using cells, with cell death assessed 24 hours post transfection by 
trypan blue exclusion. 
 
 
 
9.3. Topical application of lopinavir – a Phase I clinical trial 
 
9.3.1. Drug penetration studies 
 
Prior to commencing a planned phase I clinical study, it will be essential to evaluate the ability 
of lopinavir to penetrate human skin. In order to assess this, we intend to use the full-thickness in 
vitro model of human skin recently developed by Stratatech 
(http://www.stratatechcorp.com/products/stratatest.php). It is intended to use this cell system to 
assess the ability of lopinavir as a single agent, or formulated as Kaletra® to penetrate from the 
apical cell surface through to the basement membrane and accumulate in sufficient quantities (≥ 25 
µM).  Working in collaboration with the laboratories of Professor Roy Goodacre and Dr Dong-Hyun 
Kim (Manchester Interdisciplinary Biocentre, Manchester, UK), we have developed Fourier 
Transformation Infra Red spectroscopy techniques to analyse the metabolic changes occurring in 
lopinavir treated cervical carcinoma cells [184] and direct Raman spectroscopic imaging to identify 
the site of action of the drug in cells [185]. 
In addition, working in collaboration with Professor I. Zehbe (Lakehead University, Canada) 
organotypic air interface raft cultures of primary human foreskin keratinocytes that have been 
retrovirally transfected and immortalised with HPV16 E6/E7 cDNA (figure 7.2) will also be used to 
assess the cellular penetration of lopinavir in 3D cell culture systems [342]  
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Figure 7.2 – 3D organotypic raft cultures of human keratinocytes   
       
  
 
Figure 7.2 - Sections from 3D organotypic raft cultures of human keratinocytes expressing HPV 
type 16 E6 & E7 proteins. Vector control cells are included, demonstrating anucleated differentiated 
cells (arrowed). 
 
Karyotypically normal, Telomerase immortalised keratinocytes (Tert cells) will be used to 
produce the same type of 3D organotypic cultures shown in figure 7.1 [343]. The ability of lopinavir, 
at a range of final concentrations, to penetrate into the cell will then be assessed using these cell 
systems. Treated and control untreated cultures will be harvested, frozen sections cut and these 
evaluated by H&E staining and the extent of drug penetration assessed by the techniques of 
Fourier transform infrared (FT-IR) spectroscopy and Raman micro-spectroscopy [185, 344].  
These methods are based on vibrational spectroscopy and will be calibrated using cellular 
extracts where the drug levels have been quantified using HPLC-MS. Having determined the 
optimum drug dosage required to achieve biologically active concentrations of lopinavir in these 
homogenous cultures, organotypic raft cultures composed of mixed E6/E7 and Tert keratinocyte 
organotypic cultures will then be used. The effects of lopinavir treatment on these mixed cultures 
will then be assessed by immunohistochemical analysis of the expression of known protein 
markers of E6/E7 activity (p16INK4a, p53, RNase L, mTOR). We will also use TUNEL apoptosis 
staining (TACS XL In situ Apoptosis Kit, R & D Systems, Minneapolis, USA) to evaluate the 
cytotoxic effects of these various drug treatments on homogenous and mixed culture. As we have 
previously demonstrate the ability of lopinavir to selectively target immortalised cells, the expected 
outcome will be a lopinavir dose that eliminates E6/E7-immortalised cells whilst maintaining Tert 
cells in mixed organotypic cultures of these cell types. All these experiments will be repeated using 
a 4:1 ratio of lopinavir: ritonavir since this is the commercially available HIV drug Kaletra that will be 
used in our planned clinical trial. 
 
 
 
 
 
 
HPV16 E6/E7 in human 
keratinocyte 3D raft 
Vector control in human 
keratinocyte 3D raft 
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9.3.2. Phase I clinical trial 
 
 
Extensive preparations have been made for a Phase I clinical trial. However, in brief, the 
clinical trial will be carried out at the Kenyatta National Hospital, Nairobi, Kenya, in association with 
Dr Innocent Maranga, a University of Manchester student predicted to obtain his PhD in early 
2011. The study subjects will be recruited among patients attending the specialist colposcopy clinic 
at the Kenyatta National Hospital, Nairobi, Kenya. Initially, the trial will aim to recruit 30 HIV-
negative CIN II/III positive women and will be in the form of a dose-escalating phase I clinical trial 
with three main objectives: 
 
• To assess tolerability of the soft-gel capsule formulation 
• To assess adverse side effects of lopinavir when administered as a vaginal pessary 
• To gauge potential benefit of lopinavir in the treatment of pre-cancerous lesions of the 
cervix 
 
Prior to commencing the trial, each participant will undergo standard Pap smear/ LBC screening to 
assess CIN status. The trial will use a generic soft-gel formulation of lopinavir and ritonavir, 
manufactured by Cipla (www.cipla.com) containing 133 mg lopinavir and 33 mg ritonavir. On 
commencing the trial, the 30 participants will be randomly assigned to one of 3 dosing groups: 
 
• 1 capsule, once a day 
• 1 capsule, twice a day 
• 1 capsule, three times a day 
All participants will receive their assigned dose for a period of 14 days, and will be 
assessed every two days for signs of unwanted adverse effects. In addition to the pre-trial 
cytological assessment, participants will also be assessed at 1 and 3 months for HPV.  
As mentioned previously it is essential that any new treatment for use in a low resource 
country be low-cost requiring minimal expertise in applying the treatment. In light of these 
requirements, generic soft gel capsules, marketed as ‘lopimune’ will be used. Currently, lopimune 
is sold in containers of 180 capsules for $160, working out as less than $1/capsule, making vast 
financial improvements on the prices of the current vaccinations (£120/dose, for a 3-dose regime). 
Clearly, any further clinical evaluation of lopinavir as a topical agent will depend of the 
information gathered as part of this phase-I clinical trial. 
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Appendix 1 - Vector Information 
 
 
pZsProsensor-1 Vector – Proteasome Sensor Vector 
 
 
 www.clontech.com/images/pt/PT3712-5.pdf 
 
 
 
 
pReceiver-M02 – Mammalian RNase L Expression Vector 
 
 
http://www.genecopoeia.com/tech/omicslink/pReceiver-M02.pdf 
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Appendix 2 
Solutions 
 
All solutions were prepared using sterile filtered water and autoclaved for 11 
minutes at 121°C using a Prestige Medical 2100 seri es bench top autoclave 
(Prestige Medical, Blackburn, UK) 
 
1x Phosphate Buffered Saline (PBS) 
 
2 PBS tablets dissolved in 400ml distilled water (autoclaved for sterile 1 x PBS) 
 
10x TAE buffer (1L) 
Tris base 48.4g 
Acetic acid 11.4ml 
EDTA (0.5M) (pH8) 20ml 
Made up to 1L with distilled water 
 
1x TE Buffer 
Tris base 0.12g 
EDTA (0.5M)  200µl 
Made up to 100ml with distilled water 
 
10x Laemmli Buffer 
Tris base 15.2g 
Glycine 72.1g 
Made up to 500ml with distilled water 
 
 
Bioline PCR BioMixTM Red 
 
BIOTAQ DNA Polymerase  
dNTPs  2mM 
(NH2)2SO4 32mM 
Tris HCl (pH 8.8 at 25°C) 125mM  
Tween 20 0.02% 
MgCl2 4mM 
Stabiliser   
Inert Dye  
 
 
1% Agarose 
1g Agarose dissolved in 100ml 1x TAE buffer and microwaved until dissolved 
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Luria Bertani (LB) media 
 
Sodium chloride 10g 
Select peptone/ tryptone 10g 
Select yeast extract 5g 
Made up to 1L with distilled water 
 
LB Agar 
As for LB media with added 1.5% Agar 
 
 
 
Β-Galactosidase reporter gene staining solution 
 
Magnesium chloride 
(200mM) 10µl 
Potassium Ferricyanide 
(400mM) 10µl 
Potassium Ferrocyanide 
(400mM) 10µl 
X-Gal solution (20mg/ml)* 50µl 
1xPBS 920µl 
*Lab stock of 100mg/ml X-Gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) 
solution diluted 1/5 with N-N-Dimethylformamide 
 
 
Western Blotting Solutions 
 
10x Laemmle running Buffer (500ml) 
Tris 15.2g 
Glycine 72.1g 
Made up to 500ml with distilled water – for 1x running buffer add SDS to 0.1% (i.e. 
5ml in 500ml) 
 
Transfer Buffer (500ml) 
 
2.9g Tris base 2.9g  
1.5g Glycine 1.5g  
Dissolve the above in 200ml 
distilled water  
Methanol 200ml 
 
 
1M Tris pH 6.8 (100ml) 
Tris 12.1g 
Distilled water 100ml 
pH to 6.8 with HCl 
 
 [208] 
 
 
1.5M Tris pH 8.8 (100ml) 
Tris 18.1g 
Distilled water 100ml 
pH to 8.8 with HCl 
 
2 x Loading Buffer (Laemmle)  
Tris (pH 6.8) 0.6 ml (60 mM Final) 
10% SDS 2 ml 
Bromophenol Blue (0.05%) To colour 
Glycerol (50%) 1 ml 
Dithiothreitol (DTT) (0.1M) 1ml 
sdH20 5.4 ml 
 
 
Stacking Gel 
 
distilled Water 2.7ml 
Acrylamide Mix 0.67ml 
Tris (pH 6.8) 0.5ml 
SDS (10%) 0.04ml 
APS (10%) 0.04ml 
TEMEDa 0.004ml 
a
 – N, N, NI, NI-Tetramethylethylenediamine 
 
Resolving/ Separating Gel (15ml of 12% Gel Solution) 
 
distilled water 5ml 
Acrylamide mix 6ml 
Tris (0.5M) pH 8.8 3.8ml 
SDS (10%) 0.15ml 
APS (10%) 0.15ml 
TEMEDa 0.006ml 
a
 – N, N, NI, NI-Tetramethylethylenediamine 
 
 
Preparation of Competent XL-1 Blue E.coli 
TFB-1 
Potassium acetate 0.59g 
Calcium chloride 0.294g 
Manganese chloride 1.98g 
Rubidium chloride 2.42g 
Glycerol 15% 
  
Filter Sterilise  
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Made up to 200ml with distilled water and pH to 5.8 with 1M acetic acid 
 
TFB - 2 
MOPS 0.23g 
Calcium chloride 1.1g 
Rubidium chloride 0.121g 
Glycerol  15% 
  
Filter Sterilise  
Made up to 100ml with distilled water and pH to 6.5 with potassium hydroxide 
 
Plasmid Preparation Solutions 
Solution 1 
Glucose 4.51g 
Tris (1M) 12.5ml 
EDTA (0.5M) 10ml 
Made up to 50ml with distilled water 
 
Solution 2 
Sodium Hydroxide (10M) 400µl 
10% Sodium dodeycl 
sulphate (SDS) 2ml 
Made up to 20ml with distilled water – Made fresh every time. 
 
Solution 3 
Potassium acetate 147.2g 
Acetic acid 57.5ml 
Made up to 500ml with distilled water 
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Appendix 3 - PCR primers and thermal cycling conditions 
 
β-Actin-F 5'-TCC-ATC-ATG-AAG-TGT-GAC-GT-3' 55.3ºC 
β-Actin-R 5'-TCA-GGA-GCA-ATG-ATC-TT-3' 55.3ºC 
Product 
Length 161bp 
Stage Temp (°C) Time  No Cycles 
Denature 95 5min 1 
Denature 94 25sec 
32 Anneal 53 25sec 
Extend 72 25sec 
Extend 72 5 min 1 
Hold 4     
Tm 
ZsG-F 
5'-ATC-TTG-TCC-GCC-GCC-TTC-AAC-
TA-3' 62.4ºC 
ZsG-R 
5'-TTC-ACG-CCG-TAG-AAC-TTG-GAC-T-
3' 60.3ºC 
Product 
Length 212bp 
Stage Temp (°C) Time  No Cycles 
Denature 95 5min 1 
Denature 94 25sec 
32 Anneal 57 25sec 
Extend 72 25sec 
Extend 72 5 min 1 
Hold 4     
Tm 
GAPDH-F 5’-CATTGACCTCAACTACATGGT-3’ 62.4ºC 
GAPDH-R 5’-TCGCTCCTGGAAGATGGTGAT-3’ 60.3ºC 
Product 
Length 130bp 
Stage Temp (°C) Time  No Cycles 
Denature 95 5min 1 
Denature 94 25sec 
30 Anneal 58 25sec 
Extend 72 25sec 
Extend 72 5 min 1 
Hold 4     
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RNASEL-F 5’-AGC-AGA-CTC-TGG-AAG-CGT-GTT-3’ 60.3ºC 
RNASEL-R 5’-TGC-CAG-GTG-AGC-AGC-TTT-CTT-3’ 60.3ºC 
Product 
Length 194bp 
Stage Temp (°C) Time  No Cycles 
Denature 95 5min 1 
Denature 94 25sec 
30 Anneal 56 25sec 
Extend 72 25sec 
Extend 72 5 min 1 
Hold 4     
PLA-F 5'-AAGTTCTTGATCCCCAATGCT-3' 56ºC 
PLA-R 5'-GCAACCAACACATCCTATCAGAC-3' 54ºC 
Product 
Length 196bp 
Stage Temp (°C) Time  N o Cycles 
Denature 95 5min 1 
Denature 94 25sec 
33 Anneal 54 25sec 
Extend 72 25sec 
Extend 72 5 min 1 
Hold 4     
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Appendix 4 – RNase L-specific siRNA sequences 
 
Four different RNase L-specific siRNA oligonucleotides (siRNA 1-4) plus 
ALLSTARS (sequence unpublished) and MAPK control oligonucleotides with no 
significant off-target homology were designed by and obtained from Qiagen 
(Flexitube siRNA system, Qiagen, West Sussex, UK) 
 
 
siRNA-1 5' CCA-GAC-TAC-ACT-AGT-CCA-TAA 3' 
  
 
 
siRNA-2 5' CAA-GTG-GAC-GAC-TAA-GAT-TAA 3' 
  
 
 
siRNA-3 5' CAG-GAA-GTC-AAG-AGA-GAT-CTA 3' 
  
 
 
siRNA-4 5' CCC-TAT-GAT-TGG-CAA-ACT-CAA 3' 
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Background: We have previously shown that the HIV 
protease inhibitor lopinavir has selective toxicity against 
human papillomavirus (HPV)-positive cervical carcinoma 
cells via an unknown mechanism.
Methods: SiHa cervical carcinoma cells were stably 
transfected with the proteasome sensor vector pZsPro-
Sensor-1 to confirm lopinavir inhibits the proteasome 
in these cells. The Panorama Xpress profiler 725 anti-
body array was then used to analyse specific changes 
in protein expression in lopinavir-treated versus control 
untreated SiHa cells followed by PCR and western blot-
ting. Colorimetric growth assays of lopinavir-treated 
E6/E7 immortalised versus control human keratino-
cytes were performed. Targeted small interfering RNA 
gene silencing followed by growth assay comparison of 
lopinavir- treated/untreated SiHa cells was also used.
Results: Lopinavir induced an increase in the fluorescence 
of pZsProSensor-1 transfected SiHa cells, indicative of 
proteasomal inhibition. Ribonuclease L (RNASEL) protein 
was shown to be up-regulated in lopinavir-treated SiHa 
cells, which was confirmed by PCR and western blot. Tar-
geted silencing of RNASEL reduced the sensitivity of SiHa 
cells to lopinavir. Selective toxicity against E6/E7 immor-
talised keratinocytes versus control cells was also seen 
with lopinavir and was associated with up-regulated 
RNASEL expression.
Conclusions: These data are consistent with the toxicity 
of lopinavir against HPV-positive cervical carcinoma cells 
being related to its ability to block viral proteasome acti-
vation and induce an up-regulation of the antiviral protein 
RNASEL. This is supported by the drug’s selective toxic-
ity and up-regulation of RNASEL in E6/E7 immortalised 
keratinocytes combined with the increased resistance to 
lopinavir observed in SiHa cells following silencing of 
RNASEL gene expression.
Human papillomavirus (HPV) has been unequivocally 
implicated as a causative agent in the development of 
cervical cancer [1,2] with >490,000 women worldwide 
diagnosed every year and >273,000 deaths per annum. 
Although there are over 100 subtypes of HPV, 70% of 
cervical cancer cases are attributed to infection with 
just two high-risk types, 16 and 18 [3,4].
There are currently large differences in the incidence 
of this disease between developed and developing coun-
tries, mainly due to the implementation of effective 
screening strategies in the former [5]. For example, in 
the UK, cervical cancer now rates as the 11th most com-
mon women’s malignancy, whereas in Africa it remains 
the most prevalent. Lack of screening is not the only 
contributory factor here, as many African nations also 
carry the additional burden of HIV infection, which is 
known to predispose to HPV-related cervical neopla-
sia [6]. Whilst surgery remains the current treatment of 
choice for HPV-related pre-cancerous lesions, this is not 
generally advocated for low-grade disease for which a 
‘wait and see’ approach is usually adopted. Unfortu-
nately for HIV-positive women, surgery is far less effec-
tive and recurrence rates of cervical cancer are much 
higher in these women than those with a negative HIV 
status [7]. Surgical intervention for cervical cancer in 
HIV-positive women can also lead to a massive post-
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operative increase in vaginal fluid HIV titre, thereby 
greatly increasing the chances of sexual transmission of 
the virus [8,9].
The production of an HPV vaccine has prompted 
many developed countries to implement anti-HPV vac-
cination programmes which aim to target females prior 
to their first sexual exposure [10]. However, this will 
still leave large numbers of already infected women at 
risk, in addition to those infected with high-risk types 
of HPV not covered by the current vaccines. In devel-
oping areas like Africa the cost of such a vaccination 
programme, even with subsidies, is likely to be prohibi-
tively expensive. Furthermore, there is also evidence to 
indicate that vaccination will be less effective in HIV-
positive women [11,12].
For the foreseeable future it is clear that development 
of a non-surgical, preferably self-applied, treatment for 
HPV-related cervical dysplasia would be extremely val-
uable. This would have particular impact and benefit 
in low-resource settings where high levels of HIV infec-
tion can aggravate this condition.
We previously investigated the ability of HIV protease 
inhibitors to combat HPV infection and demonstrated 
that the antiretroviral drug lopinavir could stabilise 
the p53 protein and induce apoptosis of HPV-positive 
cervical carcinoma cells in vitro, albeit at higher doses 
than those achieved by oral administration [13]. These 
data indicated that lopinavir could potentially be used 
topically as an anti-HPV therapeutic. Prior to a clinical 
trial to test this new indication, we set out to further 
characterise how lopinavir works against HPV. In this 
regard we have used Fourier Transformation Infra Red 
spectroscopy to analyse the metabolic changes occur-
ring in lopinavir-treated cervical carcinoma cells [14] 
and direct Raman spectroscopic imaging to identify the 
site of action of the drug in cells [15]. We now provide 
evidence to further support our initial observations and 
present data on the specific molecular mechanisms by 
which lopinavir works against HPV.
Methods
Cell culture
HPV16-positive SiHa and CaSki cells derived from 
cervical carcinoma were obtained from the American 
Type Culture Collection (Manassas, VA, USA) and 
were cultured at 37°C in a humidified atmosphere 
containing 5% CO2 in RPMI-1640 medium (Invit-
rogen, Paisley, UK) supplemented with 10% fetal 
bovine serum (Sigma–Aldrich, Dorset, UK) and 2 mM 
L-glutamine (Sigma–Aldrich). Primary human fore-
skin keratinocytes (PHFKs) immortalised by retrovi-
rally transducing with HPV16 E6 and E7 genes were 
grown in serum-free keratinocyte medium as recently 
described [16].
Protease inhibitor
Lopinavir was provided as a kind gift by Abbott Lab-
oratories (Abbott Park, IL, USA). A 20 mM working 
stock solution of lopinavir was prepared in DMSO 
(Sigma–Aldrich).
Derivation and use of pZsProSensor-1 transfected 
SiHa cells
The pZsProSensor-1 proteasome sensor vector (Clontech, 
Mountain View, CA, USA) was used to assess the ability 
of lopinavir to induce proteasomal inhibition and thus 
alter cellular protein levels. Linearised vector was used 
to stably transfect SiHa cells using Lipofectamine-2000 
according to the manufacturer’s recommendations (Inv-
itrogen). Successfully transfected cells were selected using 
G-418-sulphate (Geneticin; Invitrogen).
pZsProSensor-1 transfected SiHa cells were seeded 
in duplicate wells of an eight-well slide flask (BD Bio-
sciences, Bedford, UK). At 70% confluency, the growth 
medium was aspirated and replaced with growth 
medium supplemented with the non-specific protea-
some inhibitor MG-132 as a positive control (Merck 
[Calbiochem], Nottingham, UK) at a final concentra-
tion of 10 µM for 4 h or lopinavir at a final concentra-
tion of 25 µM for 6 h. DMSO-treated control cells were 
also included. Following the incubation, cells were fixed 
in 2% paraformaldehyde and counter stained for 10 
min using Hoechst nuclear stain at 0.5 µg/ml (Sigma–
Aldrich). Expression of the green fluorescence reef coral 
protein (GFP) was detected through a standard FITC 
filter using an Olympus widefield microscope (Olym-
pus, Southend-on-Sea, UK). Images were acquired using 
the Metavue software package (Metavue, Downington, 
PA, USA).
Analysis of changes in protein expression using 
antibody microarrays
The Panorama XPRESS Profiler-725 antibody micro-
array was used according to the manufacturer’s instruc-
tions (Sigma–Aldrich; Additional file 1). In brief, HPV-
positive SiHa cells were grown to 80% confluency 
before being treated for 6 h with either 25 µM lopinavir 
or DMSO control. Cells were harvested and total pro-
tein extracts from lopinavir and control DMSO-treated 
SiHa cells were fluorescently labelled with Cy3 fluoro-
phore. The levels of expressed proteins were compared 
by immunoprobing duplicate antibody microarrays and 
scanning with a Perkin Elmer  ProScanArray fluorescent 
scanner (PerkinElmer, Waltham, MA, USA). Although 
Affymetrix full expression profile microarrays require 
multiple-comparison statistical analysis, the Panorama 
XPRESS Profiler-725 antibody microarray compares 
protein expression levels using duplicate antibody 
spots, combined with a variety of antibodies against 
house keeping protein for signal normalisation. The 
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accompanying PerkinElmer ProScanArray fluorescent 
scanner software was used to convert scan intensities 
into numerical values and treated versus control cell 
values plotted for each protein. This analysis produces 
a ratio rendering the data quantitative. More traditional 
protein quantitation techniques, such as western blot-
ting were used to validate antibody array results.
RT-PCR
All reverse transcription (RT)-PCR work was carried 
out using an Applied Biosystems GeneAmp PCR System 
2700 (Applied Biosystems, Carlsbad, CA, USA). The 
‘Cells-to-cDNA™ II Kit’ (Invitrogen) was used accord-
ing to the manufacturer’s recommendations to synthesise 
complementary DNA (cDNA) from SiHa cells treated 
with either lopinavir (6 h at 25 µM) or DMSO control 
as previously described [13]. PCR was carried out in a 20 
µl reaction volume containing 10 µl Biomix red (Bioline, 
London, UK), 0.5 µl each of ribonuclease L (RNASEL) 
forward primer (5′-AGC-AGA-CTC-TGG-AAG-CGT-
GTT-T-3′) and reverse primer (5′-TGC-CAG-GTG-
AGC-AGC-TTT-CTT-A-3′), and 2 µl cDNA sample. 
Cycle parameters were as follows: denaturing at 94°C 
for 5 min, followed by amplification for 32 cycles with 
denaturing at 94°C for 25 s, annealing at 53–57°C for 
25 s, extension at 72°C for 25 s for 33 cycles followed 
by a final extension period of 3 min at 72°C. HPV16 E6 
forward (5′-AAT-GTT-TCA-GGA-CCC-ACA-GG-3′) 
and reverse (5′-CAT-ACA-GCA-TAT-GGA-TT-CC-
C-3′) test primers were used and GAPDH control PCR 
was carried out using the forward primer (5′- CAT-
TGA-CCT-CAA-CTA-CAT-GGT-3′) and reverse primer 
(5′-TCG-CTC-GTG-GAA-GAT-GGT-GAT-3′).
Western blotting and antibodies used
Protein lysates were prepared from duplicate flasks 
treated with either lopinavir or DMSO control. Briefly, 
the growth medium was aspirated, and cells were 
washed with 1× phosphate-buffered saline (PBS) and 
detached from the culture flask using pre-warmed 
trypsin/EDTA (0.25%; Invitrogen) with incubation at 
37°C/5% CO2. Trypsin was then neutralised by addi-
tion of 10 ml complete RPMI-1640 medium containing 
fetal bovine serum. A cell count was carried out and 
5×105 cells were pelleted by centrifugation at 295 × g. 
Total protein from 5×105 cells, was lysed with 2× Lae-
mmli sample buffer, and separated by 12% SDS PAGE 
for 2 h. Following this, proteins were transferred onto 
Hybond C Extra nitrocellulose membranes (Amersham 
Biosciences, Buckinghamshire, UK) using a semi-dry 
blotter (Whatman Biometra, Goettingen, Germany). 
Immunoprobing was carried out as described previ-
ously [13], with the following primary antibodies, both 
supplied by Abcam (Cambridge, UK), polyclonal rabbit 
anti-RNASEL (ab32307) 1:500 in 1×PBS overnight at 
+4°C and mouse monoclonal anti-GAPDH (ab9484), 
1:1,500 in 1×PBS, 1.5 h at room temperature. This was 
followed by washing and incubation with appropriate 
horse radish peroxidase-conjugated secondary antibod-
ies at 1:2,000 in 5% milk powder in PBS for 2 h at 
room temperature. Swine anti-rabbit and rabbit anti-
mouse horse radish peroxidase conjugated secondary 
antibodies were obtained from Dako, Cambridge, UK. 
Proteins were visualised using ECL and exposure to 
hyperfilm (Amersham Biosciences).
Analysis of growth and RNASEL expression in lopinavir-
treated E6/E7 immortalised and control PHFKs
Stable E6/E7 immortalised PHFKs were treated with 
lopinavir at concentrations between 5 µM and 40 µM 
and cell growth assessed at 72 h by means of the 
CellTitre 96® AQueous One Solution Cell Proliferation 
Assay (AQ-96 assay; Promega, Southampton, UK). 
RNASEL protein levels were determined in lopinavir-
treated E6/E7 immortalised PHFKs by western blot-
ting as described.
siRNA silencing of RNASEL expression
Four different RNASEL-specific siRNA oligonuce-
otides (siRNA 1-4) plus AllStars and MAPK control 
oligonucleotides with no significant off-target homol-
ogy were designed and obtained from Qiagen (Flex-
itube siRNA system; West Sussex, UK; siRNA-1, 
5′-CCA-GAC-TAC-ACT-AGT-CCA-TAA-3′; siRNA-2, 
5′-CAA-GTG-GAC-GAC-TAA-GAT-TAA-3′; siR-
NA-3, 5′-CAG GAA-GTC-AAG-AGA-GAT-CTA-3′; 
siRNA-4, 5′-CCC-TAT-GAT-TGG-CAA-ACT-CAA-3′). 
These were transiently transfected into SiHa cells using 
Lipofectamine-2000 reagent according to the manufac-
turer’s instructions (Invitrogen). RNASEL down-regu-
lation was assessed by western blot 24 h post-transfec-
tion following 6 h of treatment with 25 µM lopinavir. 
SiHa cells were seeded in 96-well plates and trans-
fected with siRNA-1 or the AllStars negative control 
as described above. Twenty four h post-transfection the 
growth medium was aspirated and replaced with fresh 
medium and initial cell viability determined by means 
of the AQ-96 assay. Growth medium in the remaining 
wells was supplemented with lopinavir to final concen-
trations of 20 µM, 25 µM, 30 µM or DMSO control. 
AQ-96 assay was then used to assess cell viability at 
each lopinavir concentration at 24, 48 and 72 h. Every 
data point was the result of three separate assays from 
three separately transfected wells.
Results
Lopinavir inhibits proteasome activity
Our previous studies have shown that lopinavir-treated 
cervical cancer cell culture lysates have decreased 
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proteasome activity [13]. In order to verify this finding 
in vivo the SiHa HPV-positive cervical cancer cell line 
was stably transfected with the pZsProSensor-1 vector. 
This allows real-time monitoring of the proteasome in 
living cells, whereby addition of proteasome-inhibiting 
drugs results in accumulation of the fluorescent rapidly 
degraded proteasome target ZS-Green(GFP)/murine orni-
thine decarboxylase fusion protein encoded by the vector. 
The pZsProSensor-1 transfected SiHa cells were treated 
with lopinavir, the known proteasome inhibitor MG132 
or a DMSO control. Lopinavir and MG132 produced a 
marked increase in detectable GFP levels when compared 
to DMSO-treated cells (Figure 1), demonstrating that, in 
a similar fashion to MG132, lopinavir has the ability to 
inhibit proteasomal activity. As the proteasome is a major 
cellular mechanism for regulating the concentration of a 
wide range of proteins, it follows that treatment of SiHa 
cells with lopinavir will result in changes in the cellular 
protein expression profile. Antibody microarray screen-
ing was therefore utilised in order to assess the extent of 
these changes on a number of proteins.
Lopinavir induces specific changes in protein 
expression in SiHa cells
Of the 725 proteins on the antibody array representing 
a wide range of biological pathways, 38 showed altered 
expression levels after lopinavir treatment (Table 1). 
Only three showed a reduction in levels whilst the 
remaining proteins all showed a drug-induced increase. 
A detailed discussion of the potential significance of 
all of these changes is beyond the scope of this com-
munication. However, for information, we have tabu-
lated the main functions currently ascribed to these 
proteins based on published literature searches. Signifi-
cantly, several classical apoptosis-related proteins were 
up-regulated such as annexin 5, tumour necrosis factor, 
active caspase 3, Tp63 and Tp53. This finding was rel-
evant as it substantiated our previous work where we 
demonstrated apoptotic cell death in HPV-positive SiHa 
cells following lopinavir treatment. Of particular inter-
est, however, was the upregulation of the interferon-in-
duced RNASEL since it had previously been reported to 
have antiviral activity [17,18]. Figure 2A highlights the 
differential RNASEL antibody array protein signal we 
obtained from lopinavir versus control DMSO-treated 
SiHa cells. This was confirmed by immuno-probing a 
western blot of proteins isolated from these cells where 
a significant up-regulation of RNASEL was observed 
(Figure 2B). Since RT-PCR demonstrated no obvi-
ous difference in the RNASEL messenger RNA levels 
between replicate DMSO-treated control and lopinavir-
treated SiHa cells (Figure 2C) these data support the 
hypothesis that lopinavir inhibits proteasomal degrada-
tion of the RNASEL protein and this was prioritised for 
further study.
Lopinavir induces both dose- and time-dependent 
changes in RNASEL protein levels in SiHa cells but has 
no effect on CaSki cells
To further investigate the association between lopinavir 
treatment of SiHa cells and variations in RNASEL pro-
tein levels, both dose- and time-dependent effects were 
assessed. Lopinavir produced a clear dose-dependent 
increase in RNASEL levels over a range of concentra-
tions tested (Figure 3A). This was repeated on a sec-
ond HPV-positive cervical carcinoma cell line, CaSki, 
which we had previously reported as refractory to 
lopinavir treatment [13]. No evidence of RNASEL up-
regulation was observed in CaSki cells, which is inter-
esting in light of the fact that they express much higher 
No protease inhibition 10 µM MG-132/4 h 25 µM Lopinavir/6 h
Figure 1. Lopinavir inhibits the proteasome in SiHa cells
Fluorescent microscopy analysis of stable transfected SiHa cells expressing the proteasome sensor vector pZsProSensor-1. Cells were treated with either lopinavir 
or MG-132 at final concentrations of 25 µM and 10 µM, respectively. Control cells were treated with DMSO. Green fluorescent protein (GFP) was visualised using a 
fluorescein isothiocyanate filter on an Olympus Heinrich widefield microscope. MG-132- and lopinavir-treated cells demonstrated high levels of GFP when compared to 
control DMSO-treated transfected cells. 
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levels of HPVT16 E6 (Figure 3B). SiHa cells were then 
tested further by treating with a fixed concentration of 
lopinavir (25 µM) and RNASEL levels assessed at vari-
ous time points (Figure 3C). There was a clear time-
dependent increase of RNASEL protein over the 2 h 
intervals up to 12 h of treatment. This was followed 
by drop in level at 24 h. However, as the housekeeping 
GAPDH control signal also dropped at 24 h this was 
likely due to the previously reported toxic effects of 
25 µM lopinavir at this time point [13].
Lopinavir induces selective toxicity against E6/E7 
immortalised PHFKs with an associated up-regulation 
of RNASEL
The SiHa cervical carcinoma cell line has proved 
itself as a useful laboratory tool and has been used 
Gene Protein name Function/association Fold change
ANXA5 Annexin 5 Calcium-binding protein 2.15
CTBP1 (C-terminal)a C-Terminal binding protein 1 Transcription regulatory protein 1.87
CHEK2a CHK2 checkpoint homolog Serine/threonine kinase 1.84
RAB5A Ras related protein Rab 5A GTPase 1.84
RNASELa Ribonuclease L Ribonuclease 1.76
ACTR3 Actin related protein 3 Cytoskeletal protein 1.73
GRB2 Growth factor receptor bound protein 2 Adapter molecule 1.73
SYNPO Synaptopodin Cytoskeletal-associated protein 1.72
CASP3 Caspase 3 (active) Cysteine protease 1.69
EGF Epidermal growth factor Growth factor 1.68
TP63a Tumour protein p63 Transcription factor 1.68
BIRC5a Survivin Adapter molecule 1.67
ILKa Integrin-linked kinase Serine/threonine kinase 1.59
ERK2 Mitogen-activated protein kinase 1 Serine/threonine kinase 1.56
SYNPO Synaptopodin Cytoskeletal-associated protein 1.56
SNCA α-Synuclein Chaperone protein 1.56
PADI4 Peptidylarginine deiminase 4 Enzyme: hydrolase 1.52
CHEK1a Cell cycle checkpoint kinase Serine/threonine kinase 1.52
TUB Tubulin/tyrosine Cytoskeletal-associated protein 1.50
NOS1a Nitric oxide synthase 1 Enzyme: synthase 1.50
CTBP1 (N-terminal)a C-Terminal binding protein 1 Transcription regulatory protein 1.49
TNF Tumour necrosis factor-α Ligand 1.48
H2AFX H2A Histone Family, member X DNA binding protein 1.47
AKT1a Protein kinase B-alpha Serine/threonine kinase 1.47
CHEK2a CHK2 checkpoint homolog Serine/threonine kinase 1.47
FANCD2a Fanconi anemia, complementation group D2 Cell cycle control protein 1.47
DIABLOa SMAC protein Cell cycle control protein 1.46
PAWR PRKC, apoptosis, WT1, regulator Transcription regulatory protein 1.45
ILKa Integrin-linked kinase Serine/threonine kinase 1.45
MC3R Melanocortin 3 receptor Cell surface receptor 1.44
APP Amyloid precursor protein Receptor activity 1.43
MKI67a MKI67 (FHA domain) interacting nucleolar RNA-binding protein 1.43
 phosphoprotein
CFL2a Cofilin 2 Cytoskeletal-associated protein 1.38
DMDa Dystrophin Structural protein 1.37
CENPE Centromeric protein E DNA-binding protein 1.36
PTK2(pp125) Focal adhesion kinase 2 (pp125) Tyrosine kinase 1.35
TP53a Tumour protein p53 Transcription factor 1.28
DMDa Dystrophin Structural protein 1.25
TP53a Tumour protein p53 Transcription factor 1.18
GJA1a Connexin 43 Membrane transport protein 0.76
GFAP Glial fibrillary acidic protein Structural protein 0.63
GJA1a Connexin 43 Membrane transport protein 0.60
Table 1. Summary of proteins with altered expression levels following exposure of SiHa cells to lopinavir
Different antibodies against the same protein are represented more than once on the array. Since fold changes shown are based on duplicate data points, statistical 
significance has not yet been assigned. Thus, other than RNASEL, these results require immunoblot confirmation. aThese proteins are known to be subject to 
proteasomal degradation. 
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extensively by many groups over the last 40 years. It 
is, however, a fully transformed cell line and if lopi-
navir is to be used as a topical treatment for the pre-
cancerous target cells that are present in HPV-related 
cervical dysplasia, then cells more representative 
of the intended cell type should also be tested. For 
this reason it was decided to investigate the effects 
of lopinavir against HPV16 E6/E7 immortalised pri-
mary human foreskin keratinocytes (PHFKs) and con-
trol PHFKs which were treated over a 72 h period 
using a dose range of 5–40 µM (Figure 4A). This 
demonstrated greatly increased toxicity of lopinavir 
for E6/E7-expressing PHFKs when compared to nor-
mal (non-transduced) PHFKs. While the growth of 
normal PHFKs progressed relatively uninhibited up 
to concentrations of 25 µM, both SiHa and E6/E7 
PHFKs showed markedly reduced growth. Further-
more, RNASEL protein levels in E6/E7 transduced 
PHFKs also increased, albeit at a slower rate than 
was observed in SiHa cells (Figure 4B). While 25 µM 
lopinavir treatment caused a peak RNASEL signal 
in SiHa cells after 8 h and a subsequent drop after 
24 h (Figure 3B), E6/E7-expressing PHFKs peaked 
at 48 h followed by a subsequent drop after 72 h 
(Figure 4B).
siRNA-targeted silencing of RNASEL reduces the 
toxicity of lopinavir in SiHa cells
An extensive reduction in RNASEL protein level 
was seen following transfection with four different 
RNASEL targeting siRNAs and siRNA oligonucle-
otide 1 (siRNA-1) was found to be the most effec-
tive (Figure 5A) and was used in subsequent experi-
ments. The effects of transfection with siRNA-1, or 
the AllStar negative control on SiHa cell growth in 
the presence of DMSO control or different concen-
trations of lopinavir was assessed. Both AllStar and 
siRNA-1 transfected cells treated with DMSO control 
showed steady growth over the whole 72 h period 
(Figure 5B) although siRNA-1 transfected cells had 
a modest growth advantage. Exposure of identically 
transfected cells to 20, 25 and 30 µM concentrations 
of lopinavir demonstrated a dose-dependent inhibi-
tion of growth over 72 h (Figure 5C, 5D and 5E). 
DMSO
control DMSO Lopinavir
25 µM
Lopinavir
RNASEL
GAPDH
RNASEL
GAPDH
80 kDa
37 kDa
A
B C
Low level High level
Signal strength
Figure 2. Lopinavir induces an up-regulation of the RNASEL protein in SiHa cells
(A) The antibody array Cy3 fluorophore signal obtained for ribonuclease L (RNASEL). Protein levels are colour coded from low expression in blue, through to high 
protein expression in white. The left and right panels represent the untreated and treated protein lysates, respectively. The red boxed pair, on each panel, represents 
an internal negative control in duplicate, whilst the green boxes represent the positive control. The yellow boxed pair of signals represents duplicate spots of the 
RNASEL antibody which have increased signals following lopinavir treatment. (B) Western blot of protein lysates prepared from duplicate lopinavir-treated and DMSO 
control SiHa cells as used for the antibody microarray. These were immunoprobed with rabbit anti-RNASEL using anti-GAPDH as loading control. Lopinavir treatment 
caused an increase in the levels of RNASEL protein, when compared to DMSO-treated control cells. (C) Agarose gel electrophoresis of RNASEL primer specific reverse 
transcription-PCR products derived from messenger RNA isolated from lopinavir or DMSO-treated SiHa cells. No significant increase in RNASEL messenger RNA was 
found following lopinavir treatment when compared to DMSO-treated control cells. 
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Figure 3. Lopinavir induces a dose- and time-dependent increase in levels of the RNASEL protein in SiHa but not CaSki cells
(A) Western blot and quantitative densitometry of proteins isolated from SiHa cells treated with increasing doses of lopinavir and immunoprobed with ribonuclease 
L (RNASEL) and GAPDH antibodies. Lopinavir produced a clear dose-dependent increase in RNASEL protein levels. (B) Western blot of proteins isolated from CaSki 
cells treated with increasing doses of lopinavir and immunoprobed with RNASEL and GAPDH antibodies. Lopinavir did not increase the levels of RNASEL in these cells. 
Reverse transcription-PCR analysis of T16 E6 and GAPDH expression showing much higher levels of E6 messenger RNA are present in CaSki than in SiHa cells. (C) 
Western blot and quantitative densitometry of SiHa cells treated with DMSO or lopinavir at a final concentration of 25 µM. Cells were harvested at the times indicated 
and immuno-probed with RNASEL and GAPDH antibodies. Lopinavir produced a time-dependent increase in RNASEL protein levels, with a peak occurring after 
approximately 12 h incubation with lopinavir. This peak was followed by a decrease in protein levels observed at 24 h. 
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At a 25 µM concentration of lopinavir, siRNA-1 
transfected cells showed a significant (P<0.05 at 
72 h) growth advantage over AllStar transfected cells 
(Figure 5D), whereas at 30 µM there was equivalent 
growth inhibition (Figure 5E). This finding is consist-
ent with the observed toxic effects of lopinavir on 
E6/E7 immortalised and control PHFKs shown in 
Figure 4A where the growth of normal PHFKs was 
unaffected at concentrations up to 25 µM lopinavir, 
whereas at 30 µM they were inhibited by this treat-
ment. The data from the RNASEL silencing experi-
ments thus provides strong evidence that this protein 
plays a role in the observed selective toxicity of lopi-
navir in HPV E6/E7 cells up to an optimum concen-
tration of 25 µM.
Discussion
Our data are the first to show that the HIV protease 
inhibitor lopinavir induces an increase in the levels 
of the RNASEL protein in HPV-positive cervical car-
cinoma cells and in stable HPV16 E6/E7 transfected 
human keratinocytes. Lopinavir was also shown to 
have enhanced toxicity against E6/E7 immortalised 
PHFKs when compared to normal PHFKs and our 
results are consistent with RNASEL contributing to 
this selective toxicity.
In agreement with the results shown in Figure 1, 
other groups have shown lopinavir can induce selective 
inhibition of the proteasome and this ability is thought 
to play a significant role in the anti-HIV effects of this, 
and other related compounds [19–22]. In addition to 
HIV, many viruses including HPV, have been shown 
to subvert/hijack the activity of the host proteasome in 
order to eliminate proteins that would be detrimental to 
viral persistence [23]. In HPV-infected cells the E6 and 
E7 oncoproteins are largely responsible for this activity, 
whereby they signal the destruction of selected cellular 
proteins (for example, p53 and Rb) in order to execute 
the viral life cycle [24].
Based on these observations, we opted to use anti-
body array screening of lopinavir-treated SiHa cells to 
analyse changes in protein expression following this 
treatment. This identified a whole range of cellular 
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Figure 4. Lopinavir shows selective toxicity against E6/E7 immortalised versus normal control PHFK cells with an associated 
increase in RNASEL
(A) E6/E7 immortalised primary human foreskin keratinocytes (PHFKs), normal PHFKs (Ker) and SiHa cells were treated for 72 h with lopinavir over a dose range of 
5–40 µM. Cell growth was assessed and expressed in terms of percentage growth change when compared to untreated control cells. Mean values ± standard deviations 
were based on triplicate data points which were calculated in Microsoft Excel 2003 (Microsoft, Redmond, WA, USA). (B) Western blot of proteins isolated from E6/E7 
immortalised PHFKs treated from 24 to 72 h with 25 µM lopinavir immunoprobed with ribonuclease L (RNASEL) and GAPDH antibodies. A time-dependent increase in 
RNASEL was observed which peaked at 48 h of incubation. 
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Figure 5. siRNA-mediated gene silencing of RNASEL reduces the toxicity of lopinavir in SiHa cells
(A) Western blot and quantitative densitometry of ribonuclease L (RNASEL) expression in proteins isolated from lopinavir-treated (25 µM for 6 h) SiHa cells transiently 
transfected with RNASEL small interfering RNAs (siRNAs; 1–4) in addition to AllStar and mitogen activated protein kinase (MAPK) siRNA controls. (B–E) 72-h cell 
proliferation assays were carried out 24 h after RNASEL siRNA 1 or control AllStar siRNA transfection of SiHa cells. Cells were treated with DMSO, or 20 µM, 25 µM or 
30 µM concentrations of lopinavir respectively, and cell proliferation recorded over 72 h. Mean values ± standard deviations were based on triplicate data points and 
were calculated in Microsoft Excel 2003 (Microsoft, Redmond, WA, USA). A Student t-test was performed using Microsoft Excel 2003 (Microsoft) and P-values <0.05 
were considered significant. 
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proteins that were up-regulated (Table 1), including 
Tp53 which is consistent with our previously reported 
findings [13]. Indeed, as we have discussed, lopinavir 
induced changes in the levels of several other apopto-
sis-related proteins and it is also significant that the 
majority of the proteins listed in Table 1 are known 
to be regulated by proteasomal degradation. On this 
point, an interesting finding was the observed lopina-
vir-induced down-regulation of GFAP which is known 
to be capable of inhibiting the proteasome [25]. Since 
p53 is a target of high-risk HPV E6, we searched the 
Virus Molecular INTeraction (VirusMINT) data-
base [26] for any other known E6 and E7 targeted 
proteins which are affected by lopinavir treatment 
(Table 1). At this time, only Tp53 is a confirmed target 
of high-risk HPV.
Given that SiHa cells are a fully malignant cell type, 
we opted to investigate the toxicity of lopinavir against 
E6/E7 immortalised and normal control PHFKs. This 
showed that at a concentration of 25 µM, lopinavir up-
regulated RNASEL expression in the E6/E7 cells which 
were much more susceptible to lopinavir-induced cell 
death than control PHFKs. At higher concentrations of 
drug, this selectivity was lost and these data indicate 
that lopinavir has a good therapeutic index for E6/E7 
PHFKs at concentrations up to 25 µM. Since these cells 
are not transformed it is most likely that this is due to 
the ability of lopinavir to activate apoptotic antiviral 
systems which are suppressed by E6/E7.
Curiously, it is known that HIV patients receiving 
oral lopinavir as part of HAART do not show enhanced 
clearance of HPV-related lesions [27]. On this point, it 
is noteworthy that the concentration of lopinavir found 
in the vaginal fluid of HIV patients taking oral Kaletra 
is <2 µM [28], which has been discussed in our previous 
study [13].
In order to address the issue of whether the observed 
HPV-specific toxicity of lopinavir is related to its abil-
ity to block RNASEL degradation by E6/E7, siRNA 
RNASEL gene silencing experiments were carried 
out in lopinavir-treated SiHa cells. These experiments 
showed that, at the optimum therapeutic dose range of 
25 µM, lopinavir had much reduced toxicity in RNA-
SEL siRNA transfected SiHa cells when compared to 
the same cells transfected with AllStar control siRNA. 
These results support the hypothesis that the selective 
toxicity of lopinavir in HPV E6/E7 expressing cells is at 
least in part mediated by up-regulated expression of the 
RNASEL protein.
It is also notable that our results support the conclu-
sion that HPV can compromise the antiviral activity of 
RNASEL. The observation that CaSki cells are insensi-
tive to lopinavir [13] and do not up-regulate RNASEL is 
significant since CaSki cells express much higher levels 
of E6 than do SiHa (Figure 3B). Indeed, investigation of 
the effects of E6 on RNASEL toxicity is the subject of 
our continued work.
Thus, the logical conclusion from these  observations 
is that inactivation of the RNASEL response by HPV 
infection of the cervix could lower host antiviral 
defences and increase the likelihood of infection with 
other viruses. This is highly significant when consid-
ered with the previously discussed findings that genital 
HPV infections can predispose to increased risk of HIV 
transmission in both men and women [29,30].
In conclusion, our data support the potential use 
of lopinavir as a topical, self-administered treatment 
for HPV-related cervical dysplasia. If successful, this 
treatment would be particularly useful in low-resource 
countries which lack cytology screening and surgical 
services, and where HIV infection is often a significant 
additional complication. With current pricing strate-
gies, anti-HPV vaccines are not an option in such set-
tings, and as previously discussed, they will most likely 
have reduced efficacy in HIV-positive women. Further-
more, in view of the observation that infection with 
HPV can enhance the sexual transmission of HIV in 
both men and women [29,30], this clearly indicates 
that a simple, non-surgical treatment for HPV-related 
precancerous lesions may not only reduce the burden 
of cervical cancer but may also reduce the chances of 
HIV transmission.
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Raman chemical mapping reveals site of action of HIV
protease inhibitors in HPV16 E6 expressing cervical
carcinoma cells
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Abstract It has been shown that the HIV protease
inhibitors indinavir and lopinavir may have activity against
the human papilloma virus (HPV) type 16 inhibiting HPV
E6-mediated proteasomal degradation of p53 in cultured
cervical carcinoma cells. However, their mode and site of
action is unknown. HPV-negative C33A cervical carcinoma
cells and the same cells stably transfected with E6
(C33AE6) were exposed to indinavir and lopinavir at
concentrations of 1 mM and 30 μM, respectively. The
intracellular distribution of metabolites and metabolic
changes induced by these treatments were investigated by
Raman microspectroscopic imaging combined with the
analysis of cell fractionation products by liquid chromatog-
raphy–mass spectrometry (LC-MS). A uniform cellular
distribution of proteins was found in drug-treated cells
irrespective of cell type. Indinavir was observed to co-
localise with nucleic acid in the nucleus, but only in E6
expressing cells. Principal components analysis (PCA)
score maps generated on the full Raman hypercube and
the corresponding PCA loadings plots revealed that the
majority of metabolic variations influenced by the drug
exposure within the cells were associated with changes in
nucleic acids. Analysis of cell fractionation products by
LC-MS confirmed that the level of indinavir in nuclear
extracts was approximately eight-fold greater than in the
cytoplasm. These data demonstrate that indinavir undergoes
enhanced nuclear accumulation in E6-expressing cells,
which suggests that this is the most likely site of action
for this compound against HPV.
Keywords HPV. Indinavir . Lopinavir . Raman chemical
mapping . LC-MS
Introduction
Globally, an estimated 493,000 women are affected by
cervical cancer resulting in a staggering 273,500 deaths
each year (National Cervical Cancer Coalition; www.nccc-
online.org). Indeed, in many low-resource countries, it is
the greatest cause of women’s cancer-related mortality.
Human papilloma virus (HPV) is the major cause of
cervical cancer [1], and there are >120 different types of
HPV associated with a variety of clinical lesions [2]. There
are approximately 13 so-called high-risk types which are
associated with cervical cancers [1, 3], although HPV16
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and 18 are the most prevalent high-risk types, accounting
for >60% of cases [4, 5].
Surgery is currently the treatment of choice for HPV-
related pre-cancerous cervical intraepithelial neoplasia [4,
6]. However, since it carries an increased risk of infertility,
this is restricted to high-grade disease [7].
Many countries are implementing prophylactic anti-HPV
vaccination programmes, yet these primarily protect against
types 16 and 18 only, which leaves a significant proportion
of high-risk HPV-related disease unprotected. Furthermore,
vaccination is most effective when given to women prior to
HPV infection, and it is expensive. Thus, since cervical
cancer can take from 10 to 20 years to develop, persistently
infected women will still be at risk for many years,
particularly in low-resource countries that cannot afford
vaccination. It is also notable that such countries do not
have routine cervical screening services. Thus, it is clear
that a low-cost, self-applied treatment for HPV-related
disease would have many benefits, particularly in low-
resource settings.
The E6 and E7 viral oncoproteins from high-risk types of
HPV are responsible for their oncogenic properties, and their
continued expression is essential for the growth and survival
of HPV transformed cells [8]. We have previously shown that
the anti-HIV protease inhibitors (HIV PIs) indinavir and
lopinavir inhibit E6-mediated proteasomal degradation of
p53 and selectively kill E6-dependant cervical carcinoma
cells in vitro [9]. We have also recently shown that these
compounds cause very specific alterations in the metabolism
of cultured E6-expressing cervical carcinoma cells [10].
Indeed, anti-HIV drugs are now becoming increasingly
recognised as having significant off-target antineoplastic
properties [11]. However, the site and mode of action of
this type of drug with respect to HPV is unknown. In order
to address this question, we used Raman microspectroscopic
imaging to investigate changes in the intracellular distribu-
tion of metabolites and macromolecules, and the subcellular
location of indinavir and lopinavir in control cervical
carcinoma cells treated with these compounds.
Materials and methods
Cell line and culture medium
HPV-negative human C33A cervical carcinoma cells were
maintained in RPMI 1640 (Invitrogen, Paisley, UK) supple-
mented with 10% foetal bovine serum and 2 mM L-glutamine
(Sigma-Aldrich Company Ltd., Dorset, UK; complete
medium) at 37 °C, 5% CO2. C33A cells stably transfected
with HPV16 E6 (termed “C33AE6”) and the pcDNA3.1
control vector (termed “C33AV”) were derived and cultured
as previously described [12].
Protease inhibitor
Indinavir was obtained through the NIH AIDS Research
and Reference Reagent Program (Division of AIDS,
NIAID, NIH): indinavir sulphate (8145). Lopinavir was
provided as a generous gift from Abbott Laboratories (Park
Road, Abbott Park, IL 60064-6187, USA). Indinavir and
lopinavir were dissolved in sterile distilled water and
DMSO (Sigma-Aldrich Company Ltd.), respectively, at a
working stock concentration of 20 mM.
Raman sample preparation
Each 1×106 of C33AV and E6 cells was seeded in T75
culture flasks with 20 mL of the complete medium and then
incubated at 37 °C, 5% CO2. Prior to confluence, the
medium was removed and the cells were detached by
trypsinisation for 3 min at 37 °C, 5% CO2. Following this,
2×104 cells were seeded onto a single CaF2 disc (Crystran
Plc, Dorset, UK, 20-mm diameter×2-mm thickness) in
3 mL of the complete medium in a six-well culture dish and
allowed to adhere overnight at 37 °C, 5% CO2. Previous
work [9] reported dose-dependent experiments on the HIV
protease inhibitors indinavir and lopinavir to inhibit the
degradation of p53 promoted by E6. Based on this study,
cells were then treated with either 1 mM of indinavir,
30 μM of lopinavir, water or DMSO (as controls) and
incubated for 24 h at 37 °C, 5% CO2. The cells were
subsequently fixed in ice-cold methanol for 4 min at −20 °C,
then washed and stored in phosphate-buffered saline (PBS) at
4 °C until use.
Raman microspectroscopy and data analysis
Raman point spectra for the chemical maps were obtained
on a Renishaw System 2000 Raman microscope (Renishaw
Plc., Old Town, Wotton-under-Edge, Gloucestershire, UK),
and spectra were recorded directly on single CaF2 disc
mounted cells. All cells were mounted in PBS under
coverslips during the acquisition of spectra to avoid
desiccation. An 830-nm NIR diode laser was used for
excitation, with laser power of ~5 mW at the sample using a
×50 microscope objective, with 0.95 NA which resulted in
~0.75-μm lateral spatial resolution. At each location
(or pixel), a Raman spectrum was acquired over the region
from 400 to 2,000 cm−1. The stage was then moved in 1-μm
steps for each acquisition, with the overall result generating a
3D hypercube over the single cell of dimensions X vs. Y vs.
Raman spectra (see Electronic supplementary material
(ESM) Fig. S1). Spectral acquisition was performed using
GRAMS WiRE software (Galactic Industries Corp., Salem,
NH, USA) and data processing was carried out with Matlab
7 (The MathWorks, Inc., Natick, MA, USA). Chemical
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image maps were generated against a variety of univariate
metrics, including peak area and S/N ratios with the full
process illustrated in Fig. 1.
Matlab was also used to perform principal components
analysis (PCA) using the NIPALS (nonlinear iterative
partial least squares) algorithm [13]. PCA is a multivar-
iate technique that is used widely to reduce the dimen-
sionality of complex spectroscopic data from many
wavenumber assignments to a few principal components
(PCs), which retain the majority of variance within the
data [14, 15]. Upon collection, the individual spectral data
cubes were concatenated to produce a single large dataset
within Matlab which was subjected to PCA. The first few
PCs were extracted as these explained the majority of the
variance and lower ones are likely to contribute only
noise. Image maps were constructed from plotting each of
the PC scores individually. The data cube was reshaped (in
order to plot each PC as a function of X and Y) and PC
scores false colour coded to generate chemical maps; the
corresponding PC loadings were plotted for the first few
scores.
Subcellular fractionation of C33AE6 cells
C33AE6 cells were treated with 0.3 mM of indinavir for
24 h and detached as described in “Raman sample
preparation”. These were resuspended in complete medium
and washed twice with PBS. Cytoplasmic and nuclear
extracts were prepared by the use of the NE-PER kit
(Pierce, USA) according to the manufacturer’s protocols.
Western immunoblotting of sub-fractionated samples
Western immunoblotting was carried out as described in [9,
16] loading 25 μg of each extract per track. Anti-histone
deacetylase (HDAC1, Cell Signalling Technology, UK) was
used at 1:800 and GAPDH (Abcam, UK) at 1:1,000.
Following washing, membranes were incubated with
1:2,000 of HRP-conjugated secondary antibody and visual-
ised with ECL and Hyperfilm (GE Healthcare Life
Sciences, Buckinghamshire, UK).
LC-MS analysis of cell sub-fractions
Yields of 1,055 μL of cytoplasmic and 500 μL nuclear
fractions were obtained, which reflect the nucleus/cytoplas-
mic ratio for these cell lines. Aliquots (25 μL) of these
extracts were treated with 5 volumes of cold acetone for 1 h
at −20 °C, centrifuged at 14,500×g for 15 min and the
supernatant recovered. These were then dried by speed
vacuum concentration for approximately 1 h at 45 °C to
reduce the samples to their original volume of ~25 μL.
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A 10-min LC methodology using 10 mM ammonium
formate, pH 9, as mobile phase A and acetonitrile as
mobile phase B was performed with an Acquity UPLC™
(Waters Ltd., Manchester, UK). A 2-μL sample injection
was made onto a 2.1×10-mm HSS T3 (C18) Acquity
column held at 45 °C; the mobile phase flow rate was
0.6 mL/min. The following gradient elution was
employed (time (min), %B): (0, 2), (8, 98), (8.6, 100),
(9.1, 2).
A Xevo™ QTof (Waters Ltd.) MS instrument was
used in electrospray ionisation (ESI) positive ionisation
mode. Prior to sample analysis, the instrument was
calibrated with sodium formate following the instrument
setup wizards. Sample data were acquired in MSE mode
[17, 18] with a 0.05-s scan time; the lockspray standard
applied was leucine enkephalin (Leu Enk) and two points
were employed for lockmass: m/z 556.2771 and a
fragment ion from Leu Enk m/z 120.0813. ESI was
operated using an extraction cone voltage of +3 V, a
sampling cone voltage of +45 V, and the capillary voltage
was set at +3 kV. The source and desolvation temperatures
were 120 and 400 °C, respectively, and the cone and
desolvation gas flow rates were 20 and 800 Lh−1,
respectively. Data were acquired over the m/z range 50–
1,000 with six biological replicate samples to account for
analytical variability.
Results
Raman analysis of C33AV control cells
A representative population of C33AV cells exposed to 1 mM
of indinavir or 30 μM of lopinavir were imaged by Raman
microspectroscopy. The average spectra for drug-treated and
control untreated cells are shown in Fig. 2, which also shows
peak centres. Cellular components such as proteins, lipids,
nucleic acids and carbohydrates all contribute to this type of
analysis, as illustrated in Table 1. As can be seen in Fig. 2
and Table 1, the band at 1,004 cm−1 originates from the
aromatic ring vibration of phenylalanine and is characteris-
tically observed in biological samples.
Chemical maps of drug-treated C33AV and untreated
control cells were employed to analyse and visualise the
biochemical distribution of the above intracellular compo-
nents. White light images, which were used to provide
information on the cell shape, and the Raman chemical
image maps of cells are shown in Fig. 3. In order to
enhance the detection of relevant biological information,
CaF2 substrate background removal was carried out before
the image maps were generated (as illustrated in the
schematic in Fig. 1). These chemical maps were generated
with a spatial resolution of 1 μm from the peak area to
baseline of each band within the Raman spectra acquired
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from the cell and surrounding area. The intense red regions
indicate a higher concentration of a chemical constituent(s)
relative to the low-intensity signal recorded from the CaF2
disc substrate, which is represented by blue-coloured pixels.
Raman analysis of C33AE6 cells
The average spectra of C33AE6 and drug-exposed C33AE6
cells are shown in Fig. 4a–c. Since the expression of
HPV16 E6 subverts the function of the 26S proteasome to
degrade the p53 tumour suppressor and other cellular
proteins [1, 3, 19, 20], it is predicted that the intracellular
composition of C33AE6 cells will be different from those
of the vector cells. As expected, the average spectrum
obtained from untreated C33AE6-expressing cells show
significant variations relating to increased and decreased
peak intensities when compared to C33AV control cells
(Fig. 4d). In Fig. 4a–c, several large changes were observed
between the spectra of C33AE6 cells exposed to either
indinavir (E6I) or lopinavir (E6L) when compared to
untreated control cells. No peaks were seen at 670, 680,
746, 780 and 825 cm−1 in the spectrum of the C33AE6 cell,
whereas the resulting spectra of these cells following the
treatment with both compounds revealed marked signals at
these wavenumber shifts. Interestingly, the peaks at 670,
780 and 825 cm−1 for E6I, and 680, 746 and 825 cm−1 for
E6L, correspond to peaks typically ascribed to nucleic acids
(Table 1). In contrast, no clear bands are observed at 1,063,
1,132 and 1,172 cm−1 in drug-treated C33AE6 cells, but
which are very prominent in untreated C33AE6 cells. This
also suggests an additional phenotypic effect as these can
be attributed to the reduction in proteins, lipids and
aromatic amino acids (Table 1). These spectral differences
between the C33AE6 and drug-treated C33AE6 cells are
Table 1 Tentative Raman band assignments for the C33A cells
Wavenumber (cm−1) Assignment Raman vibrational modes
642 Tyr (643) C–C twist
670 T, G (669)
680 G
712 Unidentified
746 T
780 C, U, T (782)
792 C, T n: (O–P–O) backbone
825 n: (O–P–O) backbone (828)
836 (O-P-O), Tyr (834) n: RP; n: (O–P–O)
850 p: (C–CH) aromatic def. (852)
890 n: (O–P–O) backbone (898)
p: (C–C) skeletal modes (898)
934 p: (C–C) backbone str. (937)
948 Deoxyribose (950)
1003-4 Phe (C–C) aromatic ring str.
1032 Phe protein: (C–N) str.
1047 Carbohydrate (1049) (C–O) str.
1063 p: (C–N) str.; l: chain (C–C) str.
1086 n: (O–P–O) backbone (1088); p: (C–C) skeletal modes (1086)
1109 n: (O–P–O) backbone (1106)
1128, 1133 p: (C–N) str.; l: chain (C–C) str. (1129)
1156 p: (C–C/C–N) str. (1158)
1172, 1174 Tyr, Phe (1175) (C–C) str. (1172)
1206 Phe, Tyr, Amide III (1209)
1256 Amide III(1254); C, A (1255)
1297 (CH2) def.
1341 A, G (1342) p: (CH) def. (1342)
Parenthesised numbers, original Raman shifts from [33, 37, 38]
Tyr tyrosine, Phe phenylalanine, A adenine, T thymine, G guanine, C cytosine, U uracil, RP reverse primer, str. stretching, def. deformation, p
protein, l lipid, n nucleotide
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not from the sample matrix effects as we have recently
shown that the drugs cause changes in the levels of p53
protein [9] and intracellular metabolites [10] in cultured
C33AE6, but not in C33AV cells. In addition, a very
interesting feature of the E6I spectra is the band at
880 cm−1. By comparing the spectrum of E6I to that of
the drug itself (Fig. 4e), this was deduced to be a peak
originating from indinavir itself. No discernible signal was
observed associated with chemical detection of lopinavir
within the cells.
White light and Raman spectra chemical image maps
of untreated C33AE6 and drug-treated cells were ac-
quired using the same instrumental conditions as those
applied to C33AV cells (Fig. 5). As shown previously,
vibrations arising from proteins are uniformly distributed
throughout both E6I (642 cm−1, 5B1; 1,003 cm−1, 5B4;
1,088 cm−1, 5B5) and E6L (1,003 cm−1, 5 C4; 642 cm−1,
5 C1; 850 cm−1, 5B3). The chemical image maps of the
drug-exposed C33AE6 cells show very interesting features
in terms of the spatial distribution of nucleic acids. Unlike
C33AV (Fig. 3) and untreated C33AE6 cells (Fig. 5a),
there are clear localisations from 780 cm−1 for E6I to
747 cm−1 for E6L, as shown in 2 of Fig. 5b, c,
respectively. Also, the maps from 670 to 825 cm−1 for
E6I and 680 cm−1 for E6L show the same distinct
localisations as 780 and 747 cm−1, respectively (data not
shown). Interestingly, all these wavenumbers which have
distinct distributions are assigned to nucleic acids
(Table 1).
LC-MS analysis of subcellular localisation of drug
LC-MS is a commonly used analytical approach within
the metabolomics field [21] and was applied here to
quantify the level of indinavir within nuclear and
cytoplasmic extracts from indinavir-treated C33AE6 cells.
Immunoprobing Western blots of these extracts with
GAPDH and HDAC1 antibodies demonstrated minimal
nuclear/cytoplasm cross-contamination (Fig. 6). Six bio-
logical replicates were analysed in triplicate by LC-MS for
both nuclear and cytoplasmic extracts (Table 2). White
light microscopy was used to determine the average
relative volume of the cytoplasm vs. nucleus of
indinavir-treated C33AE6 cells and was calculated as 11.6.
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Fig. 3 White light images of C33A vector control cell (a), vector cell
exposed to indinavir (b) and vector cell exposed to lopinavir (c). Scale
bar, 10 μm. Raman chemical mean filtered maps of each of these cells
are also shown based on the results from each band of a mean row
normalised spectrum with a spatial resolution of 1 μm: 1 746 cm−1
(thymine); 2 850 cm−1 (protein); 3 1,004 cm−1 (phenylalanine); 4
1,032 cm−1 (protein). The rainbow maps indicate the concentration of
each cellular component inside the cell, red showing high and blue
showing low concentration of molecules
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Fig. 5 White images of C33A E6 cell (a), E6 cell exposed to
indinavir (b) and E6 cell exposed to lopinavir (c). Scale bar, 10 μm.
Raman chemical mean filtered maps of each of these cells are also
shown based on the results from each band of a mean row normalised
spectrum with a spatial resolution of 1 μm. a 1 890 cm−1 (nucleotide);
2 1,003 cm−1 (phenylalanine); 3 1,063 cm−1 (protein); 4 1,088 cm−1
(nucleotide, protein); 5 1,133 cm−1 (protein, lipid). b 1 642 cm−1
(tyrosine); 2 780 cm−1 (nucleotide); 3 880 cm−1; 4 1,003 cm−1; 5
1,088 cm−1. c 1 642 cm−1; 2 747 cm−1 (nucleotide); 3 850 cm−1
(protein); 4 1,003 cm−1; 5 1,086 cm−1. The rainbow maps indicate the
concentration of each cellular component inside the cell, red showing
high and blue showing low concentration of molecules
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Discussion
Based on our previous studies of the effects of HIV PIs on
the survival and metabolism of cultured cervical carcinoma
cells [9, 10], we initially analysed the Raman spectra of
HPV-negative C33A cells exposed to these drugs.
Raman spectroscopy is an optical approach in which a
laser is used to irradiate a sample. Molecules within the
sample vibrate, and this results in a change in energy of the
light that can be measured and displayed as a Raman
spectrum. This spectrum relates directly to the chemical
composition of the sample [22].
The chemical mapping approach of Raman microspec-
troscopy involves coupling an optical microscope with a
Raman spectrometer, and it is a powerful tool for analysing
the chemical distribution of metabolites present at any point
and the response of metabolic and physical stresses in cells
or tissues [23]. Subtle changes in chemical composition and
distribution on cells or tissues can be monitored using this
Raman spectroscopic approach. This chemical mapping
technique not only enables visualisation of spatially
resolved chemical information but can also be used to
detect small chemical changes in order to understand
abiotic perturbations to biological systems. Thus, Raman
spectroscopy has emerged as a promising diagnostic tool
for disease detection in the biomedical field. Various
diseases have been detected by comparing the differences
of Raman spectra between normal and diseased cells or
tissues because disease progression results in changes of the
composition and abundance of metabolites [24–27]. The
biomedical application of spectroscopy for cancer detection
and disease diagnosis has been thoroughly reviewed in
[22, 28, 29]. Finally, in order to develop effective
chemotherapeutic agents and assess combinations of vari-
ous drugs against serious diseases, the response to
chemotherapy and the distribution of drugs inside cells or
tissues have also been investigated [30, 31].
As can be seen in Fig. 2a–c, the differences between the
spectra of drug-treated and control untreated C33AV cells
are very subtle, apart from a large 1,047 cm−1 carbohydrate
signal (see Table 1) which was reduced after incubation
with either of the compounds. Although C33AV cells
treated with lopinavir do not proliferate [9], the spectral
differences from the level changes in intracellular compo-
nents such as lipid, protein, DNA and RNA caused by
proliferation are very subtle [32]. Therefore, the spectral
changes between drug-challenged and non-drug-challenged
control C33AV cells were not observed by visual analysis
of vibrational bands in the Raman spectra.
Using these Raman spectral assignments, we next
employed chemical mapping of drug-treated and control
untreated C33AV cells in order to analyse intracellular
distribution of internal components within the cells (Fig. 3).
It is well known that biological molecules are not
homogeneously distributed inside cells with localised and
specific activities being related to their spatial distribution
[33]. Raman chemical maps obtained from the average
spectra of untreated and drug-treated C33AV cells show
that the concentrations of different molecules show subcel-
lular variation. Single cell image maps of proteins at 850,
1,004 and 1,032 cm−1 show a uniform distribution
throughout the whole cell, whereas, as expected, the
746 cm−1 nucleic acid signal shows a more concentrated
intracellular localisation that is consistent with specific
nuclear compartmentalisation. Curiously, no Raman spec-
tral bands that could be directly attributed to either of the
drug compounds were observed in C33AV cells.
Following on from this, we investigated whether the
expression of the E6 protein caused any discernible effects
on the Raman spectral analysis. It is well known that E6, in
association with E6AP, can facilitate the proteasomal
destruction of numerous proteins, such as p53, that are
detrimental to viral persistence [19]. Yet it is also known
that the levels of other cellular proteins are increased by
indirect effects of E6 and other viral proteins in HPV-
infected cells [34, 35]. What is clear is that infection with
C1 C2 C3 C4 C5 C6N1 N2 N3 N4 N5 N6
GAPDH 
HDAC1
Fig. 6 Western blot of sub-fractionated samples from C33A E6-
transfected cells exposed to indinavir and immunoprobed with a
HDAC1 (nuclear marker) and GAPDH loading control antibodies.
Sub-fractionation of drug-treated C33AE6 cells was carried out
successfully with only minimal cross-contamination. C cytoplasm, N
nuclear, 1–6 biological replicates
Table 2 Biological replicates of indinavir-treated C33E6 cells analysed
in triplicate by LC-MS for both nuclear and cytoplasmic extracts
Fractiona Cytoplasm
abundanceb
Nucleus
abundance
Nucleus:
cytoplasm
1 19.2 149.9 7.8
2 19.7 204.6 10.4
3 20.8 191.8 9.2
4 18.4 156.8 8.5
5 24.7 126.6 5.1
6 27.0 171.7 6.3
Mean 7.9
a Each fraction was analysed in triplicate (2 μL injected into LC-MS) and
means are shown
b Abundance is the extracted ion chromatogram for the identified indinavir
peak following scaling factors due to extraction volume differences and
cytoplasm-to-nucleus volume
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high-risk HPV produces multifactorial effects generally
aimed at targeting and perturbing the function of a
variety of cellular “hub” proteins. Thus, the spectral
comparison of C33AV and E6 cells shown in Fig. 4d
represents a snapshot of some of these effects which
reflect the changes in the levels of cellular components.
Indeed it is noteworthy that we have previously shown the
biological properties of these two cell types to be very
different. For example, xenografted experimental tumours
derived from C33AE6 cells are highly resistant to
radiotherapy when compared to tumours derived from
C33AV cells [12], and more recently, we have used the
complementary vibration technique of FT-IR spectroscopy
to elucidate gross phenotypic differences between control
C33A cells and those expressing E6 [10].
If lopinavir or indinavir can specifically target the
biological effects of E6, we hypothesised that treatment of
C33AE6 cells with these compounds may induce associated
alterations in the Raman spectra. Indeed, we found large
variations in the spectra between untreated and drug-treated
C33AE6 cells (Fig. 4) which corresponded to peaks arising
from nucleic acids and other components such as proteins,
lipids and aromatic amino acids. With regard to the function
of E6, it could be speculated that these drugs might increase
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Fig. 7 PCA chemical maps
constructed from PC scores
with the corresponding loadings
plots. E6-transfected cell ex-
posed to indinavir showing PC1
(78.5%) (a) and PC2 (14.4%)
(b) and E6-transfected cell ex-
posed to lopinavir showing PC1
(85.6%) (c) and PC2 (6.5%) (d)
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the level of specific types of nucleic acids in cells, and it is
intended to continue work on this effect by the use of
metabolic profiling [36].
To determine whether there was any difference between
drug-treated and untreated C33AE6 cells in terms of the
biochemical distribution of intracellular components,
Raman chemical maps of these cells were generated. As
can be seen in Fig. 5, although proteins are uniformly
distributed within both untreated and drug-treated E6 cells,
distinct localisation of nucleic acids was observed in drug-
treated C33AE6 cell. Based upon the comparison of the
spatial co-localisation of nucleic acids with that of the
prospective indinavir signal at 880 cm−1, it is possible that
the metabolic activity of this drug against E6 may occur in
the nucleus.
In order to investigate this hypothesis further, PCA of drug-
exposed (E6I and E6L) cells was conducted. PCA provides
the most compact representation of all the variations within
the multivariate datasets by visualising and mining informa-
tion from an XY data matrix containing the large number of
Raman-detected variables (in the Z-axis in this spectral
hypercube). Thus, in order to investigate which spatial
region is the most variable and which spectral band is
related to the area, PCA was carried out as described above.
PCA chemical maps and their loadings plots are shown in
Fig. 7. The maps and loadings plots from the PCA allow for
the selection of significant variables associated with the drug
activities from the spectrum of each cell. For C33AE6 cell
exposed to indinavir, 78.5% of the total explained variance
was recovered in the first PC and 14.4% in the second PC,
whilst for C33AE6 cell exposed to lopinavir, PC1 accounted
for 85.6% and PC2 6.5%. For these indinavir and lopinavir
exposures, the total for the first two PCs was 92.9% and
92.1%, respectively, which highlights the efficient dimen-
sionality reduction that PCA has achieved. On the basis of
chemical image maps and loadings plots from PC1 to PC2
(representing the largest and second largest variations,
respectively), many of the important variations occurring in
E6I cells are found to be associated with peaks at 670, 780
and 836 cm−1 corresponding to nucleic acids (Fig. 7a, b).
Furthermore, the large variation of the band at 880 cm−1
indicates that the drug location is related to changes in the
levels of nucleic acids which may occur in the nucleus.
For both E6I and E6L, it was found that the largest
variations (PC1) were derived from nucleic acids, although
a large contribution was also made by proteins. The second
largest variations (PC2) mostly occurred at the position
corresponding to peaks arising from the following nucleic
acid signals: 680, 747 and 1,432 cm−1 (Fig. 7c, d).
In order to support the hypothesis that indinavir localises to
the nucleus, we evaluated its levels in drug-treated sub-
fractionated C33AE6 cells by the use of LC-MS. After taking
into account the difference between the volume of the
cytoplasm compared to the nucleus, LC-MS indicated that
the concentration of indinavir was approximately eight-fold
greater in the nucleus than in the cytoplasm of these cells
(Table 2). Clearly, this orthogonal analytical technique
definitively confirms the findings from Raman chemical
mapping that indinavir is being localised to the nucleus of
E6-expressing cells, and this is presumably the site of action
for this antiviral drug.
Conclusions
We have used Raman chemical image mapping to
compare the distribution of intracellular components
within human C33A cervical cancer cells and the same
cells expressing the HPV16 E6 oncoprotein. Significant
variations were observed between the spectra of these two
cell types, which indicates that the expression of E6
induces gross phenotypic changes which are consistent
with our previous FT-IR spectroscopy-based study [10].
Finally, we also have unequivocal evidence that the HIV
antiviral drug indinavir is specifically targeted to the
nucleus of HPV16 E6-expressing cervical carcinoma cells.
This unexpected finding will facilitate the analysis of
potential drug targets for this prospective novel use of this
class of compound.
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